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Abstract
Cancer patients experience multiple symptoms. Leaving these symptoms unrelieved can
have deteriorating effects on the patients health related quality of life and functional
status. The intensity and load of this symptom burden has implications for possible
delay or termination of treatment, increased hospitalizations and medical costs, even
for the prognosis and survival of cancer patients. Therefore, understanding the pattern
of these symptoms’ interactions and recognising the symptom risk profiles of cancer
patients is a major concern for oncology care. This research supports the aforemen-
tioned goals by exploring, understanding and identifying symptom clusters as well as
their networks. It provides analytical approaches, also, on how to assess and predict
the future occurrence of these symptoms.
Risk profiling of oncology patients based on their symptom experience assists clinicians
to provide more personalized symptom management interventions. Recent findings
suggest that oncology patients with distinct symptom profiles can be identified using a
variety of analytic methods. The aim for our first experiment was to evaluate the con-
cordance between the number and types of subgroups of patients with distinct symptom
profiles using latent class analysis (LCA) and K-modes analysis. Using both analytic
methods, four subgroups of patients with distinct symptom profiles were identified (i.e.,
All Low, Moderate Physical and Lower Psychological, Moderate Physical and Higher
Psychological, All High). The percent agreement between the two methods was 75.32
% which suggests a moderate level of agreement. In both analyses, patients in the
All High group were significantly younger and had a higher comorbidity profile, worse
MSAS subscale scores, and poorer QOL outcomes.
Computational tools that predict the course and severity of these symptoms have the
potential to assist oncology clinicians to personalize the patient’s treatment regimen
more efficiently and provide more aggressive and timely interventions. Three common
and inter-related symptoms in cancer patients are depression, anxiety, and sleep dis-
turbance. In our second experiment, we elaborate on the efficiency of Support Vector
Regression (SVR) and Non-linear Canonical Correlation Analysis by Neural Networks
(n-CCA) to predict the severity of the aforementioned symptoms between two differ-
ent time points during a cycle of chemotherapy (CTX). Our results demonstrate that
these two methods produced equivalent results for all three symptoms. These types
of predictive models can be used to identify high risk patients, educate patients about
their symptom experience, and improve the timing of pre-emptive and personalized
symptom management interventions.
Oncology patients undergoing cancer treatment experience an average of fifteen unre-
lieved symptoms that are highly variable in both their severity and distress. Recent
advances in Network Analysis (NA) provide a novel approach to gain insights into
the complex nature of co-occurring symptoms and symptom clusters and identify core
symptoms. In our third expirement, we present findings from the first study that used
NA to examine the relationships among 38 common symptoms in a large sample of
oncology patients undergoing chemotherapy. Using two different models of Pairwise
Markov Random Fields (PMRF), we examined the nature and structure of interac-
tions for three different dimensions of patients symptom experience (i.e., occurrence,
severity, distress). Findings from this study provide the first direct evidence that the
connections between and among symptoms differ depending on the symptom dimension
used to create the network. Based on an evaluation of the centrality indices, nausea
appears to be a structurally important node in all three networks. Our findings can
be used to guide the development of symptom management interventions based on the
identification of core symptoms and symptom clusters within a network.
Finally, we investigate the application of Bayesian Network Analysis (BNA) methods to
evaluate the relationships between symptoms in oncology patients receiving chemother-
apy (CTX). We compare 3 different types of BNA algorithms and describe the way that
BNA methods can be used to explore the interrelationships among cancer symptoms
in a large and representative sample of 1328 cancer patients undergoing chemotherapy
who reported the occurrence of 38 symptoms. We provide, also, a case study on two
different sub-populations of cancer patients, based on gender and age, and explain the
appropriate use of BNA for reproducible and reliable findings in future cancer symptom
studies . Last, we give an example of how conditional probabilities through BNA can
provide insights for the future occurrence of cancer patients’ symptoms, supporting this
way cancer care and possibly guiding the design of future intervention studies.
Overall, this PhD research has implemented and evaluated different machine learning
methods and algorithms to assess cancer patient risk profiles, predict cancer symptoms’
future values and understand the way and order that cancer symptoms interact between
them. Though machine learning, we introduce new methods and algorithms for the
design and implementation of cancer symptom analytical tools. The results of this
research have a significant impact both on the theoretical aspect as well as the clinical
aspect of Cancer Symptom Science.
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Chapter 1
Introduction
Cancer patients usually experience multiple symptoms. [1, 2, 3] According to the liter-
ature cancer patients experience an average of 11-13 concurrent symptoms. [3] While
many of these symptoms are the result of the disease itself, it is increasing acknowledged
that some of them (e.g., pain, fatigue, sleep disturbance, cognitive disfuction) can be
related also to the cancer treatments. [3, 4, 5] Depending on the age of patients and the
type of their cancer, this symptom burden can be associated, also, with various comor-
bidities (e.g., hypertension, osteoarthritis, hypothyroidism, diabetes, coronary artery
disease). [6, 7] Demographic characteristics and life-style factors may also affect them.
[8, 9, 10, 11, 12] Leaving these symptoms unrelieved can have deteriorating effects on
patients health related quality of life and functional status. [2] Their accumulation
onto the same patient creates a heavy symptom burden which could be related with
decreased functional performance, shorter survival and poor prognosis. [13, 14, 15]
In spite the fact that research on the prevalence, defining characteristics, and man-
agement of single symptoms has been extensive, the clinical reality necessitated that
scientists should begin to explore how these multiple co-occurring symptoms can be
assessed and treated in a systematic fashion. [16] As such, one important advancement
in the domain of cancer symptom research has been the identification and exploration
of Symptom Clusters (SCs), 18 years ago. [17] As symptom cluster we define a stable
group of concurrent symptoms that are related to one another and distinct from other
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groups of different symptoms. [18] The symptoms inside a cluster may be associated
through a common etiology or mechanism, shared variance, or a common outcome. [19]
Up until now there has been no agreement about the minimum number of symptoms
required to form a cluster; the main causes of their co-occurrence; their manifestations
patterns over time; they way that symptoms interact with each other separately as well
as how symptom clusters themselves influence each other. There has been no establish-
ment of a standardized way for recognizing these clusters, consistently, among studies
as well as in the clinical setting. An advancement of this kind would provide clinicians
the capability to identify high-risk groups of patient (at risk for more severe symptoms
and/or worse outcomes) in a timely manner and provide them pre-emptive clinical and
care support. [20]
It becomes apparent that as symptoms, and their clusters, are an important subset [21]
of patients’ Health Related Quality of Life (HRQOL) , [22] the collection, identification
and analysis of them, together with the rest of the factors that determine HRQOL, is
highly important both for cancer care [23, 24, 25, 26, 27] as well as cancer research.
[28, 29, 30] In the current clinical practice there are several different Patient Reported
Outcome Measures (PROMS) with different subsets of symptoms or patient related
outcomes collected. [31, 32] There are instruments collecting only specific symptoms,
instruments collecting a variety of different symptoms, as well as generic PROMS that
collect symptoms among other HRQOL factors. With the current broad use of Infor-
mation and Communication Technology (e.g., internet, smartphones), by the public,
there are several electronic data capture systems for cancer symptoms and PROMs as
well. [33, 34, 35, 36] The most common symptom dimensions measured are related to
their occurence, severity, and level of distress they may cause to cancer patients. [37]
Most of the current analyses on these data are done only on a subset of the various
symptom dimensions (e.g., occurrence, distress, severity). There are many different
approaches, both clinical and statistical, that are used [38, 18, 39, 40, 41, 42] without
a clear consensus on which ones performs better. These approaches, in overall, focus
either on grouping the symptoms together or profiling cancer patients based on the
number and type of symptoms they experience. [42] Because of the limited perspective
3of the analyses used so far, it has become apparent that the research domain of cancer
symptoms needs new analytic strategies and tools. [43, 43, 44] Exploiting in full range
these data, is becoming of higher importance as we have already started building in-
frastructure and accumulating a plethora of different types of data (e.g. genomic data,
[45, 46] nutritional information, [47] behavioural patterns through wearable devices,
[48] biomedical and/or enviornmental information through EMRs [49, 50, 51] and the
Internet of Things (IoT) [52, 53]) around cancer patients and their care.
According to the proceedings and recommendations from the workshop on ”Advanc-
ing Symptom Science Through Symptom Cluster Research” [43] increasing evidence
suggests that symptom clusters occur in patients with other chronic conditions (e.g.,
pulmonary, cardiac, and end-stage renal disease). A very limited number of studies
have explored whether SCs remain consistent across different statistical methodologies
and what the predictors and outcomes of SCs are. There is a limited understanding on
how to investigate symptoms and a growing need to develop new frameworks as well as
methods and approaches. Identifying an individual’s susceptibility to these symptom
clusters together with the driving/or sentinel symptom(s) inside these clusters is of
paramount importance. Finally, being able to recognize the overall mechanism that
underlie these symptom clusters is essential to developing targeted interventions to
support cancer patients.
In this thesis, novel approaches, methods and solutions have been carried out and eval-
uated. Representative Machine Learning (ML) algorithms for unsupervised learning,
also knows as clustering, have been implemented and assessed against the current gold
standard in the domain of cancer symptom clusters. Two different ML algorithms for
supervised learning have been realized and evaluated in order to demonstrate the an-
alytical value of such approaches for predicting future values of symptom scales along
the different chemotherapy stages. Network analysis has been applied and evaluated,
simultaneously, on three different symptom dimensions to assess how cancer symptoms
interact with each other, create different groups among these dimensions, and poten-
tially take different roles among these groups. Finally, the application and comparison
of indicative Bayesian Networks (BNs) algorithms on cancer symptoms provided an an-
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alytic case study of how symptoms’ interactions can be modeled into specific structures
with descriptive and predictive value as well. For each study presented in this thesis,
we present the clinical significance and implications as well.
1.1 Definitions of terms
Table 1.1 provides a list of the definitions of some common and general terms used in
this thesis.
Table 1.1: Definitions of terms
Term Definition
Symptom is a physical or mental feature which is regarded as indicating a
condition of disease, particularly such a feature that is apparent
to the patient.
Symptom
Clusters
consist of two or more symptoms that are related to each other
and that occur together. Symptom clusters are composed of
stable groups of symptoms, are relatively independent of other
clusters, and may reveal specific underlying dimensions of symp-
toms. Relationships among symptoms within a cluster should
be stronger than relationships among symptoms across different
clusters. Symptoms in a cluster may or may not share a common
etiology.
Functional
Status
is an individual’s ability to perform normal daily activities re-
quired to meet basic needs, fulfill usual roles, and maintain health
and well-being.
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Quality of Life according to the World Health Organisation (WHO) is defined
as an individual’s perception of their position in life in the con-
text of the culture and value systems in which they live and in
relation to their goals, expectations, standards and concerns. It
is a broad ranging concept affected in a complex way by the per-
son’s physical health, psychological state, personal beliefs, social
relationships and their relationship to salient features of their
environment.
Quality of
Care
is the degree to which health services for individuals and pop-
ulations increase the likelihood of desired health outcomes and
are consistent with current professional knowledge.
Symptom
Management
is the care given to improve the quality of life of patients who
have a serious or life-threatening disease. The goal of symptom
management is to prevent or treat as early as possible the symp-
toms of a disease, side effects caused by treatment of a disease,
and psychological, social, and spiritual problems related to a dis-
ease or its treatment. Also called comfort care, palliative care,
and supportive care.
Risk Factor is a characteristic, condition, or behaviour that increases the
likelihood of getting a disease or injury. Risk factors are often
presented individually, however in practice they do not occur
alone. They often coexist and interact with one another.
Risk Profile is a quantitative analysis of the types of threats an organization,
asset, project or individual faces. The goal of a risk profile is to
provide a non-subjective understanding of risk by assigning nu-
merical values to variables representing different types of threats
and the danger they pose.
Data Analytics is a generic term that refers to applying analysis and processing
methodologies to infer information and insights from data by
extracting numeric values, patterns and/or events.
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Unsupervised
Learning
is a type of machine learning algorithm used to draw inferences
from datasets consisting of input data without labeled responses.
Clustering is the task of grouping a set of objects in such a way that objects
in the same group (called a cluster) are more similar to each other
than to those in other groups.
Predictive
Modeling
Predictive modeling is the process of using known results to cre-
ate, process and validate a model that can be used to forecast
future outcomes.
Network Anal-
ysis
is the mathematical analysis of complex structures or procedures
in terms of a network of related components and their interac-
tions.
Graph is a structure amounting to a set of objects in which some pairs
of the objects are interelated. The objects inside a graph corre-
spond to mathematical abstractions called vertices (also called
nodes) and each of the related pairs of vertices is called an edge
(also called arcs).
Graphical
model
is a probabilistic model for which a graph expresses the condi-
tional dependence structure between random variables.
Directed
Acyclic Graph
(DAG)
is a finite directed graph with no directed cycles.
Markov Prop-
erty
refers to the memoryless property of a stochastic process. A
stochastic process has the Markov property if the conditional
probability distribution of future states of the process (condi-
tional on both past and present values) depends only upon the
present state, not on the sequence of events that preceded it.
Markov Ran-
dom Field
is a set of random variables having a Markov property described
by an undirected graph.
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Bayesian Net-
works
is a probabilistic graphical model that represents a set of vari-
ables and their conditional dependencies via a directed acyclic
graph (DAG).
1.2 Research Challenges
Symptom data are subjective in nature and they are usually collected in a longitudinal
fashion across different time points. They are collected through PROMs forms either
with likert or with numerical scales. [31, 32, 54] Because of the manual and repetitive
nature of the data collection process, several times there are several missing values
across the different dimensions. The number and type of symptoms may vary through
these various PROMs forms. [31, 32] This is relevant for the number of symptom
dimensions (e.g., occurerence, severity, distress, controlability, frequency) measured
and assessed as well. [54] Because of the relative youth of the domain of SCs in cancer
and the strict confidentiality issues around their data collection, the available symptom
datasets are few and rather small in size (e.g., 500 to 1200 patients).
The identification of a solid conceptual model around SCs has been difficult due to
the problematic assessment of the symptoms’ interrelationships. [54] Depending on the
type of PROM used (short or long), the symptom dimensions assessed, the number of
symptoms included in the statistical model, the analytic grouping method, the statis-
tical cutoff points to define SCs, and the time point when the symptoms were collected
and assessed the SCs composition, consistency, and stability has varied varied widely.
There is a need for new analytic approaches to identify, reliably and consistently, the
cross-sectional and temporal variability of symptom interrelationships across a patient’s
journey. [54] The aforementioned variability together with the lack of spotting how can-
cer symptom interact with each other both cross-sectionally as well as longitudinally
hinder the comparability and undermine the clinical utility of the concept of symptom
clusters.
It is noteworthy to mention that in order to complement symptom science research with
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the use of emerging ’omic’ methods the National Institutes of Health has already devel-
oped the National Institutes of Health Symptom Science Model (NIH-SSM). [55, 56, 57]
The main aim of NIH-SSM is to guide the recognition of potential targets for therapeu-
tic and clinical interventions. NIH-SSM is a sequential symptom research framework
consisting of the following steps: i) Identifying a symptom or a symptom cluster and
characterising these into distinct phenotypes; ii) determining which of the individuals’
data (e.g., demographic, biological, clinical, behavioral, environmental data) determine
this phenotype; iii) illuminate, through genomics and the rest of the -omics approaches,
[58, 59] potential biomarkers, [59] measures of normal biological processes, pathogenic
processes, or pharmacologic responses for this phenotype; [59, 60] 4) design and imple-
ment interventions to predict, prevent, and/or treat the patients’ symptoms.
Nevertheless, until such data is appropriately collected and linked together [61] we only
have symptom data collected from PROMs forms. There is a need to identify analytical
approaches and methods to take full advantage of the available data, depending on
their sample size, [62] on the ratio between expert-driven and data-driven effort that is
needed to create a clinical decision making solution, [63] as well as on the complexity
of structure of the accumulated data. [64] This will support the domain of symptom
clusters and symptom management research with further findings as well as useful
applications for clinical practise. Furthermore, it will provide important insights for
the future, aforementioned, directions.
A final challenge for symptom clusters research is related to the limitations of each cul-
ture of statistical modeling, meaning the data and algorithmic modeling. [65, 66, 64, 67]
In his seminal paper Breiman [65] explains that there are two cultures in the use of
statistical modeling to reach conclusions from data. One assumes that the data are gen-
erated by a given stochastic data model. The other uses algorithmic models and treats
the data mechanism as unknown. Depending on a variety of parameters concerning the
problem to be solved (e.g., sample size, assumption of linearity, number of variables,
the need to conceptualize the structure and importance of interactions among the pre-
dictive variables, interpretability of the analytic model) these two approaches could be
complementary and not adversarial. In the case of symptom clusters research where we
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have a lot of missing values, small sample sizes, a lack of a concrete conceptual model
and understanding of how cancer symptoms interact with each other, and how symp-
toms diversify along the cancer patient’s journey, these considerations should be taken
into account when selecting the clinical problem to solve and the analytic solution to
design and apply. For example, if a clinician needs a practical prediction rule to be
integrated in his daily clinical practise, the interpretability of the prediction rule may
not be the priority. [66] On the other hand, when clinical experts and researchers need a
conceptual and interpretable model to design more efficient and personalised symptom
management interventions, the selection of the analytic models should be taken with
this promise into account.
1.3 Research Objectives
The research challenges mentioned in section 1.2 indicate that the research and clinical
practise of cancer symptom clusters require new approaches for validating and extend-
ing the underlying theories as well as the clinical applications. More specifically, the
specific domain of research requires new methods for risk profiling cancer patients,
as well as predicting future cancer symptoms and their values. Furthermore, it re-
quires new approaches for understanding the complex and inter-nested nature and role
of cancer symptoms in order to drive self-management applications to more efficient
and personalized applications. The main research objectives pursued in this thesis are
summarized as follows.
• Objective 1: No studies were identified that evaluated for congruence between
two methods of classifying oncology patients based on their distinct experiences
with common symptoms associated with cancer treatment. We evaluated differ-
ent unsupervised learning (i.e., clustering) algorithms in comparison to the gold
standard (i.e., Latent Class Analysis (LCA)) for cancer symptom clusters re-
search. The aim was to evaluate the concordance between the number and types
of subgroups of patients with distinct symptom experiences.
• Objective 2: As a first study of its kind, we implemented and evaluated the use
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two different machine learning techniques (i.e., Support Vector Regression (SVR),
Non-linear Canonical Correlation Analysis by Neural Networks (n-CCA)) to ac-
curately predict the severity of three common symptoms (i.e., sleep disturbance,
anxiety, depression) from one week before to one week after the administration of
CTX. The aim was to assess whether these types of predictive models can be used
to identify high risk patients, educate patients about their symptom experience,
and improve the timing of pre-emptive and personalized symptom management
interventions.
• Objective 3: Using two different models of Pairwise Markov Random Fields
(PMRF), we examined the nature and structure of interactions for three different
dimensions of patients symptom experience (i.e., occurrence, severity, distress).
The aim was multifold: i) to provide an approach of explaining the interactivity
and role of cancer symptoms inside their clusters; ii) to provide a first evidence
that the connections between and among symptoms differ depending on the symp-
tom dimension used to create the network; iii) to provide insights that could be
used to guide the development of symptom management interventions based on
the identification of core symptoms and symptom clusters within a network.
• Objective 4: We implemented and evaluated the use of 3 different families of
Bayesian Network Analysis (BNA) algorithms on cancer symptoms. The aim
of this study was three-fold: i) we described how BNA methods can be used
to explore the interrelationships among 38 co-occurring symptoms in a large,
clinically relevantly, and representative sample of 1328 cancer patients undergoing
CTX; ii) we showed how these methods can be used appropriately to asses the
notable differences in the Bayesian Netowrks (BNs) created using gender and age
(i.e., <65 versus >65 years of age); iii) we explained how BNA can be used to
infer how symptoms interact with each other, supporting symptom management
care.
The overall scope of this thesis was to explore the application of the two different
approaches (i.e., data modeling, algorithmic modeling) of statistical modeling, with
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an emphasis on Machine Learning, on cancer symptom science and cancer symptom
clusters research. The aforementioned work introduced new analytic approaches on
the domain as well as new hypotheses regarding the symptoms interactions and their
relevant role inside and between each cluster. Its findings could provide support in
further research on the domain as well as applications inside the clinical practise.
1.4 Research Outcome
This thesis and its contributions have been published and presented in the following
Journals and Conferences.
1.4.1 Accepted Publications
• Papachristou, Nikolaos, et al. ”Comparing machine learning clustering with
latent class analysis on cancer symptoms’ data.” Healthcare Innovation Point-Of-
Care Technologies Conference (HI-POCT), 2016 IEEE. IEEE, 2016.
• Papachristou Nikolaos, Payam Barnaghi, et al. ”Congruence between latent
class and K-modes analyses in the identification of oncology patients with distinct
symptom experiences.” Journal of pain and symptom management 55, no. 2
(2018): 318-333.
• Nikolaos Papachristou, Daniel Puschmann, Payam Barnaghi, Bruce Cooper,
Xiao Hu, Roma Maguire, Kathi Apostolidis, Yvette P. Conley, Marilyn Hammer,
Stylianos Katsaragakis, Kord M. Kober, Jon D. Levine, Lisa McCann, Elisabeth
Patiraki, Eileen P. Furlong, Patricia A. Fox, Steven M. Paul, Emma Ream, Fay
Wright, Christine Miaskowski, ”Learning from Data to Predict Future Symptoms
of Oncology Patients”, PLoS ONE 13(12), 2018.
• Nikolaos Papachristou, Payam Barnaghi, Bruce Cooper, Kord M Kober, Roma
Maguire, Steven M Paul, Marilyn Hammer, Fay Wright, , Jo Armes, Eileen P Fur-
long, Lisa McCann, Yvette P Conley, Elisabeth Patiraki, Stylianos Katsaragakis,
Jon D Levine, Christine Miaskowski, ”Network Analysis of the Multidimensional
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Symptom Experience of Oncology”, Scientific Reports, Nature, volume 9, Article
number: 2258, 2019.
1.4.2 To be Submitted
• Nikolaos Papachristou, Payam Barnaghi, Sarah J. Allison, Christine Miaskowski,
”Bayesian Networks and Causal Inference for the Interpretation of Patients’
Symptom Experience.
1.5 Structure of thesis
This thesis is divided into 6 Chapters. Chapter 1 (Introduction) introduces some key
definition of terms used in this thesis and describes the research challenges, objectives
and outcome. Furthermore, a summarised list of scientific contributions has also been
presented.
Chapter 2 (Background) provides a short overview of the domain of cancer symptom
research. It explains what symptoms are and how they accumulate in symptom clusters.
It presents, also, how cancer symptom data are collected together with the main analytic
methods used upon them.
Chapter 3 (Grouping Cancer Patients by Their Symptoms) addresses the problem of
identifying a generally accepted analytic method for the identification of distinct symp-
tom profiles among oncology patients. The chapter presents the comparison of different
analytic approaches on risk profiling cancer patients based on their symptom experi-
ence. It reports a secondary analysis on cancer symptom data, evaluating the con-
cordance of the best candidate (i.e., K-modes), out of five different Machine Learning
(ML) clustering algorithms, with Latent Class Analysis (LCA).
Chapter 4 (Predicting Future Values of Cancer Symptoms) addresses the problem of
predicting future values of cancer symptoms across the chemotherapy stages. The
chapter presents the efficiency of Support Vector Regression (SVR) and Non-linear
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Canonical Correlation Analysis by Neural Networks (n-CCA) to predict the severity
of three common and inter-related cancer symptoms (i.e.,depression, anxiety, sleep
disturbance) between two different time points during a cycle of chemotherapy (CTX).
Chapter 5 (Identifying Cancer Symptoms Clusters and Sentinel Symptoms with Pair-
wise Random Markov Fields) addresses the problem of analysing the interactivity
among cancer symptoms and between their symptom clusters. Using two different
models of Pairwise Markov Random Fields (PMRF), the chapter presents the nature
and structure of interactions for three different dimensions of patients symptom expe-
rience (i.e., occurrence, severity, distress). Findings from this study provide the first
direct evidence that the connections between and among symptoms differ depending
on the symptom dimension used to create the network.
Chapter 6 (Bayesian Networks and Causal Inference for the Interpretation of Cancer
Symptom Experience) provides further information for the interactivity among can-
cer symptoms, by the exploration of the use of Bayesian Network Analysis on cancer
symptoms. The chapter describes how BNA methods can be used to explore the inter-
relationships among 38 co-occurring symptoms. It provides, also, a case study of how
these methods can be used appropriately for reproducible research, presenting the com-
parison of their application in different groups of cancer patients based on their gender
and age (i.e., <65 versus >65 years of age). This chapter is accompanied with online in-
teractive diagrams. With the use of BNA probability inference such diagrams could be
used in monitoring cancer patients in clinical care as well as to guide the development
and testing of future intervention studies to improve symptom management.
Chapter 7 (Conclusions and Future Work) summarises the outcome of this research.
An outlook for future work is presented, and a discussion on the possible extension of
our current work has also been provided.
14 Chapter 1. Introduction
Chapter 2
Background
In this chapter, we provide a short introduction to the evidence and theory behind
cancer symptoms and cancer symptom clusters. We present the conceptual hypotheses
behind their manifestations, the approaches by which they are observed, as well as the
analytic methods with which they are analysed and conceptually explored. We discuss
their importance in cancer care together with the limitations of current research.
2.1 What is a symptom?
A symptom is defined as a subjective experience related to changes in the biopsychoso-
cial functioning, sensations, or cognition of an individual. [68, 69] In contrast, a sign is
defined as any abnormality indicative of disease that is detectable by the individual or
by others. Both signs and symptoms are important cues that can support the diagnosis,
treatment and self-management of patients. Ideally, patients should be educated about
the importance of signs and learn to identify them until their meaning and relationship
to an underlying cause is properly evaluated. [68] The fact that symptoms could be
monitored and collected cost-effectively every day makes them an indispensable health
indicator for cancer research.
With the term ”symptom experience” we mean an individual’s perception of a symp-
tom, assessment of the meaning of this symptom and response to this symptom. [68]
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Perception of symptoms refers to whether an individual notices a change from the way
he or she usually feels or behaves. People evaluate their symptoms by making judge-
ments about the severity, cause, treatability and effects on their lives. Responses to
symptoms include physiological, psychological, sociocultural and behavioural compo-
nents. Understanding the interaction of these components of the symptom experience
is essential if symptoms are to be effectively managed. [68]
The symptoms that cancer patients experience may persist for weeks, months, or years
and may get worse, even when the cancer gets better. [70] These symptoms diminish
quality of life in a notable manner as they can limit vocational activity and inhibit
interpersonal and social recovery. Nevertheless, some types of cancer and types of
patients can be managed much like other serious chronic disease. [71] In order to do
so a patient needs to extend its treatment for many years together with the frequent
monitoring and managing of treatment and lifestyle related symptoms. [69] The ability
to prevent, control and self-manage these symptoms could be of crucial benefit to
thousands of cancer patients, as well as cancer survivors. [69, 23, 72]
As we have already mentioned symptoms may affect a cancer patients quality of life,
even the disease prognosis. Cancer-related symptoms can affect a patients quality of
life to a significant extent, hindering an individuals ability to function, accumulatively
producing a symptom burden upon the patient that can be considered as the subjective
equivalent of the tumor burden caused by the disease to the human body. Multiple
symptoms may occur together and may influence the severity of one another (e.g.,
pain is often connected with affective disturbance, sleep problems, complications with
concentration, and fatigue). Although cancer-related symptoms are well known to be
causing an important level of distress to cancer patients, we still know few things about
the mechanisms that contribute to the emergence of these symptoms. Identifying the
correlations and causal mechanisms between symptoms and the various different types
of cancer, therapies and lifestyles is very important for cancer care.
Insights from animal models suggest an underlying common mechanism behind these
co-occurring symptoms. [73, 74, 75, 76] Connecting insights from animal models to-
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gether with data from human trials may give us a better understanding of these mecha-
nisms. Durie et al. [77] recommended that the ultimate goal of every cancer treatment
should be to achieve a clinical response that offers the best quality of remission for the
longest period. Research around symptoms may help us create new treatment and self-
management protocols that can reduce the symptom burden, even improve the diseases
prognosis. This is extremely necessary for cancer patients with incurable cancer, where
survival time may be extending at the expense of intolerable symptoms. With symp-
tom science research we have the opportunity, in parallel with the development of new,
targeted therapies, to identify pathways to reduce the burden of chemotherapy-related
side effects while the disease control and the patients quality of life improves.
2.2 Cancer symptom clusters
Unrelieved symptoms may result in non-compliance and interruption of treatment, [78]
reduced functioning in everyday life, [68] or inferior quality of life. [79] Symptom
clusters research aims to elaborate on the causes, experiences, and consequences of
the multiple co-occuring symptoms related to cancer. The initial conceptualisation
of a symptom cluster included three or more co-occurring symptoms, [68] where co-
occurring symptoms did not need to be related (e.g., hair loss and constipation). It
was considered that co-occurring symptoms could act synergistically and affect nega-
tively important patient outcomes such as the functional status. A newer review of
the concept re-defined the definition of a symptom cluster as follows: A symptom clus-
ter consists of two or more symptoms that are related to each other and that occur
together. Symptom clusters are composed of stable groups of symptoms, are rela-
tively independent of other clusters, and may reveal specific underlying dimensions of
symptoms. Relationships among symptoms within a cluster should be stronger than
relationships among symptoms across different clusters. Symptoms in a cluster may or
may not share a common etiology. [18]
While symptoms inside the same cluster may share a common etiology (e.g., anorexia,
diarrhoea, and nausea may be related with a gastrointestinal tumour or chemotherapy),
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they may not share a mutual biologic mechanism. [76] To the contrary, symptoms in-
side the same cluster may have different etiologies (e.g., pain from bone metastasis,
fatigue from treatment, depression from family problems), but have a common biolog-
ical mechanism. [76] The understanding around the field becomes significantly more
complex if we consider that carious psychological, social, and environmental factors can
also affect how symptoms are experienced.
If the clinical hypothesis of mutual causes of multiple symptoms in cancer patients
stands true, then identifying their physiological, psychological, behavioural, or bio-
logical mechanisms could help to distinguish these clusters more effectively. [76, 80]
Demystifying these causes, underlying mechanisms and interactions could result in op-
portunities for new clinical interventions. Where common mechanisms do exist, there
is a probability that treating one symptom in a cluster may relieve other related symp-
toms in the same cluster, result in condensed treatment needs and enhanced patient
outcomes. [81, 82] Contrariwise, the same approach may contribute in identifying
symptom interventions which worsen other symptoms, or create new symptoms as side
effects. Until we can have availability of multi-modal symptom clusters related data
(i.e., diagnostic images, omics’ data, biomarkers, demographic, social administration
and clinical data, behavioral and environmental data) around the same group of cancer
patients, a multi-view exploration of cancer symptom clusters could begin from the
different dimensions (e.g., occurrence, severity, distress) that these symptoms manifest
in each cancer patient.
It is quite clear from the literature that symptom clusters can influence patient out-
comes. The large number of co-occuring symptoms that cancer patients experience are
distressing not only for the patients but for the families as well. The symptom burden
that these clusters impose can negatively impact the patients’ daily life activities, phys-
ical and mental functionality, as well as their Health Related Quality of Life (HRQOL).
[83, 84, 85] Symptom clusters research may offer new guidance in the assessment and
management of these multiple symptoms. As symptoms may be caused and influenced
by many different factors, an individual faces many problems managing the symptom
experience. While the pathophysiological mechanisms of many cancer-related symptom
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remain unknown, we ought to focus on controlling symptoms and reducing their effect.
2.3 Cancer symptom measurement
Although symptoms are based on complex biological and behavioral factors, because
of their subjective nature their measurement is typically restricted to self-report forms.
[69] These form collect the patients’ stated sensation or perception of how their normal
function is disturbed by the disease itself or by its treatment. Because symptoms can
be collected and observed only though the patient’s subjective report, it is by definition
a Patient Reported Outcome (PRO).
Symptom reports are a subset of a larger domain of patient perceptions about health
status referred to as Health Related Quality of Life (HRQOL). [69] HRQOL itself is a
multidimensional construct comprising from at least four dimensions:
• physical function (e.g., daily activities, self care),
• psychological function (e.g., emotional or mental state, mood),
• social role function (e.g., social interactions, family dynamics),
• disease related or treatment related symptoms (e.g., pain, nausea).
Symptoms can be viewed as the patient report closest to the physical and psychological
perceptions of the disease process and the immediate effects of treatment on these
perceptions. [69, 86] It is noteworthy to mention here that self-reported symptoms are
internal bodily and mental states that we cannot know in an objective manner, like
height or weight. Because of this subjectivity, the measurement of symptoms depends
on the science of psychometrics, which measures the precision of symptoms’ self-reports.
[69]
Up until now, there are several symptom measurement instruments differing in the num-
ber and dimensions of symptoms collected, measuring scale, timeframe of assessment,
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and validity. [31] Regarding their content these instruments can differ in the number,
type of symptoms (e.g., physical or psychological) and additional information collected
(e.g., activity, symptom interference with daily life, family anxiety, and depression).
[31] They differ, also, regarding the use of numerical (e.g., 0-3) or verbal scales (e.g.,
”Yes”/”No”, none/mild/moderate/severe), or even visual analog scales. This variation
in response-option format, in particular, produces measurement errors across studies
and it is one of the main reasons that many of these instruments are still unvalidated.
[31, 69]
The most common symptom dimensions captured with the aforementioned scales are
prevalence (i.e., occurrence), severity and distress. Frequency and duration are less
frequently reported except in instruments for treatment toxicity. [31] Cancer patients
are asked to record and report their symptom experience across different timeframes.
These timeframes can vary from ”at present time” to ”weeks”. [31] Depending on their
research or clinical purpose they vary also on their length. Some of them have a shorter
form, with fewer symptoms and dimensions collected, making them more practical to
be completed by patients due to their small time to completion. [31] Most of these
symptom measurement instruments are designed for patient self-assessment or assisted
self assessment. [31] However, with the use of healthcare technology cancer symptom
related self-report instruments can now be administered and collected not only via
paper form but also through the internet and mobile apps. [33, 34, 87, 35, 36]
2.4 Analytical approaches for cancer symptom clusters
The observation that cancer patients usually experience multiple disease- and treatment-
related symptoms has prompted the exploration of symptom clusters. In the literature
of cancer symptom clusters research, there are two main conceptual approaches to
identify and evaluate the impact of multiple symptoms on cancer patients. [42] The
first approach entails the identification of separate symptom clusters in patients with
cancer. The second approach involves the identification of different subgroups of on-
cology patients based on their experiences with a specific symptom cluster. The latter
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approach allows further analysis to assess whether these subgroups of patients differ on
important clinical outcomes.
Correlation analysis was the first method to explore a symptom cluster and its conse-
quences. [38] Based on clinical expertise or theoritical knowledge researchers selected
a possible cluster explored it using correlation among symptoms. [17, 38] Correla-
tion analysis examines the covariation of two symptoms with the correlation coefficient
quantifying its direction and strength. As one of its forms, partial correlation can be
used to quantify the residual relationships between two symptoms after controlling for
the other variables in the dataset. In general, correlation methods can provide an ana-
lytical assessment of a selected cluster, but they have limitations when symptoms have
complex interrelationships. [38, 39]
In order to identify symptom clusters, according to the aforementioned first conceptual
approach, factor analysis has been frequently used in oncology. [38, 40, 41] Factor
analysis explains the observed associations among many variables by using unobserved
variables, which are called factors. Its main assumption lies on the hypothesis that the
linear combinations of some unknown source variables create the observed variables.
Common factors are the common underlying sources for multiple observed variables
and thus, induce correlations among variables. [88, 38] By identifying these common
factors, the relationships that underlie a set of observed variables can be recognised.
For example, when two or more symptoms share one common factor they are considered
to form a symptom cluster. In contrast to correlation analysis, factor analysis can be
useful when complex relationships among many symptoms may exist. On the other
hand, its limitations include the subjectivity in determining the final solution, the need
for a large sample, and the need for specialized approaches for categorical data. [38]
Principal Component Analysis (PCA) is another method used to create symptoms
clusters. [38, 40, 41] PCA assumes that all variances of a set of variables can be
summarized into components. A component is simply a combination of correlated
variables whereas a common factor induces correlations among observed variables. [88,
38, 40] PCA and factor analysis seem similar as both approaches result in a smaller
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number of dimensions from the initial set of analysised items (i.e., symptom indicators).
Nevertheless, their proper use depends on the purpose of the analysis, as well as the
theoretical assumptions around the relations of the analysed symptoms. [89, 38] PCA
makes no assumptions about the relations among the variables. It is useful to reduce a
large number of variables to a smaller, more manageable number, especially when we
have sample size. Furthermore, it is effective when symptoms are minimally correlated.
On the other hand, factor analysis is useful when there is a conceptualized common
variable that might underlie several observed symptoms. Factor analysis is likely to
yield poor results when indicators are not well correlated, as that suggests that no
common factor exists. In practise, on the same sample PCA and factor analysis yield
different symptom clusters due to the small number of symptoms and low correlation
levels among these symptoms [15,20]. [90]
Cluster analysis is a method used to separate symptoms into homogeneous subgroups
based on the relative similarities among them. [90, 38] These subgroups, which are
referred to as clusters, are statistical terms and should be differentiated from the con-
ceptual term of symptom cluster used in cancer symptom research. Clustering analysis’s
goal is to create mutual exclusive subgroups, with symptoms belonging to only one clus-
ter. Cluster analysis can be used for both of the conceptual approaches used in cancer
symptoms research, meaning grouping symptoms or patients together. Regarding the
first approach, cluster analysis has the advantage of enabling the assessment of a large
number of symptoms items with limited sample size. Nevertheless, the final solution
needs subjective assessment and handling of missing data can be tedious. [90, 38]
Regarding grouping cancer patients together based on their symptom experience, the
groups identified cannot be guaranteed to exist in patients. [38] Identifying cancer pa-
tients who experience a particular cluster, which is a specific phenotype of symptom
experience, can be further used to identify the outcomes of this phenotype as well as
the biological, clinical and environmental factors characterising the patients belonging
to this phenotype.
Latent class analysis (LCA) is a rather new and most commonly used method for
grouping patients in oncology. [38] It has similarities with cluster analysis but its use is
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limited to patient risk profiling. In a similar fashion with factor analysis, LCA assumes
there is a latent nominal variable categorizing patients into subgroups. Each of these
latent nominal variables summarizes the correlation between symptoms and represent
the nature of the subgroups. LCA uses an iterative process through the expectation
maximization algorithm to find the best solution. Theoretically, it provides stronger
model fit statistics than cluster analysis. [38] On the other hand, as LCA may involve
several subjective decision-making steps (e.g., cut-off points for subgroups) in the anal-
ysis and in determining the final solution its use needs careful model construction and
selection. [91] The main difference between LCA and factor analysis lie in the nature
and distribution of the latent variable. [92] In LCA the latent variable is categorical
with multinomial distribution, whereas in factor analysis the latent variable is contin-
uous with normal distribution. According to Ruscio et al. [93] we define categogical
latent variables as these in which ”qualitative differences exist between groups of people
or objects” and continuous or dimensional latent variables as these in which ”people or
objects differ quantitatively along one or more continua”. [92]
Although there are several advancements in the conceptualization and evaluation of
cancer symptom clusters through the aforementioned analytic methods, a number of
areas justify further analyses to advance the conceptual knowledge on the domain. [43]
According to the recommendations from the workshop on Advancing Symptom Science
Through Symptom Cluster Research [43] the future directions for symptom cluster
research lie in the following five areas:
• Defining the characteristics of symptom clusters
• Exploring the underlying mechanisms and prioritising symptom clusters
• Solving the relevant problems to the measurement of symptoms clusters
• Designing and implementing targeted interventions
• Designing and applying new analytic strategies
As one of the most important clinical and analytic problems to be solved, the presence
of symptom clusters seem to deteriorate patient outcomes in comparison with a single
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symptom. In some studies, the symptom cluster of pain, fatigue, sleep disturbance and
mood disturbance resulted in statistically significant decrements in patients functional
status and QOL. [43, 94, 95, 96] Furthermore, there is a small amount of evidence
suggesting that treating one symptom may ”cross-over” and reduce the severity of
the other symptoms included in the same cluster. [97] The analytic identification and
description of this complex relationship between and among symptoms within a cluster,
could provide new targets for interventions to reduce the negative impact of multiple
co-occurring symptoms on patient outcomes.
2.5 Summary
Symptom data are subjective in nature. Cancer patients usually suffer from multiple
symptoms, which can be categorised in distinct groups called symptom clusters. The
data that is related to these symptoms and their symptom clusters are collected through
various self-reporting forms. The number, type, scale, dimensions and timeframe of the
collected symptom data may vary. Variation can exist, also, on the analytic methods
that are used upon these symptom data. In general, there are two main conceptual
analytic approaches. One grouping symptoms together and the other grouping cancer
patients between them. Designing and applying new analytic strategies is a major
priority for symptom cluster research. Explaining the pattern by which symptoms
appear in time, as well as how they interact with each other, in order to identify
new targets for symptom management interventions is an important problem to solve
through these analytic strategies.
Chapter 3
Grouping Cancer Patients by
Their Symptoms
In this chapter, we discuss and evaluate the current analytic approach of risk profiling
cancer patients based on their symptom experience. Findings suggest that oncology
patients with distinct symptom profiles can be identified using a variety of analytic
methods. Nevertheless, there is not a consensus on which method performs better.
Identifying a generally accepted analytic method is important in order to be able to
utilize and process all the available data. We report a secondary analysis on cancer
symptom data, comparing the performance of five Machine Learning (ML) clustering
algorithms in doing so. Based on how well they separate specific subsets of symptom
measurements we select the best candidate. Finally, we proceed to evaluate the concor-
dance between the number and types of subgroups of patients with distinct symptom
profiles using latent class analysis (LCA) and K-modes analysis.
3.1 Introduction
Both clinical experience and research findings suggest that oncology patients experience
significant interindividual variability in their symptom experience. [98, 99] In the era
of precision medicine, [100] which focuses on the identification of patients who are at
greater risk for chronic conditions like cancer, it is imperative to identify the optimal
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methods to risk profile patients based on their symptom burden. In two reviews of the
state of the science in symptom clusters research, [101, 43] it was noted that future
studies need to focus on an evaluation of the concordance between the various analytic
methods that can be used to identify patients who are at greatest risk for a higher
symptom burden.
Recent findings [102, 103, 104, 105, 106, 107, 108, 109] have identified subgroups of
patients with distinct symptom experiences using approaches like Hierarchical Cluster
Analysis (HCA) and Latent Class Analysis (LCA). In the earliest of these studies,
[102, 106, 109] cluster analysis was used to create the patient subgroups. In the later
studies, [104, 105, 110] LCA was the preferred statistical approach. While across these
thirteen studies, the number of subgroups ranged from two to five, a common finding
across all of these studies was the identification of a group of patients who reported
low levels of symptoms and a group of patients who reported high levels of symptoms.
However, none of these studies determined whether the use of two different analytic
approaches produces congruent results (e.g., the percentages of patients in the all high
groups are equal and are the same patients).
As noted in a recent review, [43] machine learning techniques may provide useful ap-
proaches to identify subgroups of patients with distinct symptom profiles. Some specific
machine learning techniques that can be used for this purpose include: K-means, [111]
K-modes, [112, 113] Spectral Clustering, [114] Birch, [115] or Agglomerative Hierar-
chical Clustering (AHC). [116, 117] For binary variables (e.g., symptom occurrence),
K-means and K-modes are two centroid based algorithms that calculate the distance
between each pair of data points using Euclidean distance or a dissimilarity measure,
respectively. The clusters derived from K-means and K-modes analyses are described
by the centroid, which is the multidimensional mean and mode, respectively, of the
samples inside them. [111, 113] Spectral clustering is a graph distance based algorithm
that performs a dimensionality reduction before clustering the lower-dimension dataset
in a similar fashion to K-means. It is used when the clusters are not linearly separated
in the original space, providing better results than algorithms such as K-means (which
tends to find spherical clusters). [118] Birch is a hierarchical clustering algorithm that
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can provide an advantage in datasets that are non-uniformly distributed and every
data point is not equally important. It concentrates on densely occupied partitions
and follows a hierarchical order of analysis that focuses on calculating and updating
measurements that capture the natural closeness of data. Therefore, it is more robust
to noise (i.e., data points that are not part of the underlying pattern). [115] Finally,
AHC is a decision tree, bottom-up clustering method that starts with every single data
point in a single cluster. In each successive iteration, it agglomerates (merges) the clos-
est pair of clusters by satisfying a similarity criterion, until all of the data are in one
cluster. A matrix tree plot visually demonstrates the hierarchy within the final cluster,
where each merger is represented by a binary tree. AHC can be both informative for
data display and helpful for the discovery of smaller clusters. [116]
No studies were identified that evaluated for congruence between two methods of clas-
sifying oncology patients based on their distinct experiences with common symptoms
associated with cancer treatment. Drawing insights from the secondary analysis of past
collected cancer symptoms data [119, 120] this study provides an evaluation of different
ML algorithms in contrast to LCA. Based on how well the machine learning methods
described above perform during our initial analyses, [121] K-modes was selected as
the method to compare with LCA. The purpose of this study, in a sample of patients
(n=1329) who were undergoing chemotherapy (CTX) for breast, lung, gastrointestinal
(GI), or gynecological (GYN) cancers was to evaluate the concordance between the
number and types of subgroups of patients with distinct symptom experiences that
were identified using LCA and K-modes analyses. We hypothesized that the number
and types of subgroups would be similar using these two analytic methods.
3.2 Methods
Patients and Settings
According to the studys eligibility criteria: patients were 18 years of age; had a diagnosis
of breast, GI, GYN, or lung cancer; had received CTX within the preceding four weeks;
were scheduled to receive at least two additional cycles of CTX; were able to read,
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write, and understand English; and gave written informed consent. Patients were
recruited from two Comprehensive Cancer Centers, one Veterans Affairs hospital, and
four community-based oncology programs.
3.2.1 Instruments
A demographic questionnaire obtained information on age, gender, ethnicity, marital
status, living arrangements, education, employment status, and income. The Karnof-
sky Performance Status (KPS) scale [122] was used to evaluate patients functional
status. The Self-administered Comorbidity Questionnaire (SCQ) [123] evaluated the
occurrence, treatment, and functional impact of thirteen common comorbid conditions
(e.g., diabetes, arthritis).
A modified version of the Memorial Symptom Assessment Scale (MSAS) was used to
evaluate the occurrence, severity, frequency, and distress of 38 symptoms commonly
associated with cancer and its treatment. In this study, six symptoms were added
to the original list of 32 MSAS symptoms (i.e., hot flashes, chest tightness, difficulty
breathing, abdominal cramps, increased appetite, weight gain). The MSAS is a self-
report questionnaire designed to measure the multidimensional experience of symptoms.
Patients were asked to indicate whether or not they had experienced each symptom in
the past week (i.e., symptom occurrence). If they had experienced the symptom, they
were asked to rate its frequency of occurrence, severity, and distress. The reliability
and validity of the MSAS is well established in oncology patients. [124, 125]
Three subscale scores (i.e., physical [MSAS-PHYS], psychological [MSAS-PSYCH],
global distress index [MSAS-GDI]) were calculated. The MSAS-PHYS is the aver-
age of the frequency, severity, and distress ratings for twelve physical symptoms (i.e.,
lack of energy, feeling drowsy, pain, nausea, vomiting, change in the way food tastes,
lack of appetite, dry mouth, constipation, feeling bloated, dizziness, and weight loss).
The MSAS-PSYCH is the average of the frequency, severity, and distress ratings for six
psychological symptoms (i.e., worrying, feeling sad, feeling nervous, feeling irritable,
difficulty in sleeping, difficulty concentrating). The MSAS-GDI is the average of the
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distress ratings for six physical symptoms (i.e., lack of energy, feeling drowsy, pain, lack
of appetite, dry mouth, constipation) and the frequency ratings for four psychological
symptoms (i.e., worrying, feeling sad, feeling nervous, feeling irritable).
Quality of life (QOL) was evaluated using disease-specific (i.e., Quality of Life Scale-
Patient Version (QOL-PV)) [126, 127, 128] and generic (i.e., Medical Outcomes Study-
Short Form-12 (SF-12)) [129] measures. The QOL-PV is a 41-item instrument that
measures four dimensions of QOL (i.e., physical, psychological, social, and spiritual
well-being) in oncology patients, as well as a total QOL score. Each item is rated on
a 0 to 10 numeric rating scale (NRS) with higher scores indicating a better QOL. The
QOL-PV has established validity and reliability. [128, 130, 131, 132]
The SF-12 consists of 12 questions that evaluate physical, mental, and overall health
status. Individual items on the SF-12 are evaluated. In addition, the instrument
is scored into physical component summary (PCS) and mental component summary
(MCS) scores. These scores can range from 0 to 100. Higher PCS and MCS scores
indicate a better QOL. The SF-12 has well established validity and reliability. [129]
3.2.2 Data Analyses
3.2.3 Dataset
We used two similar datasets, named as N1 and N2, consisting of n1=582 and n2=1329
full patient registry records, respectively. Our initial analysis entailed the exploratory
use of five different clustering algorithms on the aforementioned datasets. Their respec-
tive performances were compared against each other and the algorithm with the best
overall performance was selected for further analyses and comparison with the LCA
method applied to the dataset N2.
3.2.4 Comparing Machine Learning clustering algorithms
Data was analysed using algorithms developed in PyCharm Professional Edition 4.5
and the Scikit-Learn library [133]. We explored dataset N1 (n1 samples x M features)
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utilizing different subsets from it (n1 samples x m features; m ≤M).
Following the criterion used for LCA on similar datasets in previous analyses [119, 120],
we divided our dataset in 2 different subsets. We used the MSAS symptoms that
occurred at least in 30% (subset A = 25 Symptoms) and 40% (subset B = 15 Symptoms)
of the patients. We ran our analysis only on the occurrence measurements of these
symptoms, which take two discrete values “Yes” or “No”.
During this initial analysis, we utilised both subsets and ran analyses with five different
clustering algorithms (k-Means, Birch, Spectral-Clustering, Hierarchical Agglomerative
Clustering and k-Modes) Following the LCA analysis on similar datasets, we preset the
number of clusters to three and four in two distinct clusterings (3 for subset A, 4 for
subset B). [119, 120]
We used k-Means [111] which is a centroid based algorithm, clustering the samples into
k groups of equal variances. These clusters are described by the mean of the samples
inside them, which is called the cluster “centroid”. k-Means aims at choosing centroids
that minimise the within-cluster sum-of-squares distance. Spectral-Clustering [114]
aims to cluster data that is connected but not necessarily compact or clustered within
convex boundaries. It is used when the clusters are not linearly separated in the original
space, providing better results than algorithms such as k-Means. In such occasions
hierarchical clustering or density based methods may also provide better results.
Birch [115] is a hierarchical clustering algorithm which can provide an advantage in
datasets which are non-uniformly distributed and every data point is not equally im-
portant. It concentrates on densely occupied partitions and following a hierarchical
order of analysis focuses on calculating and updating measurements that capture the
natural closeness of data. Therefore, it is more robust to “noise” (data points that are
not part of the underlying pattern). Agglomerative hierarchical clustering is a bottom-
up clustering method starting with every single data point in a single cluster. In each
successive iteration, it agglomerates (merges) the closest pair of clusters by satisfying
some similarity criteria, until all of the data is in one cluster. A matrix tree plot visually
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demonstrates the hierarchy within the final cluster, where each merger is represented
by a binary tree. Agglomerative hierarchical clustering can produce an ordering of the
objects, which may be informative for data display. Furthermore, smaller clusters can
be generated, which may be helpful for discovery.
Finally, k-Modes [112, 113], is used for clustering observations based on categorical
variables. In comparison to k-Means it defines clusters based on the number of match-
ing categories between data points and not on the Euclidean distance. It is considered
a more appropriate solution for clustering categorical variables than k-Means. Its dif-
ferences with k-Means lie on using a matching dissimilarity measure instead of the
Euclidean distance between data points, replacing means of clusters by modes and us-
ing a frequency-based method to find the underlying modes for the final clusters of
data points [113].
3.2.5 Evaluating Machine Learning clustering algorithms
The identified clusters were evaluated by their Silhouette Coefficient Index (SCI) [134],
in combination with the Jaccard similarity coefficient [135].
The Jaccard similarity coefficient is used to compare both the similarity and diversity
of sample sets. It calculates similarity between fixed sample sets, and is defined as the
size of the intersection divided by the size of the union of the sample sets.
J(A,B) =
|A ∩B|
|A ∪B| =
|A ∩B|
|A|+ |B| − |A ∩B| (3.1)
On the other hand, the Silhouette Coefficient is calculated using the mean intra-cluster
distance “a” and the mean nearest-cluster distance “b” for each sample. The Silhouette
coefficient for a sample is:
b− a
max (a, b)
(3.2)
Where “b” is the distance between a sample and the nearest cluster that the sam-
ple is not a member of. Silhouette coefficient is defined only if the number of labels
constrained is:
2 ≤ nlabels ≤ nsamples − 1 (3.3)
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The score is bounded between -1 for inappropriate clustering and +1 for highly compact
clustering. Scores around zero indicate overlapping clusters. In general the score is
higher when clusters are dense and well separated.
3.2.6 Comparing k-Modes with Latent Class Analysis
After evaluating the ML clustering methods to identify the one(s) with the best perfor-
mance, we proceeded with a second analysis comparing symptom clusters made with
k-Modes and LCA. For our purpose, we used dataset N2. LCA and k-Modes were used
to evaluate whether they could produce comparable findings. As our “gold” standard
we used a recent study by Miaskowski et al. [119] where 4 distinct groups of patients
were identified among cancer patients. In order to have a sufficient number of patients
who endorsed each symptom, the LCA and K-modes analyses were done with the 25
symptoms that occurred in > 30% of the patients (i.e. difficulty concentrating, pain,
lack of energy, cough, feeling nervous, hot flashes, dry mouth, nausea, numbness or
tingling in hands or feet, feeling drowsy, difficulty sleeping, feeling bloated, diarrhea,
feeling sad, sweats, problems with sexual interest or activity, worrying, lack of appetite,
dizziness, feeling irritable, hair loss, constipation, change in the way food tastes, I do
not look like myself, changes in skin).
LCA identifies latent classes based on an observed response pattern. [92, 136] It is a
statistical method for finding subtypes of related cases (i.e., latent classes) from mul-
tivariate categorical data. The LCA was performed using MplusTM Version 7. Esti-
mation was carried out with robust Maximum-Likelihood (MLR) and the Expectation-
Maximization (EM) algorithm. [137] The optimal number of latent classes for this
LCA was selected based on the Bayesian Information Criterion (BIC), the Vuong, Lo,
Mendel, and Rubin (VLMR) likelihood ratio test, and entropy. Theoretically, the best
fitting LCA model has the lowest BIC. Nevertheless, the BIC can be supplemented
by an evaluation of the VLMR [138] which tests whether a model with K classes fits
the data better than a model with one fewer class (the K-1 class model). When this
VLMR is significant, the K-class model is considered to be a better fit for the data.
When models are evaluated sequentially, with each new model having one more class
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than the previous model, if a model is identified for which the VLMR is not significant,
then too many classes were extracted and the K-1 class model is considered to fit the
data better than the current K-class model. Furthermore, well-fitting models produce
entropy values of > 0.80. [139] In addition, the optimal fitting model should make sense
conceptually and its classes should differ as might be expected on variables not used in
the generation of the model.
As already mentioned, K-modes is a centroid method that is optimized for use with
categorical variables. Although its performance is comparable to K-means, the K-
modes distance measurement approach is theoretically a more appropriate approach to
use to cluster the categorical variable of symptom occurrence. The K-modes analysis
was implemented with PyCharm Professional Edition 4.5 and the Scikit-Learn library.
3.2.7 Evaluating the congruence between the LCA and K-modes
The optimal number of clusters for the K-modes analysis was assessed using the average
Silhouette Coefficient Index (SCI) which represents how well each case (i.e., patient)
lies within its cluster and how appropriate each cases assignment is inside a specific
cluster.
In order to evaluate the congruence between the LCA and K-modes solutions (i.e.,
number of subgroups identified), we compared the solutions using SCI diagrams. When
the SCI for a case is > 0, its assignment to this cluster is considered appropriate.
When the SCI for a case is < 0, this case may have equal similarities with cases in
another, overlapping cluster and its assignment inside a specific cluster may not be
an appropriate fit. In addition, Cohens kappa coefficient was used to evaluate the
agreement between the two analytic approaches.
3.2.8 Differences in Demographic, Clinical, and Symptom Character-
istics and QOL Outcomes
Descriptive statistics and frequency distributions were calculated for demographic and
clinical characteristics using SPSS version 23 (IBM, Armonk, NY). For each analytic
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approach, differences in demographic and clinical characteristics and QOL outcomes,
among the groups, were evaluated using analyses of variance, Kruskal-Wallis, and Chi
Square analyses. Post hoc contrasts were calculated using the Bonferroni corrected
alpha of 0.008 (0.05/6 pairwise comparisons).
3.3 Results
3.3.1 Comparing Machine Learning clustering algorithms
We ran ten different analyses testing k-Means, Birch, Spectral-Clustering, Hierarchical
Agglomerative Clustering and k-Modes on subset A (15 symptoms, prevalence ≥ 40%)
and subset B (25 symptoms, prevalence ≥ 30%). Taking into account previous analyses
on similar datasets of cancer patients’ symptoms [119, 120], we ran our experiments
under the assumption of 3 or 4 pre-existing clusters among our samples (3 for subset A, 4
for subset B). In overall, k-Modes identified the most separable clusters (see Figure 3.1,
Table 3.1).
Figure 3.1: Performance of the clustering algorithms
3.3. Results 35
Table 3.1: Performance of the clustering algorithms
Clustering algorithms Silhouette Coefficient
(clusters = 3)
Silhouette Coefficient
(clusters = 4)
K-Modes 0.169 0.191
Birch 0.141 0.163
Spectral 0.052 0.134
Agglomerative 0.160 0.175
k-Means 0.158 0.181
Table 3.2: Latent Class Solutions and Fit Indices for Two- Through Five-Class Solutions
Model LL AIC BIC Entropy VLMR
3 Class 10998.00 22150.00 22505.64 .85 413.57*
4 Classa -10835.22 21876.44 22352.17 .82 325.55*
5 Class -10765.09 21788.17 22383.99 .81 140.27NS
*p < 0.001
Abbreviations: AIC = Akaikes Information Criterion, BIC = Bayesian Information
Criterion, LL = log-likelihood, NS = not significant, VLMR = Vuong-Lo-Mendell-
Rubin likelihood ratio test for the K vs. K-1 model
3.3.2 Comparing k-Modes with Latent Class Analysis
Number of Subgroups Identified Using LCA and K-modes Approaches
For the LCA, the fit indices for the candidate models are shown in Table 3.2. The
four class solution was selected because its BIC was lower than for the 3- and 5-class
solutions. In addition, the VLMR indicated that a 4-class solution was better than a
3-class solution. However, the VLMR for the 5-class solution was not better than the
4-class solution indicating that too many classes were extracted.
Using K-modes, while the average SCI for the 3-class solution was slightly larger than
the average SCI for the 4-class solution (Table 3.3), given this trivial difference and in
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Table 3.3: K-modes Solutions and Silhouette Indices for Three- Through Five-Class
Solutions
Model Silhouette Index
3 Clustera 0.159
4 Cluster 0.156
5 Cluster 0.129
aBased on the Silhouette Index, the three-cluster solution performed higher
than both the 4- and 5-cluster solutions.
order to compare the differences in demographic, clinical, and symptom characteristics
and QOL outcomes between the two methods, we used the 4-class solution from the
K-modes analysis.
As shown in Figures 3.2 and 3.3, for the LCA and K-modes analyses, respectively, the
four subgroups were named based on the probability of occurrence of the 25 MSAS
symptoms that occurred in ≥ 30% of the patients. The All High and All Low groups
included patients who reported relatively high and low occurrence rates for most of
the 25 MSAS symptoms, respectively. The Moderate Physical and Higher Psycho-
logical and Moderate Physical and Lower Psychological groups included patients who
reported relatively moderate occurrence rates for the majority of the physical symptoms
and relatively higher or lower occurrence rates, respectively, for the five psychological
symptoms (i.e., worrying, feeling irritable, feeling sad, feeling nervous, I dont look like
myself).
The SCI diagrams for all of the patient cases within each of the 4 clusters for the LCA
and K-modes analyses (Figures 3.4 and 3.5) showed that their inefficient assignments
were mostly within two specific groups (i.e. Moderate Physical and Higher Psycholog-
ical, Moderate Physical and Lower Psychological). Both well (SCI > 0) and inappro-
priately (SCI < 0) clustered cases were included within these clusters. As illustrated in
the SCI diagrams, K-modes assigned a larger proportion of cases to these two groups
(SCI > 0). Of note, the two other groups (All Low, All High) were well defined and
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Figure 3.2: Probability of symptom occurrence for LCA analysis
separated using both the LCA and K-modes approaches (SCI > 0.4).
3.3.3 Pairwise Agreement Between the LCA and K-modes Approaches
As shown in Table 3.4, the observed agreement among the four groups was 75.32% and
the expected agreement was 26.08%. The two analyses separated patients into 4 distinct
groups with substantial agreement beyond chance (range 0.6-0.7) as measured by the
Cohens coefficient (kappa=0.666). The biggest disagreements between the LCA and
K-modes approaches were between: a) the Moderate Physical and Lower Psychological
(LCA) and All Low (K-modes) and b) the Moderate Physical and Higher Psychologi-
cal (LCA) and All High (K-modes) groups, with 92 and 101 divergent classifications,
respectively.
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Figure 3.3: Probability of symptom occurrence for K-Modes analysis
3.3.4 Group Characteristics Identified with LCA and K-modes Ap-
proaches
The All Low group consisted of 31.5% (n=419) of the sample using LCA and 40.3%
(n=536) using K-modes. The probability of occurrence of the MSAS symptoms for this
group ranged from 0.064 to 0.549 for LCA and 0.093 to 0.647 for K-modes.
The second largest group identified using LCA was named Moderate Physical and
Higher Psychological and consisted of 31.3% (n=416) of the sample. Using K-modes,
this group consisted of 21.1% (n=280) of the patients. The occurrence rates for the
majority of the physical symptoms ranged from 0.293 to 0.930 for LCA and from 0.236
to 0.939 for K-modes. For the psychological symptoms, the occurrence rates were
relatively high. They ranged from 0.541 to 0.906 for LCA and from 0.582 to 0.811 for
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Figure 3.4: Silhouette coefficient diagram for the 4-class solution with the Latent Class
Analysis. The labels represent the following classes: (0) All Low (n=419, 31.5%); (1)
Moderate Physical & Lower Psychological (n=316, 23.8%); (2) Moderate Physical &
Higher Psychological (n=416, 31.3%); (3) All High (n=178, 13.4%). The size of the
clusters in the diagram is proportional to their size inside the total sample of patients
(n=1329)
K-modes.
The third largest group identified using LCA (23.8%, n=316) was named the Moderate
Physical and Lower Psychological group. Using K-modes, this group was the smallest
one identified (15.4%, n=205). The probability of occurrence for the physical symptoms
ranged from 0.241 to 0.987 for LCA and from 0.210 to 0.956 for K-modes. For the
psychological symptoms, the range was from 0.142 to 0.282 for LCA and from 0.185 to
0.278 for K-modes.
The All High group was the smallest one for LCA (13.4%, n=178) and the second
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Figure 3.5: Silhouette coefficient diagram for the 4-cluster solution with the K-modes
analysis. The labels represent the following clusters: (0) All Low (n=536, 40.3%); (1)
Moderate Physical & Lower Psychological (n=205, 15.4%); (2) Moderate Physical &
Higher Psychological (n=280, 21.1%); (3) All High (n=308, 23.2%). The size of the
clusters in the diagram is proportional to their size inside the total sample of patients
(n=1329)
largest for the K-modes analysis (23.2%, n=308). The probability of occurrence of the
MSAS symptoms for this group ranged from 0.562 to 0.994 for LCA and from 0.429 to
0.974 for K-modes.
3.3.5 Differences in Patient Characteristics Among the Groups Iden-
tified with LCA and K-modes Approaches
Tables A.2 and A.3, in the Appendix A, summarize the differences in demographic and
clinical characteristics among the four groups of patients identified using LCA and K-
modes, respectively. For both analyses, compared to the All Low group, patients in the
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Table 3.4: Pairwise Agreement Among the Patient Groups Using Latent Class Analysis
and K-modes Analysis
Pairwise agreement among All Lowb Moderate Physical & Moderate Physical & All High Total
the patient groups Lower Psychological Higher Psychological All High n(%)
nc (%d) nc (%d) nc (%d) nc (%d)
All Lowa 406 (30.6) 4 (0.3) 9 (0.7) 0 (0.0) 419 (31.5)
Moderate Physical & 92 (6.9) 171 (12.9) 23 (1.7) 30 (2.3) 316 (23.8)
Lower Psychological
Moderate Physical & 38 (2.9) 30 (2.3) 247 (18.6) 101 (7.6) 416 (31.3)
Higher Psychological
All High 0 (0.0) 0 (0.0) 1 (0.1) 177 (13.3) 178 (13.4)
Total 536 (40.3) 205 (15.4) 280 (21.1) 308 (23.2) 1,329 (100.0)
Cohens kappa coefficient
Agreement Expected Agreement Kappa Standard Error Z p-value
75.32% 26.08% 0.666 0.016 42.64 <0.001
aFor LCA: All Low (n=419, 31.5%), Moderate Physical and Lower Psychological (n=316, 23.8%), Moderate Physical
and Higher Psychological (n=416, 31.3%), and All High (n=178, 13.4%).
bFor K-modes analysis: All Low (n=536, 40.3%), Moderate Physical and Lower Psychological (n=205, 15.4%), Moderate Physical
and Higher Psychological (n=280, 21.1%), and All High (n=308, 23.2%)
cNumber of the patients who were included in both classes
dPercentage of patients from the total sample of 1329 patients
Moderate Physical and Higher Psychological and the All High groups were significantly
younger, had a lower KPS score, had a higher SCQ score, were more likely to have breast
cancer, and were more likely to report depression and back pain. In addition, for both
analyses, compared to the Moderate Physical and Lower Psychological group and the
Moderate Physical and Higher Psychological group, patients in the All High group had
a lower KPS score and a higher SCQ score.
3.3.6 Differences in Symptom Occurrence Rates Among the Groups
Identified with LCA and K-modes
Table A.1, in the Appendix A, summarizes differences in symptom occurrence rates
among the four groups of patients identified using LCA and K-modes. Both analyses
identified two groups of oncology patients who reported moderate levels of physical
symptoms but differentiated on the occurrence of five psychological symptoms (i.e.,
worrying, feeling irritable, feeling sad, feeling nervous, I dont look like myself). For
patients in the Moderate Physical and Higher Psychological group, worrying (LCA:
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0.906, K-modes: 0.811), feeling sad (LCA: 0.813, K-modes: 0.811), and feeling irritable
(LCA: 0.649, K-modes: 0.657) were among the top symptoms. In contrast, in the
Moderate Physical and Lower Psychological group, worrying (LCA: 0.142, K-modes:
0.278), feeling sad (LCA: 0.161, K-modes: 0.259), and feeling irritable (LCA: 0.256,
K-modes: 0.224) were among the symptoms with the lowest probability of occurrences.
The remaining psychological symptoms, namely: feeling nervous (Moderate Physical
and Higher Psychological group: LCA: 0.606, K-modes: 0.693; Moderate Physical and
Lower Psychological group: LCA: 0.184, K-modes: 0.185) and I dont look like myself
(Moderate Physical and Higher Psychological group: LCA: 0.541, K-modes: 0.582;
Moderate Physical and Lower Psychological group: LCA: 0.282, K-modes: 0.259) had
significant differences between the aforementioned groups for both analyses.
Across all four groups, lack of energy was the most common symptom. While the
probability of its occurrence for the total sample was 0.832, values ranged from 0.549
to 0.994 for LCA and from 0.647 to 0.974 for K-modes. In addition, pain (LCA: 0.944-
0.334, K-modes: 0.834-0.360), difficulty in sleeping (LCA: 0.927-0.458, K-modes: 0.896-
0.537), numbness/tingling in hands/feet (LCA: 0.798-0.334, K-modes: 0.724-0.356),
change in the way food tastes (LCA: 0.837-0.274, K-modes: 0.802-0.323), and feeling
drowsy (LCA: 0.966-0.243, K-modes: 0.860-0.321) occurred in the top ten symptoms
across all four groups for both analyses.
3.3.7 Differences in MSAS Summary Scores Among the Groups Iden-
tified with LCA and K-modes
Table A.4, in the Appendix A, summarizes differences in the MSAS summary scores
among the four groups of patients identified using LCA and K-modes. For the Physical
subscale, the Psychological subscale, and the Global Distress index, the differences
among the four groups followed the same pattern for both analyses. For the MSAS total
score, as well as for the total number of MSAS symptoms, the pattern observed using
the LCA was in the expected direction (i.e., All Low < Moderate Physical and Lower
Psychological ¡ Moderate Physical and Higher Psychological< All High). For the MSAS
total score, as well as for the total number of MSAS symptoms, the pattern observed
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using K-modes was as follows: All Low ¡ Moderate Physical and Lower Psychological,
Moderate Physical and Higher Psychological and All High (i.e., 0 < 1, 2, and 3), as
well as Moderate Physical and Lower Psychological and Moderate Physical and Higher
Psychological ¡ All High (i.e., 1 and 2 < 3).
3.3.8 Differences in QOL Scores Among the Groups Identified with
LCA and K-modes
Table A.5, in the appendix A, summarizes differences in MQOLS-CA subscale and
total scores among the four groups of patients identified using LCA and K-modes. For
the MQOLS psychological and social well-being subscales, and total QOL scores, the
differences among the four groups followed the same pattern for both analyses (i.e., All
Low > Moderate Physical and Lower Psychological > Moderate Physical and Higher
Psychological > All High). In addition, for the physical well-being subscale scores, the
differences among the four groups followed the same pattern for both analyses (i.e.,
All Low > Moderate Physical and Lower Psychological, Moderate Physical and Higher
Psychological, and All High (i.e., 0 > 1, 2, and 3) and Moderate Physical and Lower
Psychological and Moderate Physical and Higher Psychological > All High (i.e., 1 and
2 > 3)).
For the SF12, for both analyses, the MCS scores followed a similar pattern (i.e., All
Low > Moderate Physical and Lower Psychological > Moderate Physical and Higher
Psychological > All High). For the PCS scores, the post hoc contrasts were different
depending on the method of analysis. For LCA, the pattern was All Low > Moderate
Physical and Higher Psychological > Moderate Physical and Lower Psychological >
All High. For the K-modes analysis, the pattern was as follows: All Low > Moderate
Physical and Lower Psychological, Moderate Physical and Higher Psychological and
All High (i.e., 0 > 1, 2, and 3), as well as Moderate Physical and Higher Psychological
¿ Moderate Physical and Lower Psychological and All High (i.e., 2 > 1 and 3).
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3.4 Summary and Discussion
This study is the first to evaluate for congruence between the ability of two different
analytic approaches to identifiy subgroups of oncology patients with distinct symptom
profiles. Using both LCA and K-modes, four groups of patients with distinct symptom
profiles were identified. The Cohens kappa coefficient of 0.666 represents a moderate
level of agreement between the two approaches. [140, 141, 142] Potential reasons for
only a moderate level of agreement may be related to differences in the underlying
assumptions of each of the methods. LCA is a model based approach where clusters (i.e.
classes) are defined by parametric probability distributions that can be interpreted to
generate homogenous points, while the whole data set is modelled by a mixture of such
distributions. [143] Its key assumption is the conditional independence of the observed
variables given the latent class. Inside the same class, the presence or the absence of
one symptom is viewed as unrelated to the presence or absence of all of the others. On
the other hand, K-modes is a distance-based clustering method that separates clusters
as data subsets that have small within-cluster distances and large separation from other
clusters. K-modes tries to find clusters that bring similar observations together without
making an assumption about their distribution or attempt to fit a mixture distribution.
Our findings, as well as others, [143, 144, 145] suggest that further research is needed,
using both approaches, to determine the most sensitive and specific method(s) to risk
profile oncology patients based on symptom occurrence rates.
While the absolute percentages of patients in the four groups differed depending on
the analytic approach, the specific symptom profiles within each of the four groups
were very similar. In addition, previous work in heterogeneous samples of oncology
patients, using a different numbers of MSAS symptoms, [104, 146] found the same
four phenotypic profiles identified in the current study. Across these three studies, the
percentage of patients in the All Low group ranged from 28.0% [104] to 40.3% (using K-
modes in the current study) and the percentage of patients in the All High class ranged
from 13.4% (using LCA in the current study) to 27.8%. [146] Across these three studies,
these relatively wide ranges may be related to differences in the number and types of
symptoms evaluated, the timing of the symptom assessments in relationship to cancer
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diagnosis and treatments, and/or the specific cancer diagnoses of the patients in each
of the studies. That said, these two extreme phenotypes were identified in previous
studies that used only four symptoms [102, 147, 105, 148] or identified only two or
three groups. [106, 109, 108]
Across the two previous studies [104, 146] and with the two analytic methods used in
the current study, the consistent phenotypic characteristics associated with membership
in the All High group were younger age and poorer functional status. The association
between younger age and a higher symptom burden is consistent with previous studies.
[102, 147] While younger patients may receive more aggressive cancer treatments, [149]
equally plausible hypotheses for this association include: that older adults experience
a response shift in their perception of symptoms; [150] that chronological age may not
be an accurate representation of the biological age of oncology patients; [151] and/or
that accelerated aging occurs with cancer and its treatment. [152, 153, 154]
Similar to age, the association between a higher symptom burden and poorer functional
status was reported previously. [148, 109, 110] In the current study and in the one
conducted in Norway, [146] that both used the KPS scale, compared to patients in the
All Low group who had KPS scores between 85 and 95, patients in the All High group
reported KPS scores in the mid-70s. This difference represents a clinically meaningful
change in functional status on this scale. Given that patients typically report lower
KPS scores than their clinicians, [155, 156] patients should be interviewed not only
about the number and severity of their symptoms but about changes in functional
status during and following cancer treatment.
An equally important finding in this study and in the two previous studies [104, 146]
is the identification of two groups of patients who differentiated based on the occur-
rence of psychological symptoms. While our phenotypic data suggest that these two
groups have lower KPS scores and a higher comorbidity profile than the All Low group
and better scores for both characteristics than the All High group, the demographic
and clinical characteristics that distinguish between these two Moderate groups are
not readily apparent. These findings are similar to previous reports [104, 146] and
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warrant investigation in future studies. An evaluation of additional psychosocial char-
acteristics (e.g., coping styles, personality, social support) may improve the phenotypic
characterization of these two Moderate groups.
In terms of the QOL outcomes, regardless of whether a generic (i.e., SF12) or disease-
specific (i.e., MQOLS-PV) measure was used, the pattern of the differences in scores
were in the expected direction, namely that as the symptom phenotype worsened, QOL
decreased. The one interesting finding on Table A.5, in the appendix A, relates to the
PCS scores from the SF12. While none of the groups had PCS scores of >50 (i.e.,
the normative value for the general population in the United States), patients in the
Moderate Physical and Lower Psychological group had worse scores than patients in
the Moderate Physical and Higher Psychological group. This finding is consistent with
the report by Astrup and colleagues.
In terms of study limitations, patients were recruited at various points in their CTX
treatment. In addition, the types of CTX were not homogeneous. While we cannot
rule out the potential contributions of clinical characteristics to patients’ symptom ex-
periences, the relatively similar percentages of cancer diagnoses, reasons for current
treatment, time since cancer diagnosis, and evidence of metastatic disease across the
four groups, suggest that the patients were relatively similar in terms of disease and
treatment characteristics. Although it is possible that patients in the All Low group
were receiving more aggressive symptom management interventions, the occurrence
rates for the five most common symptoms were relatively similar across the four classes
for both analyses. It is possible that using ratings of frequency, severity or distress to
create patients groups would provide additional information on inter-individual differ-
ences in the symptom experience of these patients.
Additional research is warranted using different analytic methods to optimize the iden-
tification of oncology patients with a higher symptom burden. Future studies can
evaluate different machine learning approaches, as well as real time collection of differ-
ent dimensions of a patients symptom experience (i.e., occurrence, severity, distress) to
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determine the most sensitive and specific methods to use to risk profile patients and
design and test more effective symptom management interventions.
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Chapter 4
Predicting Future Values of
Cancer Symptoms
In this chapter we discuss about the problem of predicting future values of cancer
symptoms across the chemotherapy stages. We present how predictive models can used
to identify high risk patients and estimate the course and severity of cancer symptoms.
Such computational tools have the potential to assist oncology clinicians to personalize
the patients treatment regimen more efficiently and provide more aggressive and timely
interventions. We elaborate on the efficiency of Support Vector Regression (SVR) and
Non-linear Canonical Correlation Analysis by Neural Networks (n-CCA) to predict the
severity of three common and inter-related cancer symptoms (i.e.,depression, anxiety,
sleep disturbance) between two different time points during a cycle of chemotherapy
(CTX).
4.1 Introduction
A growing body of evidence,[146, 157, 119] as well as clinical experience suggests that
the symptom experience of oncology patients is extremely variable. While some pa-
tients experience very few symptoms, other patients undergoing the same treatment
experience multiple co-occurring symptoms that are severe and extremely distressing.
The clinical dilemma is how to identify these high risk patients prior to the initiation
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of treatment, so that aggressive symptom management interventions can be initiated
and deleterious outcomes can be avoided. The application of machine learning tech-
niques to develop algorithms to identify this high risk phenotype is the first step toward
individualized symptom management.
For this investigation, we applied machine learning techniques to develop an algorithm
that could identify patients with the highest severity scores for three common and inter-
related symptoms (i.e., depression, anxiety, sleep disturbance). Depression occurs in up
to 60% of cancer patients.[158] Between 35% and 53% of patients report anxiety during
cancer treatment[159] and 45% of patients experience both of these symptoms.[160]
Equally deleterious and linked to both depression and anxiety are complaints of sleep
disturbance in 30% to 50% of oncology patients.[161] All three symptoms are associated
with decrements in patients ability to function on a daily basis as well as on their
quality of life. Of note, according to a systematic review by Alvaro et al. [162] as
depression, anxiety and sleep disturbances are often grouped together, the treatment
of insomnia may prevent the development of anxiety and depressive disorders, and
vice-versa. Therefore, if we can predict the patients who are at a higher risk for these
symptoms, treatments can be initiated to manage these symptoms. In addition, these
efficient machine learning methods could be used to predict the severity other symptom
in patients with cancer, as well as in patients with other chronic medical conditions.
A large variety of machine learning techniques and algorithms can be used to predict
data by learning from previous observations. Choosing the most appropriate one for the
prediction of symptom severity is a challenging task. Several common problems exist
with this type of research including: small sample sizes; a significant number of missing
values; the large number of symptom assessment instruments with different measure-
ment scales; the different types of variables (e.g., categorical, ordinal, continuous); and
the subjective nature of symptom measurements, themselves. Regression analysis is a
common supervised machine learning method that can be used to solve several biolog-
ical and clinical problems. It is used to estimate the relationship between a dependent
variable (i.e., depression, anxiety, sleep disturbance) and one or more independent vari-
ables (i.e., predictor(s)). Canonical Correlation Analysis is another analytical method
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for exploring the relationships between two multivariate sets of variables (e.g., set of
variables from Time Point 1 (TP1) and Time Point 2 (TP2) of a chemotherapry (CTX)
cycle). In this study, we used Support Vector Regression (SVR) with different kernels
(i.e., linear, polynomial, radial sigma) and Non-linear Canonical Correlation Analy-
sis by Neural Networks (n-CCA)[163] to predict efficiently our dependent variables
(i.e., symptom severity scores of depression, anxiety and sleep disturbance at TP2).
The Multiple Imputation (MI) and Maximum Likelihood Estimation (MLE) methods
were applied in order to account for missing data. Similarly, in order to accommodate
the small sample size and avoid over-training, we applied a 10-times Repeated 10-fold
Cross-validation (RCV) to our predictive models. To the best of our knowledge, this
study is the first of its kind in oncology symptom management to applying n-CCA to
predict the severity of three common symptoms in oncology patients. An overview of
our analysis is provided at Figure 4.1.
Figure 4.1: Overview of our analytic approach to learn from data to predict future
symptoms of oncology patients
Our study is organized as follows: the Methods section provides the research method-
ology along with all of the approaches used in the proposed model. The Results section
presents the comparison and evaluation of the aforementioned methods and provides a
summary of our results.
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4.2 Materials and methods
4.2.1 Study Procedure
The study, from which our data was drawn, was approved by the Committee on Hu-
man Research at the University of California, San Francisco and by the Institutional
Review Board at each of the study sites. From February 2010 to December 2013, all
eligible patients were approached by the research staff in the infusion unit to discuss
participation in the study. Written informed consent was obtained from all patients.
Depending on the length of their CTX cycles, patients completed questionnaires in
their homes, a total of six times over 2 cycles of CTX (i.e. prior to CTX administration
(Time 1 and 4), approximately 1 week after CTX administration (Time 2 and 5), ap-
proximately 2 weeks after CTX administration (Time 3 and 6). For this study, which
is a secondary analysis of existing data, symptom data from the Time 1 and Time 2
assessment were analysed. Patients were asked to report on their symptom experience
for the previous week. Medical records were reviewed for disease and treatment infor-
mation. The methods for the parent study are described in fully detail in previously
published work.[157, 164, 165]
4.2.2 Patients and Settings
We carried out a secondary analysis of existing data from this longitudinal study of
the symptom experience of oncology outpatients receiving CTX. The data used in this
study were obtained from the same dataset and relate to two different Time Points
(i.e., Time Point 1 (TP1, n1=1343; prior to CTX administration), Time Point 2 (TP2,
n2=1278; one week after CTX administration).
According to the studys eligibility criteria: patients were ≥ 18 years of age; had a
diagnosis of breast, gastrointestinal (GI), gynecological (GYN), or lung cancer; had
received CTX within the preceding four weeks; were scheduled to receive at least two
additional cycles of CTX; were able to read, write, and understand English; and gave
written informed consent. Patients were recruited from two Comprehensive Cancer
Centers, one Veterans Affairs hospital, and four community-based oncology programs.
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4.2.3 Instruments
The study instruments included a demographic questionnaire, the Karnofsky Perfor-
mance Status (KPS) scale, [166, 167] the Self-administered Comorbidity Question-
naire (SCQ),[168] the Lee Fatigue Scale (LFS),[169] the Attentional Function Index
(AFI),[170, 171] the General Sleep Disturbance Scale (GSDS),[172] the Center for
Epidemiological Studies-Depression Scale (CES-D),[173] and the Spielberg State-Trait
Anxiety Inventories (STAI-S and STAI-T).[174]
The demographic questionnaire provided information on age, marital status, years of
education, living arrangements, ethnicity, employment status and exercise. In addition
patients medical records were reviewed to obtain information on: body mass index
(BMI), hemoglobin (Hgb), type of cancer, number of metastatic sites, time since cancer
diagnosis, number or prior cancer treatments, and CTX cycle length.
To estimate changes in self-reported sleep disturbance, the GSDS was administered at
each time point. The GSDS consists of 21 items designed to assess the quality of sleep
in the past week. Each item was rated on a 0 (never) to 7 (every day) numeric rating
scale (NRS). The GSDS total score is the sum of the 21 items that can range from
0 (no disturbance) to 147 (extreme sleep disturbance). A GSDS total score of ≥ 43
indicates a significant level of sleep disturbance.[175] The GSDS has well-established
validity and reliability in shift workers, pregnant women, and patients with cancer and
HIV.[172, 176, 177]
The CES-D consists of 20 items selected to represent the major symptoms in the clinical
syndrome of depression. Scores can range from 0 to 60, with scores ≥ 16 indicating the
need for individuals to seek clinical evaluation for major depression. The CES-D has
well-established concurrent and construct validity.[173, 178, 179]
The STAI-T and STAI-S inventories consist of 20 items each that are rated from 1
to 4. The scores for each scale are summed and can range from 20 to 80. A higher
score indicates greater anxiety. The STAI-T measures an individual’s predisposition
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to anxiety determined by his/her personality and estimates how a person feels gener-
ally. The STAI-S measures an individual’s transitory emotional response to a stressful
situation. It evaluates the emotional response of worry, nervousness, tension, and feel-
ings of apprehension related to how people feel right now in a stressful situation. The
STAI-S and STAI-T inventories have well-established criteria and construct validity
and internal consistency reliability coefficients.[174, 180, 181]
4.2.4 Data Analysis and Missing Data
Our data were collected from a cohort of oncology patients at two different Time
Points, Time Point 1 (i.e., TP1, nTP1=1343), Time Point 2 (i.e., TP2, nTP2=1278).
By merging the two different Time Points we created a new dataset of 1278 samples
(nTP1+TP2=1278). When we dropped the cases with at least one missing value in one
of their variables, we were left with 799 cases (65,1% of nTP1+TP2). To assess whether
the missing values were missing completely at random (MCAR), missing at random
(MAR), or missing not at random (MNAR)[182, 183] we analysed our data with SPSS
version 23 (IBM, Armonk, NY). Furthermore, in order to avoid the problem of bias-
ing our analysis by including only the complete cases, we used two different statistical
approaches to impute the missing values, namely, Multiple Imputation (MI)[184, 183]
and the Maximum Likelihood Estimation (MLE)[185, 183].
Multiple Imputation (MI) is a statistical approach to address the problem of the missing
observations that are frequently encountered in all types of epidemiological and clinical
studies.[186] It minimizes the uncertainty around our missing data by creating different
imputed data sets several times and integrating their results into a final, pooled result.
Figure 4.2 illustrates the MI procedure with an example.
During the first stage, MI creates multiple copies of the dataset, with the missing values
replaced by imputed values. These are sampled from their predictive distribution based
on the observed data.[184] MI must fully account for all uncertainty in predicting the
missing values by inserting appropriate variability into the multiple imputed values.
During the second stage, MI fits the model of interest to each of the imputed datasets.
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Figure 4.2: Multiple Imputation
The predicted estimations in each of the imputed datasets will differ because of the
variation introduced in the imputation of the missing values. These estimates are only
useful when averaged together to give the overall, pooled predicted associations.
Maximum Likelihood Estimation (MLE) is a common statistical method for estimating
the parameters of a specific model, by finding the parameter values that maximize the
likelihood of making the observations given these parameters. To elaborate more on
this topic,[183] suppose we try an experiment with N people where the probability of a
success for an individual is p and the probability of a failure is 1-p. If n people succeed
and N-n people fail, the likelihood is proportional to the product of the probabilities of
successes and failures or pn× (1− p)N−n. The value of p that maximizes the likelihood
is n/N or the overall proportion of success. In our analysis for example, maximum
likelihood produces the best estimate of the difference in the parameters between TP1
56 Chapter 4. Predicting Future Values of Cancer Symptoms
and TP2 that maximize the probability of observing the collected data. Unlike MI,
MLE provides a unique estimate of the missing values and it requires fewer decisions
than MI.
To impute the missing values with the MI approach and the MLE, we used SPSS version
23 (IBM, Armonk, NY). For the MI approach, we configured SPSS to automatically
choose an imputation method based on a scan of our data and produce 10 output
datasets with imputed values. For the MLE approach, we configured SPSS AMOS to
use an independence model with a regression imputation and produce 1 output dataset
with imputed values.
4.2.5 Model Selection
To train and evaluate the performance of our different predictive models we divided
our dataset into two sub-sets: the Training (nTrain=1000) and Validation (nVal=278)
datasets. Cross-validation (CV) and Bootstrap are two common approaches that are
known to provide unbiased estimates for the test results of a predictive model.[187]
Cross-validation (CV) provides unbiased results but with a high error variance. On the
other hand, Bootstrap is known to have better performance in small samples, achieving
a small variance but requiring much heavier computation than CV. Combining the
strengths of both approaches, Repeated Cross-validation (RCV) appears to be a good
validation method for general use providing small bias with limited variability and a
reasonable computation load.[187] In fact, RCV is a repeated CV method, in which
the CV is repeated several times and then the average is taken. By the same rationale,
Boostrap .632 is designed to address the pessimistic bias of the standard Bootstrap
method, where the Bootstrap samples only contain approximately 63.2% of the unique
samples from the original dataset. [188, 189]
Before training our models on the data, we empirically compared all the aforementioned
validation methods on the original dataset before and after imputation for the missing
values. Based on the validation method results, we compared the two different types
of predictive models in our study with a 10-times and 10-fold RCV method.
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We divided the original dataset with the missing values into a Training set of nTrain=624
cases, and a Test set of nTest=175 cases. For the MI and MLE imputation methods, we
divided the datasets into a Train set of nTrain=1000 cases, and a Test set of nTest=278
cases. As already mentioned, the MI produced 10 such datasets, with each one of them
having a total of n=1278 cases.
Support Vector Regression
Support Vector Machine (SVM) is a popular machine learning algorithm used to analyze
a variety of oncology data,[190, 191, 192] among many other applications. SVM became
increasingly popular because of its successful application for a different set of problems
(e.g. image recognition, text categorization, biosignals, bioinformatics).[193, 194, 195]
SVM works by mapping data to a high-dimensional feature space so that data points
can be categorized, even when the data are not otherwise linearly separable. SVM
manages this challenge with an operation called the kernel trick. Through a variety of
different kernel functions (e.g. Linear, Polynomial, Radial Basis Function), SVM takes
low dimensional input space and transforms it to a higher dimensional space, thus
converting non-separable problems to separable ones. With SVM, the data are trans-
formed in such a way that separators between the different categories of the dataset can
be found, optimized, and drawn. These separators are called the Optimal Separation
Hyperplanes (OSH).
Support Vector Regression (SVR) is an extension of the SVM classifier, estimating the
continuous function of a specific dataset.[196, 197] Similarly to SVM, SVR can model
complex non-linear relationships by using an appropriate kernel function which maps
the input data points onto a higher-dimensional feature space, transforming the non-
linear relationships into linear forms. The efficiency of the procedure is determined by
the kernel function’s parameters which do not depend on the dimensionality of feature
space. Both SVM and SVR depend on defining a loss function, called epsilon intensive
(), which ignores the errors that are situated within a certain distance of the true
value. Figure 4.3 shows an example of a non-linear regression function with its epsilon
intensive band. In our study, we implemented all the different SVR models using R
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version 3.3.0 and the Caret Package. [198]
Figure 4.3: Support Vector Regression
Non-linear Canonical Correlation Analysis by Neural Networks
In our study, we adapted the n-CCA which was introduced by Hsieh et al. in 2000.[163]
Our implementation was done with PyCharm Professional Edition 4.5, using Python
2.7 and the Scikit-Learn, Theano, and Lasagne libraries.[133, 199, 200]
Canonical Correlation Analysis (CCA) is a method to identify the linear combinations
of a set of variables X that have the highest correlations with linear combinations of
a set of variables Y. It estimates the correlated modes between the two data sets of
variables X (i.e, the data from TP1) and Y (i.e., the data from TP2) by solving the
equations,
i) U = a ∗X, ii) V = b ∗ Y, (4.1)
while maximising the Pearson correlation between U and V. To achieve a better per-
formance in cases where the correlation between the two data sets is non-linear, the
equations can be modified to include a non-linear relationship. Hsieh et al.[163] have
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introduced an implementation of n-CCA utilising three neural networks. For a more
in-depth mathematical description of the method, we refer to the original paper.[163] In
this paper, we describe the concepts of how the neural networks can be used to extract
the correlation between the two sets of variables (i.e., data from TP1 and TP2).
Figure 4.4 shows the architecture, as well as the training and validation stage, of our
neural network that implements n-CCA with our data from TP1 and TP2. Our model
consists of three networks which were trained separately. The first neural network is a
double-barrelled one (illustrated in the Training-(a) section of Figure 4.4). We called
this network the inner network and the other two the outer networks (shown in the
Training-(b) and Training-(c) sections of Figure 4.4).
Figure 4.4: n-CCA Training and Validation: (i) Training of the n-CCA model, (ii)
Validation of the n-CCA model
The two barrels of the inner network (Training-(a) section of Figure 4.4) share the same
structure and take as input the data from TP1 and TP2 respectively. The input layer
of each barrel has n nodes, one for each feature of the data (nFeatures=29); see Table 4.1
for a full list of these features). The hidden layer of each barrel contains 50 nodes, that
have the hyperbolic tangent function as their activation function. The output layer of
each barrel has only one node, producing an output U for the dataset from TP1 and an
output V for the data set from TP2 respectively. The aim of the training of the inner
network is to maximise the correlation between the two vectors, U and V. This aim is
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achieved by using the negative Pearson coefficient [201] as the cost function which has
to be minimised.
The outer networks (Training-(b) and Training-(c) sections of Figure 4.4) are trained
separately, nevertheless they share the same structure. The input layer of each outer
network has only one node, taking as input the output (U and V respectively) of the
previous double-barrel inner network. The hidden layer of each of the outer networks
has 50 nodes with the hyperbolic tangent function as their activation function. The
output layer of each outer network produces the features that we need to predict. In our
study, we predicted the severity of three symptoms (i.e., sleep disturbance, depression,
anxiety). To predict them, each outer network learns the inverse function of each of
the barrels of the inner network and maps U and V, respectively, back to the features
we are interested to predict. The first outer network (Training-(b) section of Figure
4.4) maps U back to predicted values of sleep disturbance, depression and anxiety for
TP1 and the second outer network (Training-(c) section of Figure 4.4) maps V back to
predicted values of sleep disturbance, depression and anxiety for TP2. The aim of the
training of the outer networks is to minimise the Mean Squared Error (MSE) between
the predicted output and the true values. This training phase consists of 100 epochs,
during which we used a 10-times and 10-fold RCV.
When the training stage (Training section of Figure 4.4) is finished, we can use parts
of the model to predict TP2 data from new, unseen TP1 data (Validation section of
Figure 4.4). This process can be used either to validate the model or to predict the TP2
data, when new patients are introduced into the model, where only the TP1 data are
available. In both cases, the TP1 data are fed into the left barrel of the inner network
(Validation-(a) section of Figure 4.4) to estimate the U vector for these data. By
multiplying this output with the Pearson coefficient R that was calculated during the
training stage, we can estimate the corresponding V vector. This information forms the
input for the outer right network (Validation-(c) section of Figure 4.4), which predicts
the desired features for the TP2 data.
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4.2.6 Comparison between SVR and n-CCA
To compare the performances of the SVR and n-CCA models we used their Root Mean
Square Error (RMSE) and Normalised Root Mean Square Error (NRMSE). The latter,
was calculated by dividing their RMSE with the mean of the measured values.
NRMSE =
RMSE
mean
, (4.2)
Normalising the RMSE allows the comparison of models with different scales. Lower
values among these calculations indicate less residual variance for the predicted out-
comes.
In order to compare the results produced with the SVR and the n-CCA models we used
the BlandAltman plot.[202, 203] The Bland-Altman plot is a graphical method to com-
pare two different measurement techniques. The difference between each technique’s
measurement for each case is plotted against the average of the other technique’s mea-
surement for the same case. The former is represented on the y-axis and the latter on
the x-axis. The full Bland-Altman plot draws these differences and averages for every
case in the test dataset. In our study, the mean difference and the mean difference plus
and minus 1.96 times the standard deviation of the differences are represented on the
Bland-Altman plot with horizontal lines (see Figure 4.5).
In order to evaluate the agreement between the real and predicted values, we compared
the mean, range, and kernel density plots of the results from the analyses on the dataset
with the MLE imputation. We compared the predictions of the SVR with polynomial
kernel and n-CCA models against the real values of our Test set (nTest=278 cases).
4.3 Results
4.3.1 Data Analysis and Handling Missing Data
Our initial dataset that contained the data from both TP1 (prior to CTX administra-
tion) and TP2 (one week after CTX administration; nTP1+TP2=1278), had 799 fully
completed cases (65,1% of nTP1+TP2). The empty values in the dataset were missing
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Figure 4.5: Bland - Atman plot of the SVR model with the polynomial function and
the n-CCA model on the dataset with Maximum Likelihood imputation
completely at random (Little’s MCAR test, p>0.05; Figure 4.6). These missing values
are due to missing responses from patients. In order to use the collected values of all
of our cases, we applied the MI[184, 183] and MLE[185, 183] to compensate for missing
values.
4.3.2 Model Selection
As our validation method, we selected a 10-times and 10-fold RCV. Beforehand, we
compared the performance of this validation method with Bootstrap, Bootstrap .632
and 10-fold CV. As predictor variables we used the data collected from TP1 (for a full
description of these predictors see Table 4.1). Moderate correlations were found among
a number of predictors (see Figure 4.7). Type of cancer was correlated with gender
because 40.6 % (n=519) of the patients in our study had breast cancer. The number
of prior cancer treatments was correlated with time from patients initial cancer diag-
nosis. Income was correlated with being married and living alone. KPS score[166, 167]
was moderately correlated with sleep disturbance, attentional function, depression,
and morning fatigue. Finally regarding the symptoms collected in our dataset, moder-
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Figure 4.6: Missing Values Pattern (Little’s MCAR test, p>0.05)
ate correlations were found between sleep disturbance, anxiety, depression, attentional
function, morning energy, and morning fatigue.
Table 4.1: Predictor variables for the Support Vector Regression (SVR) and the Non-
linear Canonical Correlation Analysis by neural networks models.
Variables Type of variable Range
Age Continuous 19.9 - 90.72
Gender Nominal 1 - 3
Education Continuous 4 - 23
BMI Continuous 15.21 - 54.58
Ethnicity Nominal 0-3
Married Binary 0 - 1
Do you live alone Binary 0 - 1
Working Binary 0 - 1
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Income Nominal 1 - 4
Caregiver to children Binary 0 - 1
Caregiver to adult Binary 0 - 1
Karnofsky Performance status Continuous 30 - 100
Self-administered comorbidity questionnaire
(SCQ) score
Nominal 0 - 21
Number of metastatic sites out of 9 Nominal 0 - 6
Type of cancer Nominal 1 - 4
Time of diagnosis to start of study in years Continuous 0.041 - 38.32
Number of prior treatments out of 9 Nominal 0 - 7
Hemoglobin (HgB1) Continuous 6.7 - 16.1
Exercise on a regular basis Binary 0 - 1
Cycle length Nominal 1 - 3
General Sleep Disturbance Scale Continuous 7-119
Morning fatigue measured as part of the Lee
Fatigue Scale
Continuous 0 - 9.84
Evening fatigue measured as part of the Lee
Fatigue Scale
Continuous 0 - 10
Morning energy measured as part of the Lee
Fatigue Scale
Continuous 0 - 10
Evening energy measured as part of the Lee
Fatigue Scale
Continuous 0 - 10
Attentional function index Continuous 0.54 - 10
Center for Epidemiological Studies-Depression
Scale
Continuous 0 - 56
State Anxiety Scale Continuous 20 - 80
Occurrence of pain Nominal 0 - 2
Our analytical models were implemented in all three types of datasets (i.e. the original
ones with the missing values, the ones imputed with MI, the ones imputed with MLE).
4.3. Results 65
Figure 4.7: Correlation analysis of predictor variables
The performance of the models was evaluated based in the RMSE and the NRMSE.
Table 4.2 shows the performance of different SVR models for predicting depression
(CES-D) at TP2.
Based on these results (Table 4.2), we selected the 10-times and 10-fold RCV as our
preferred validation method to test and compare the remaining analyses. The best
overall performance for predicting CES-D at TP2 with SVR was implemented with the
polynomial kernel on the MI imputed dataset (RMSE=6.191, NRMSE=0.644). This
result could be due to the method of imputation used in the latter dataset and the type
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Table 4.2: Performance of Support Vector Regression (SVR) models for predicting
Depression (CES-D) at TP2
10-times
Repeated
10-fold CV
10-fold CV Bootstrap Bootstrap .632
Dataset Kernel RMSE NRMSE RMSE NRMSE RMSE NRMSE RMSE NRMSE
Missing
data
Linear 6.484 0.589 6.484 0.589 6.484 0.589 6.484 0.589
Polynomial 6.435 0.592 6.435 0.592 6.436 0.592 8.268 0.416
Radial Sigma 6.475 0.591 6.470 0.592 6.473 0.591 6.752 0.559
Multiple
Imputation
Linear 6.201 0.644 6.201 0.644 6.201 0.644 6.201 0.644
Polynomial 6.191 0.644 6.191 0.644 6.193 0.644 8.121 0.517
Radial Sigma 6.401 0.628 6.387 0.630 6.389 0.630 6.512 0.587
Maximum
Likelihood
Linear 7.102 0.548 7.102 0.548 7.102 0.548 7.102 0.548
Polynomial 7.081 0.549 7.081 0.549 7.053 0.552 9.954 0.323
Radial Sigma 7.189 0.540 7.182 0.541 7.192 0.540 7.393 0.508
of kernel function that was used to construct the prediction model. All four valida-
tion methods provided equivalent results with their best performance implemented on
the MI datasets. Bootstrap .632 combined with the polynomial kernel had the worst
performance on all three types of datasets (i.e. RMSE=9.954, NRMSE=0.323).
4.3.3 Comparison between SVR and n-CCA
To compare the different approaches used in our study, we applied three different SVR
and three n-CCA models to predict the severity of depression (CES-D), sleep distur-
bance (GSDS), and state anxiety (STAI-S) at TP2. The SVR models were implemented
with three different kernels (i.e. Linear, Polynomial, Radial Sigma). All of our models
were tested on all three types of datasets. As predictors we used all the data collected
at TP1 (see Table 4.1).
We compared the performance of the models based on their RMSE, their RMSE/mean
ratio (see Tables 4.3, 4.4), and their differences in the Bland-Atman plots (Figure 4.5).
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In general the SVR models provided better fitted models with lower prediction error.
All the models provided better results using the MI dataset. For the prediction of
sleep disturbance, the SVR with the polynomial kernel achieved a RMSE of 13.153 and
a RMSE/mean ratio of 0.209. For sleep disturbance, the n-CCA achieved a RMSE
of 16.113 and NRMSE of 0.306. For the prediction of anxiety, the polynomial kernel
achieved a RMSE of 7.983 and a RMSE/mean ratio of 0.220. For anxiety the n-CCA
achieved a RMSE of 8.941 and a RMSE/mean ratio of 0.677. Finally, for the prediction
of depression, the polynomial kernel achieved a RMSE of 6.191 and a RMSE/mean ratio
of 0.465. For depression, the n-CCA achieved a RMSE of 6.907 and a RMSE/mean
ratio of 0.221.
Table 4.3: Performance of Support Vector Regression (SVR) models for predicting
Sleep Disturbance (GSDS), Anxiety (STAI-S) and Depression (CES-D) at TP2
Sleep Dis-
turbance
Anxiety Depression
Dataset Kernel RMSE NRMSE RMSE NRMSE RMSE NRMSE
Missing
data
Linear 13.302 0.251 8.084 0.244 6.484 0.509
Polynomial 13.379 0.251 8.082 0.245 6.435 0.506
Radial Sigma 13.709 0.258 8.147 0.247 6.475 0.518
Multiple
Imputation
Linear 13.156 0.212 7.985 0.221 6.201 0.465
Polynomial 13.153 0.209 7.982 0.220 6.191 0.465
Radial Sigma 13.243 0.239 8.045 0.228 6.401 0.488
Maximum
Likelihood
Linear 13.316 0.248 8.583 0.256 7.102 0.537
Polynomial 13.331 0.246 8.476 0.251 7.081 0.536
Radial Sigma 13.836 0.256 8.625 0.258 7.189 0.556
Regarding the discrepancies between the two types of measurements as shown on the
Bland-Atman plots (Figure 4.5), the mean differences in the measurements of all three
symptoms (i.e., sleep disturbance, anxiety, depression) were close to zero. Most of these
differences were between +1.96SD and -1.96SD from the mean difference, which sug-
gests a normal distribution. The two types of analysis (i.e., SVR with polynomial kernel
and n-CCA) show a moderate to high level of agreement between their measurements.
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Table 4.4: Performance of n-CCA for predicting Sleep Disturbance (GSDS), Anxiety
(STAI-S) and Depression (CES-D) at TP2
Sleep Disturbance Anxiety Depression
Dataset RMSE NRMSE RMSE NRMSE RMSE NRMSE
Missing
data
19.955 0.307 12.238 0.681 9.661 0.222
Multiple
Imputation
16.113 0.306 8.941 0.677 6.907 0.221
Maximum
Likelihood
16.680 0.305 9.320 0.676 7.583 0.218
Comparison Between the Real and Predicted Values
For all three symptoms (i.e., sleep disturbance, anxiety, depression), the means of the
predicted values were very close to the means of the real values (Table 4.5). Regarding
their ranges, the ranges of the predicted values from the SVR models were much closer
to the ranges for the real values (Table 4.5). In general, the distributions of predicted
values, from both analytical models, were very similar to the distributions for real
values (Figure 4.8). n-CCA, as a Neural Network based algorithm, appears to be
affected by our relatively small sample size and the distribution of data on the edges of
the symptom scales. In general, it performed better where the data were denser (i.e.,
more data). On the other hand, SVR with polynomial kernel appears to be less affected
by the aforementioned factors and provided predicted values with a high concordance
with the real values.
4.4 Summary and Discussion
This study is the first to use two different machine learning techniques to accurately
predict the severity of three common symptoms (i.e., sleep disturbance, anxiety, de-
pression) from prior to through one week following the administration of CTX. The
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Table 4.5: Sleep Disturbance (GSDS), Anxiety (STAI-S) and Depression (CES-D) Real
values compared to the Predicted values with the SVR (polynomial kernel) and n-CCA
on the dataset with the Maximum Likelihood Estimation imputation
Symptoms
Real
Values
(mean)
Real
Values
(range)
SVR (polynomial kernel) n-CCA
Predicted
Values
(mean)
Predicted
Values
(range)
RMSE NRMSE
Predicted
Values
(mean)
Predicted
Values
(range)
RMSE NRMSE
Sleep Disturbance 54.796
7.000
-
105.000
54.089
20.044
-
100.214
13.331 0.246 54.600
38.427
-
86.368
16.680 0.305
Anxiety 34.481
20.000
-
76.000
33.749
19.495
-
74.236
8.476 0.251 34.865
24.895
-
57.583
9.320 0.267
Depression 14.119
0.000
-
49.000
13.205
0.097
-
49.110
7.081 0.536 13.792
4.578
-
33.338
7.583 0.550
Figure 4.8: Density plots of the Sleep Disturbance (GSDS), Anxiety (STAI-S) and
Depression (CES-D) Real values compared to the density plots of Predicted values with
the SVR (polynomial kernel) and n-CCA on the dataset with the Maximum Likelihood
Estimation imputation
predictions were constructed using the features of the experimental dataset collected
at the first Time Point. Using the SVR method, the differences between the real val-
ues (i.e., symptom severity scores that the patients reported) and the predicted values
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were not meaningful differences. Furthermore, we obtained fairly similar results with
n-CCA at the expense of having a smaller variance among the predicted values (i.e.
higher ratio of RMSE/mean in most cases). The results indicate that relatively similar
findings were obtained independent of the number of missing values or the imputation
method used to compensate for missing values in our dataset. The ability to predict
the severity of future symptoms in oncology patients will be a powerful tool for on-
cology clinicians. Developing computational tools using machine learning techniques
will assist clinicians to risk profile patients and implement pre-emptive symptom man-
agement interventions. Using this information, clinicians will be able to customize a
patients treatment, increase their tolerance for CTX, and improve their quality of life.
Following replication, these methods can be evaluated as a decision support tool to as-
sist clinicians to improve symptom management in patients receiving CTX. Finally, the
approaches presented in this paper, may be applicable to the same set of co-occurring
symptoms in other chronic medical conditions.
The optimization of the feature selection process was one of the limitations of our
study. Being an exploratory study for the performance of the aforementioned predictive
models, we focused on the construction of predictive models and their evaluation and
comparison. This effort was implemented through comparison of different imputation
techniques ( i.e. MI, MLE), validation (i.e. RCV, CV, Bootstrap, Bootstrap .632)
and evaluation methods (i.e. RMSE, Bland-Altman plot). Future work will focus
on defining an effective set of predictors, as well as pre-processing and enhancing the
data collection and representation to improve the efficiency of both of the SVR and
the n-CCA models. In addition, we will develop an incremental learning method with
additional time points and evaluate it on a similar dataset.[204]
Chapter 5
Identifying Cancer Symptoms
Clusters and Sentinel Symptoms
with Pairwise Random Markov
Fields
In this chapter we present the problem of analysing the interactivity among cancer
symptoms and between their symptom clusters. We present Network Analysis (NA) as
a novel approach to gain insights into the complex nature of co-occurring symptoms and
symptom clusters and identify core symptoms. Using two different models of Pairwise
Markov Random Fields (PMRF), we examine the nature and structure of interactions
for three different dimensions of patients symptom experience (i.e., occurrence, severity,
distress). Findings from this study provide the first direct evidence that the connections
between and among symptoms differ depending on the symptom dimension used to
create the network.
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5.1 Introduction
Oncology patients undergoing cancer treatment experience an average of fifteen unre-
lieved symptoms that are highly variable in both their severity and distress. [205, 206,
207] In order to advance symptom management science and gain a better understand-
ing of oncology patients symptom experiences, research has focused on the evaluation
of symptom clusters using techniques such as exploratory factor analysis or cluster
analysis. [208, 101, 209] One of the underlying assumptions of this research is that
symptoms that cluster together may share underlying mechanisms that are potential
targets for therapeutic interventions. While progress is being made in symptom clusters
research, [208] one of the major gaps in knowledge using standard statistical approaches
is that the nature of the relationships among individual symptoms and symptom clus-
ters have not been evaluated. This gap in knowledge prevents the identification of
key symptom(s) that exert an influence on other co-occurring symptoms or symptom
clusters that may be potential target(s) for therapeutic interventions. In this study,
we investigate the application of Network Analysis (NA) methods to better understand
and interpret the associations among co-occurring symptoms and symptom clusters in
oncology patients receiving chemotherapy (CTX).
NA [210, 211, 212] is a graph theory based methodology that is being used to gain new
insights into systems biology [213, 214] depression, [215, 216] post-traumatic stress,
[217] complex bereavement, [218] quality of life (QOL), [219] and identifying high-risk
cancer sub-population. [220] In terms of oncology patients, NA allows one to visualize
and interpret quantitatively the relationships among various symptoms and symptom
clusters that patients are experiencing. While NA is being used to understand the
associations among psychiatric symptoms [221, 222, 223, 224, 225] and substance abuse
and dependence symptoms, [226] only one study was found that used NA to evaluate
symptoms in oncology patients. [227] Using data on the occurrence of 18 symptoms
in 665 oncology patients, a force directed layout algorithm was used to visualize a
patient-symptom bipartite network. Then four quantitative methods were used to
analyse the patterns of symptom occurrence suggested by the network visualizations.
The authors concluded that cancer symptoms occur in a nested pattern as opposed to
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distinct clusters.[227]
While a historic study,[227] the conclusions regarding the absence of distinct symptom
clusters warrants additional exploration because of the limitations and associated im-
plications of the NA methods that were used. For example, modularity optimization
has a resolution limit that may prevent it from detecting clusters which are compar-
atively small with respect to the graph as a whole, even when they are well defined
communities.[228] In addition, during unweighted or weighted one-mode projection,
some information is lost and the final models do not hold the complete structural in-
formation of bipartite networks.[229] As mentioned by the authors,[227] their methods
concealed how the groups of symptoms co-occurred, as well as their globally optimal
co-occurrence frequencies. In the current study, we explore the complex organisation
and interconnectedness of cancer symptoms and associated clusters by using two dif-
ferent models of Pairwise Markov Random Fields (PMRF)[230, 231, 232] on binary
symptom occurrence and ordinal symptom severity and distress data.
As part of a symptom assessment, oncology patients are asked to rate not only the
occurrence of the symptom, but its associated severity and distress.[233, 234, 235, 236]
Two of the unanswered questions in symptom clusters research is whether the number
and types of symptom clusters differ based on the dimension used to create the cluster
and how symptoms within and across clusters are related to each other.[208, 237] Our
study is the first to use NA to evaluate the relationships among symptoms and symptom
clusters using ratings of symptom occurrence, severity, and distress, in a sample of
oncology patients undergoing chemotherapy (CTX; n=1328). We used NA to examine
the relationships among 38 common symptoms and to explore if the network structures
for occurrence, severity, and distress have different properties. Our analyses show the
prevalence, importance, and influence of each symptom within each network and the
overall connectivity of cancer symptoms within each symptom dimension network. In
addition, the interrelationships among symptoms inside and outside of a symptom
cluster are described.
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5.2 Material and Methods
5.2.1 Patients and Settings
This secondary analysis is part of a longitudinal study of the symptom experience of
oncology outpatients receiving CTX. The methods for this study are described in detail
in our previous publications.[238, 239, 240] For this NA, enrollment assessment data
from the parent, longitudinal study were analysed (n=1328). Patients were eligible to
participate if they: were ≥ 18 years of age; had a diagnosis of breast, gastrointestinal
(GI), gynecological (GYN), or lung cancer; had received CTX within the preceding
four weeks; were scheduled to receive at least two additional cycles of CTX; were able
to read, write, and understand English; and gave written informed consent. Patients
were recruited from two Comprehensive Cancer Centers, one Veterans Affairs hospital,
and four community-based oncology programs. This study was approved by the Com-
mittee on Human Research at the University of California, San Francisco. All methods
were performed in accordance with the relevant guidelines and regulations. A written
informed consent was obtained from all patients.
5.2.2 Cancer Symptom Dimensions
A modified version of the Memorial Symptom Assessment Scale (MSAS)[236] was used
to evaluate the occurrence, severity, and distress of 38 symptoms commonly associated
with cancer and its treatment. In addition to the original 32 MSAS symptoms, the
following six symptoms were assessed: hot flashes, chest tightness, difficulty breathing,
abdominal cramps, increased appetite, and weight gain. The MSAS is a self-report
questionnaire designed to measure the multidimensional experience of symptoms. Using
the MSAS, patients were asked to indicate whether or not they had experienced each
symptom in the past week (i.e., symptom occurrence). If they had experienced the
symptom, they were asked to rate its severity and distress. Symptom severity was
measured using a 4-point Likert scale (i.e., 1 = slight, 2 = moderate, 3 = severe, 4 =
very severe). Symptom distress was measured using a 5-point Likert scale (i.e., 0 = not
at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). The reliability
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and validity of the MSAS are well established in studies of oncology inpatients and
outpatients.[236]
5.2.3 Network analysis
In general, networks are defined as a collection of interconnected components (i.e., in
this paper, symptoms). These components are called nodes and their interaction links
are called edges.[241] A Pairwise Markov Random Field (PMRF)[232] is an undirected
graphical model of a set of random variables having a Markov property, described by
this undirected graph (or network). Its edges indicate the full conditional association
between two nodes after conditioning on all of the other nodes in the network. When
a relationship exists between two nodes (i.e., symptoms) that cannot be explained by
any other node in the network, these two nodes are connected. The absence of an
edge between two nodes (i.e., symptoms) indicates that these nodes are conditionally
independent of each other given the other nodes in the network (Figure 5.1).
Figure 5.1: A Pairwise Markov Random Field (PMRF) or an undirected graphical
model with 6 nodes, A to F. The presence of edges between nodes indicates the condi-
tional dependency between them.
When estimating a PMRF, the number of parameters that need to be estimated grows
quickly with the size of the network.[242] In our 38-node networks, 741 parameters (i.e.,
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38 threshold parameters and 38 × 37/2 = 703 pairwise association parameters) needed
to be estimated.[242] To estimate this number of parameters in a reliable fashion, the
number of observations in our sample needed to be at least equivalent, which it was
given a sample size of 1328 patients.
To create the networks, we used the generalization of the Ising model presented in
the IsingFit R-package[243] for the occurrence data and the polychoric correlation
method[231] for the severity and distress data, using the R-package qgraph [244]. Both
approaches entailed the application of a statistical regularization technique, which pro-
vided an extra penalty for model complexity. The edges that were likely to be spurious
or false positives were removed from the models, leading to networks that were more
interpretable.
The model used in the IsingFit R-package[243] is a binary equivalent of the Gaussian
approximation method. Its variables can have only two states and interactions are
considered pairwise. The aforementioned model contains two node-specific parameters:
the interaction parameter βjk, representing the strength of the interaction between
variable j and k, and the node parameter τj , which represents the autonomous disposi-
tion of the variable to take the value of one - ”1” - regardless of neighboring variables.
The IsingFit model estimates the aforementioned parameters using logistic regression.
Through repetition, every variable is regressed on all of the other variables. To obtain
sparsity, an `1-penalty is imposed on the regression coefficients. The level of shrinkage
depends on the penalty parameter of the lasso. In the IsingFit method, the Extended
Bayesian Information Criterion (EBIC) is used to select the set of neighbor nodes that
yield the lowest EBIC and in this way constructs the final “true” network.
By viewing Xj as the response variable and all the other variables X\j as the predictors,
the EBIC is represented as:
BICγ(j) = −2`(Θˆj) + |J | · log(n) + 2γ |J | · log(p− 1) (5.1)
in which `(Θˆj) is the log likelihood of the conditional probability of Xj given its neigh-
bours, Xne(j), |J| is the number of neighbours selected by logistic regression at a certain
5.2. Material and Methods 77
penalty parameter ρ, n is the number of observations, p - 1 is the number of covariates
(predictors), and c is a hyperparameter, determining the strength of prior information
on the size of the model space. The model with the set of neighbours J that has the
lowest EBIC is selected.
For severity and distress, we used the R-package qgraph[244] and applied the polychoric
correlation method in combination with the graphical ”least absolute shrinkage and
selection operator” (glasso) algorithm.[231, 245, 246] The glasso algorithm by inverting
its input, which is the sample’s polychoric correlation matrix, returns a sparse network
model where only a relatively small number of edges are used to explain the covariance
structure in the data. More precisely, the graphical lasso estimator is the Θˆ such that:
Θˆ = argminΘ≥0
tr(SΘ)− log det(Θ) + λ∑
j 6=k
|Θjk|
 (5.2)
where S is the sample’s polychoric correlation matrix, and λ is a penalizing parameter.
Glasso utilizes this penalizing parameter to control the degree to which regularization
is applied. This penalising parameter can be selected by minimizing the EBIC. In
general, graphical lasso controls the relationships between the variables in a network
and gives partial correlations between variables, which increases the parsimony of the
final network models.[231, 246]
The above mentioned techniques allowed us to create and construct the networks using
the symptom occurrence, severity, and distress data. However, it is crucial to establish
robust methods to assess the stability and accuracy of the network. The next section
discusses our approach to assess and evaluate the constructed networks.
5.2.4 Network Assessment
In network model representations, nodes (symptoms) are represented as circles and links
between nodes (edges) are represented as lines (see Figures 5.2A, 5.3A, and 5.4A). The
size of each node (i.e., symptom) is proportional to the occurrence rate, severity rating,
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or distress rating of each symptom. Each link in the network represents the intercon-
nections between two symptoms after conditioning on all of the other symptoms in
the network. Green lines indicate positive inter-connections. Red lines indicate nega-
tive inter-connections. Thicker lines indicate stronger inter-connections. Because the
strength of the relationships between symptoms are taken into account, the networks
are considered weighted. The layout of these networks is based on the Fruchterman-
Reingold algorithm, which estimates the optimal layout so that nodes with stronger
and/or more connections are placed closer to each other.[247]
In order to gain additional insights into the structural importance of each node (i.e.,
symptom) in each of the networks, three centrality indices (i.e., betweenness, closeness,
strength) were estimated.[248, 231] Nodes with high centrality indices are considered
core nodes in the network. Betweenness measures the number of times a node lies on
the shortest path between two other nodes. This index indicates which nodes may act as
bridges between other nodes in the network. Closeness summarizes the average distance
of a node to all other nodes in the network. Closeness allows for the identification of
nodes (i.e., symptoms) that are in a position to have a substantial influence on other
node(s) (i.e., other symptom (s)) in the network. Strength indicates which node has the
strongest overall connections. It is calculated by summing the absolute edge weights
that are connected to a specific node. Strength provides a measure for identifying the
most connected node (i.e., symptom) inside a network.
Figures B.1-B.3 in the Appendix B illustrate the distribution of each symptom within
each dimension (i.e. occurrence, severity, distress). These data are presented to assess
whether some of our findings could be due to floor or ceiling effects that affect the
properties of our centrality indices.[249]
5.2.5 Network Accuracy and Stability
Inherent in NA is the problem of obtaining network structures that are sensitive to
a specific dataset, or to the specific variables included in a study, and/or the specific
estimation methods used. As recommended in the literature,[242] we used bootstrap
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confidence regions to examine the certainty of the edges and tested for significance
between edge weights with α = 0.05 based on 1000 bootstrap iterations. To estimate
the stability of the order of the centrality indices, we used a case- and node-dropping
sub-setting bootstrap technique together with the correlation stability coefficient (Cs-
coefficient), which is an index of the stability of the centrality indices. The Cs-coefficient
quantifies the maximum proportion of cases or nodes, respectively, can be dropped at
random to retain, with 95 % certainty, a correlation of at least 0.7 with the centralities
of the original network.[242] While no strict cut-off value exists for the CS-coefficient,
its value should be at least 0.25 and preferably higher than 0.5.
Additionally to the aforementioned analyses, we tested the stability of the centrality
indices on four equally divided and randomly assigned subsets. This analysis showed
the stability of the identified networks as well as the repeatability of the NA approach
on cancer symptoms’ dimensions.
In order to determine whether and how symptoms clustered together inside our net-
works, we used the Walktrap algorithm.[250, 251] The Walktrap algorithm identifies
communities (i.e., clusters) of nodes (i.e., symptoms) that are relatively highly con-
nected with each other. Nodes in a community are more likely to connect to other
nodes in the same community than to nodes in other communities. Each community
corresponds to a connected subgraph. In Figures 5.2B, 5.3B, and 5.4B, these commu-
nities (i.e., symptom clusters) are visualized with different colors.
5.3 Results
The 38 cancer symptoms illustrated in the nodes in each of the Figures
5.2-5.4 are coded in the following fashion: difcon: Difficulty Concentrating, pain:
Pain, energy: Lack of Energy, cough: Cough, nervous: Feeling Nervous, hotflash:
Hot Flashes, drymouth: Dry Mouth, nausea: Nausea, drowsy: Feeling Drowsy, numb:
Numbness or Tingling in Hands or Feet, chest: Chest Tightness, difbreath: Difficulty
Breathing, difsleep: Difficulty Sleeping, bloat: Feeling Bloated, urinate: Problems with
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Urination, vomit: Vomitting, sob: Shortness of Breath, diarrhea: Diarrhea, sad: Feel-
ing Sad, sweats: Sweats, sexual: Problems with Sexual Interest or Activity, worry:
Worrying, itch: Itching, appetite: Lack of Appetite, abdominal: Abdominal Cramps,
increaseapp: Increased Appetite, wtgain: Weight Gain, dizzy: Dizziness, swallow: Dif-
ficulty Swallowing, irritable: Feeling Irritable, mouthsore: Mouth Sore, wtloss: Weight
Loss, hairloss: Hair Loss, constipat: Constipation, swelling: Swelling, taste: Change in
the Way Food Tastes, myself: I Do Not Look Like Myself, skin: Changes in Skin.
textbfSample Characteristics - Of the 1328 patients in this study, 77.7% were female
and their mean age was 57.2 (+12.4) years. The majority of the patients had breast
(40.2%) or gastrointestinal (30.7%) cancer. These patients reported an average of 13.9
(+7.2) symptoms prior to their next dose of CTX. Additional sample characteristics
are summarized in Table B.1 in Appendix B.
5.3.1 Network Models of Symptom Occurrence, Severity, and Dis-
tress
Occurrence - For the occurrence dimension, created using the IsingFit method (see
Figure 5.2A), we used a gamma value of 0.25 and the OR rule for the nodewise esti-
mation. All of the symptoms were directly or indirectly associated with the network
and the network had a medium density (i.e., 36.42% of the potential connections were
observed in the network). All connections were positive except for weight gain (wtgain)
and weight loss (wtloss).
Severity - For the severity dimension, created using the polychoric correlation method
and the glasso algorithm (Figure 5.3A), we used a tuning parameter of 0.25. All of the
symptoms were directly or indirectly associated with the network and the network had a
medium density (i.e., 54.48% of the potential connections were observed in the network).
All of the connections were positive except for: increased appetite (increaseapp) and
lack of appetite (appetite); hair loss (hairloss) and difficulty with urination (urinate);
and diarrhea (diarrhea) and constipation (constipat).
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Figure 5.2: The estimated networks of 38 cancer symptoms across the ”occurrence”
dimension (a) without the identified communities and (b) with the identified commu-
nities (walktrap algorithm). Nodes represent symptoms and edges represent pairwise
dependencies between the symptoms, after controlling for all of the other correlations
of a given node.
Distress - For the distress dimension, created using the polychoric correlation method
and the Glasso algorithm (Figure 5.4A), we used a tuning parameter of 0.25. All of the
symptoms were directly or indirectly associated with the network and the network had a
medium density (i.e., 50.92% of the potential connections were observed in the network).
All of the connections were positive except for: increased appetite (increaseapp) and
lack of appetite (appetite); weight gain (wtgain) and weight loss (wtloss); diarrhea
(diarrhea) and hot flashes (hotflash); and hot flashes and swelling of the arms and legs
(swelling).
To inspect the statistical importance and possible role of each symptom inside each
of the the networks, we calculated their centrality indices (Figure 5.5). As shown
in Supplemental Table B.2 in the Appendix B, for the symptom occurrence network,
nausea and lack of appetite had the highest scores for all three centrality indices. For the
severity network, lack of appetite had the highest scores for all three centrality indices
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Figure 5.3: The estimated networks of 38 cancer symptoms across the ”severity” di-
mension (a) without the identified communities and (b) with the identified communities
(walktrap algorithm). Nodes represent symptoms and edges represent a partial correla-
tion between the symptoms, after controlling for all of the other correlations of a given
node.
and lack of energy had the highest scores across two centrality indices (betweenness and
closeness). For the distress dimension, lack of appetite had the highest scores across
all three centrality indices.
5.3.2 Network Accuracy and Stability
Bootstrap confidence regions for the edges’ weights were mostly overlapping (shown in
Appendix Figure B.4). The results of the case- and node-dropping bootstrap techniques
that were used to estimate the stability of the centrality indices are shown in Appendix
Figures B.5. Robustness analyses of the centrality indices showed the following CS-
coefficients for each dimension: 1) Occurrence: 0.517 for strength, 0.128 for closeness,
and 0.128 for betweenness; 2) Severity: 0.361 for strength, 0.05 for closeness, and 0.284
for betweenness; and 3) Distress: 0.361 for strength, 0.205 for closeness, and 0.128
for betweenness. Across the three symptom dimensions, node strength was the most
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Figure 5.4: The estimated networks of 38 cancer symptoms across the ”distress” di-
mension (a) without the identified communities and (b) with the identified communities
(walktrap algorithm). Nodes represent symptoms and edges represent a partial correla-
tion between the symptoms, after controlling for all of the other correlations of a given
node.
reliable centrality index.
We also obtained similar results for the node strength for the 4 equally divided and
randomly assigned subsets of patients, for each symptom dimension (i.e. occurrence,
severity, distress) (See Appendix Figures B.6 and B.7).
5.3.3 Communities Within Each Symptom Dimension Network
Occurrence - Using the walktrap algorithm (Figure 5.2B), the symptoms appear to
group into six main clusters: psychological symptom cluster [shown in gold], hormonal
symptom cluster [shown in blue], respiratory symptom cluster [shown in green], nu-
tritional symptom cluster [shown in white, yellow, and brown], CTX-related symptom
cluster [shown in red], and pain and abdominal symptom cluster [shown in purple].
Severity - Using the walktrap algorithm (Figure 5.3B), the symptoms appear to group
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Figure 5.5: Centrality indices for the estimated network of 38 cancer symptoms shown
in Figures 5.2A to 5.4A.
into five main clusters: psychological symptom cluster [shown in gold], hormonal symp-
tom cluster [shown in blue], respiratory symptom cluster [shown in green], nutritional
symptom cluster [shown in white and brown], and CTX-related symptom cluster [shown
in red].
Distress - Using the walktrap algorithm (Figure 5.4B), the symptoms appear to group
into seven main clusters: psychological symptom cluster [shown in gold], hormonal
symptom cluster [shown in blue], respiratory symptom cluster [shown in green], nu-
tritional symptom cluster [shown in white and brown], CTX-related symptom cluster
[shown in red], GI symptom cluster [shown in pink], and epithelial symptom cluster
5.3. Results 85
[shown in purple].
It should be noted, in the communities (i.e., symptom clusters) that were constructed
using the walktrap algorithm, while a number of the symptom clusters have the same
names, the specific symptoms within each of these clusters vary across the three di-
mensions (Table 5.1).
Table 5.1: Symptom Clusters Derived From Network Analyses of Occurrence, Severity,
and Distress
Psychological Symp-
tom Cluster
difficulty sleeping difficulty sleeping difficulty sleeping
worrying worrying worrying
feeling sad feeling sad feeling sad
feeling irritable feeling irritable feeling irritable
feeling nervous feeling nervous feeling nervous
difficulty concen-
trating
difficulty concen-
trating
difficulty concen-
trating
lack of energy lack of energy
feeling drowsy feeling drowsy
problems with
sexual inter-
est/activity
problems with
sexual inter-
est/activity
Hormonal Symptom
Cluster
sweats sweats sweats
hot flashes hot flashes hot flashes
problems with
sexual inter-
est/activity
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Respiratory Symp-
tom Cluster
shortness of
breath
shortness of
breath
shortness of
breath
difficulty breath-
ing
difficulty breath-
ing
difficulty breath-
ing
cough cough cough
chest tightness chest tightness chest tightness
Nutritional Symp-
tom Cluster
weight gain weight gain weight gain
weight loss weight loss weight loss
increased ap-
petite
increased ap-
petite
increased ap-
petite
nausea nausea
vomiting vomiting
lack of appetite lack of appetite
change in way
food tastes
Chemotherapy-
related Symptom
Cluster
itching itching
hair loss hair loss
changes in skin changes in skin
I don’t look like
myself
I don’t look like
myself
change in way
food tastes
change in way
food tastes
lack of appetite
mouth sores mouth sores mouth sores
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difficulty swal-
lowing
difficulty swal-
lowing
difficulty swal-
lowing
dry mouth dry mouth dry mouth
vomiting
nausea
dizziness dizziness dizziness
constipation constipation
swelling of arms
or legs
swelling of arms
or legs
problems with
urination
problems with
urination
diarrhea
abdominal
cramps
numbness/tingling
in hands/feet
numbness/tingling
in hands/feet
pain Pain
feeling bloated
lack of energy
feeling drowsy
Pain and Abdominal
Symptom Cluster
diarrhea Not identified Not identified
abdominal
cramps
feeling bloated
swelling of arms
or legs
pain
numbness/tingling
in hands/feet
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problems with
urination
Gastrointestinal
Symptom Cluster
Not identified Not identified diarrhea
abdominal
cramps
constipation
feeling bloated
Epithelial Symptom
Cluster
Not identified Not identified hair loss
I don’t look like
myself
itching
skin changes
5.4 Discussion
This study is the first to use NA methods to examine the relationships among 38 com-
mon symptoms in a large sample of oncology patients undergoing CTX using ratings of
occurrence, severity, and distress. The use of NA to understand the symptom experi-
ence of oncology patients has the potential to increase our knowledge of the structural
relationships among co-occurring symptoms and symptom clusters; the core symptoms
driving associations between and among symptoms, and how co-occurring symptoms
and symptom clusters change based on the dimension of the symptom experience that
is used to create the network .
Our hypothesis that the network structure for the distress dimension would differ from
the occurrence and severity dimensions was partially supported based on visual inspec-
tion of the network structures and the larger number of symptom clusters identified in
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the distress network. For over four decades, emphasis has been placed on an evaluation
of multiple dimensions of the symptom experience because each dimension provides
distinct and useful information.[233, 234, 235, 236, 252, 253] Occurrence data are used
to identify the most common symptoms in oncology patients. Severity data are used to
determine the magnitude of a specific symptom and to guide treatment decisions. An
evaluation of symptom distress provides information on “the physical or mental anguish
or suffering” associated with a symptom.[252] While symptom theory[254, 255, 256, 257]
and data from studies that used the MSAS suggest that these three dimensions are
distinct,[235, 236, 258, 259, 260] findings from our study provide the first direct ev-
idence that the connections between and among symptoms differ depending on the
symptom dimension that was used to create the network.
Because oncology patients experience an average of fifteen unrelieved symptoms that
are highly variable in their occurrence, severity, and distress,[205, 206, 207] an equally
important question in symptom research is to determine which symptom or symp-
toms is driving the other symptoms. While our NA of cross-sectional data does not
demonstrate causality, the centrality indices provide some insights into the structural
importance of each of the symptoms within each of the networks. In terms of the
occurrence network, nausea had the highest scores for all three centrality indices. In
this sample, 47.48% of patients reported nausea prior to their next dose of CTX. While
vomiting is well controlled with newer antiemetic regimens, nausea is a persistent symp-
tom that compromises a patient’s nutritional status, results in significant psychological
distress, has a negative impact on quality of life, and can result in the discontinuation
of cancer treatment.[261, 262, 263] For both the severity and distress networks, lack
of appetite had the highest scores for all three centrality indices and it was the symp-
tom with the second highest centrality scores for the occurrence dimension. While this
symptom was reported by 41.31% of the patients in this study, it is a symptom that
is not routinely assessed in oncology patients undergoing cancer treatment. Based on
network theory,[222, 264, 265, 266, 267] given their high centrality index scores, these
symptoms may be targets for therapeutic interventions that if successful would reduce
other symptoms in the network.
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While a tremendous amount of research has focused on the evaluation of symptom clus-
ters in oncology patients,[208, 237] our study is the first to use NA to visualize how one
symptom cluster is associated with other symptom clusters. To date, the majority of
the work to create symptom clusters was done using cluster analysis or factor analysis.
While these approaches identified some of the most common symptom clusters in on-
cology patients, these symptom clusters are created as independent “factors”. Our NA
represents a major breakthrough in symptom cluster research. Within each dimension,
our graphical representation allows us to visualize how the various symptom clusters
within the network are inter-connected with other symptom clusters in the same net-
work. Based on network theory,[264, 268, 269] we can hypothesize that symptoms on
the edges of each of the clusters may have an influence on that cluster. For example,
in Figure 5.2B, difficulty sleeping and hot flashes are on the edges of their respective
symptom clusters. While we cannot demonstrate causality, it is known that the occur-
rence of hot flashes disrupts patients’ sleep.[270, 271] If our findings are confirmed in
an independent sample, future NAs can evaluate for causality and test interventions to
reduce symptoms across clusters.
In terms of the specific symptom clusters identified for each of the symptom dimensions,
our finding of a psychological symptom cluster across all three dimensions is consistent
with findings from a recent review that noted that this cluster is one of the most common
clusters identified in oncology patients.[208] The other four symptom clusters that were
common across all three symptom dimensions (i.e., hormonal, respiratory, nutrition,
and CTX-related) were reported in previous symptom cluster studies.[272, 273, 274,
275, 276] The fact that two additional and unique symptom clusters were identified
within the distress network provide additional support for the hypothesis that symptom
distress is a distinct dimension of the oncology patients’ symptom experience. Future
research will need to evaluate causality among symptoms within each of the dimension
networks and whether common or distinct interventions are needed to decrease the
severity and distress associated with a specific symptom.
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5.4.1 Limitations and Future Directions
Several limitations warrant consideration. While our sample was rather large in com-
parison to the number of parameters estimated, the heterogeneity introduced by the
specific demographic and clinical characteristics of the patients in this study may in-
fluence the stability of our estimated networks. Since this study is the first to use NA
to examine the relationships among co-occurring symptoms and symptom clusters, our
findings warrant replication in an independent sample of oncology patients undergoing
CTX. In addition, this analysis of cross-sectional data does not allow for causal infer-
ences on the role of each symptom within each of our networks. Finally, because no
standards exist to interpret the significance and robustness of networks and because
the validity of the visual interpretation of complex networks is subjective, additional
research is warranted to confirm our findings.
In terms of directions for future research, our findings warrant replication in an in-
dependent sample with similar demographic and clinical characteristics. In addition,
comparisons of network structures need to be done among different cancer diagnoses,
across different stages of disease, and among different cancer treatments. The impact
of various demographic (e.g., age, gender) and clinical (e.g., comorbid conditions, func-
tional status) characteristics on the network structure of cancer symptoms warrants
evaluation. Using longitudinal data, NA will allow us to explore the causal relation-
ships among co-occurring symptoms and symptom clusters.[215]
5.5 Summary
In this study, we used NA to investigate the relationships among 38 common symptoms
in oncology patients receiving CTX. As the first NA of cancer symptoms, our work
provides new insights into the inter-relationships among co-occurring symptoms and
symptom clusters. Findings from this study suggest that the connections between and
among symptoms may differ depending on the symptom dimension used to create the
network. Our findings suggest that distress may be a different dimension of a patient’s
symptom experience. In addition, this study provides the first visualizations of the
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inter-relationships among symptom clusters across three dimensions of the patients’
symptom experience. While these findings warrant confirmation in an independent
sample, we believe that NA has the potential to improve our understanding of the on-
cology patients’ symptom experience so that individualized and targeted interventions
can be prescribed to reduce each patient’s symptom burden.
Chapter 6
Bayesian Networks and Causal
Inference for the Interpretation
of Cancer Symptom Experience
In this chapter we present the implementation and evaluation of algorithms from 3 dif-
ferent families of Bayesian Network Analysis (BNA) algorithms on cancer symptoms.
Identifying sentinel or core symptoms at early onset is crucial in oncology practice, but
it is also the most complex of tasks. To address this, we use a Bayesian Network Analy-
sis (BNA) approach on a comprehensive dataset of 38 different but co-occurring cancer
symptoms from a sample of 1328 cancer patients receiving chemotherapy. We evaluate
three classes of algorithms (constrained-based, score-based, hybrid algorithms) on their
structure stability and performance with different sample sizes and demographic char-
acteristics (age and gender); We demonstrate their clinical use for casual discovery and
inference. The hybrid algorithm identified more dense network structures that were
clinically relevant, not only for the entire sample but for our case studies of gender and
age. This work demonstrates how to process a comprehensive set of symptom experi-
ence data for interactions and provides guidance on using BNA findings appropriately
and reproducibly for clinical practice when using different algorithms, sample sizes and
comparative sub-populations.
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6.1 Introduction
Cancer and its treatment create a significant symptom burden onto oncology patients
across all tumor types, stages, and phases of care. [277, 278] Oncology patients under-
going cancer treatment experience an average of 10 to 15 unrelieved symptoms that
can be highly variable in their occurrence, severity and distress.[205, 206, 207] Re-
search on these symptoms and relevant Patient Reported Outcomes (PROs) comes as
a consequence of the realisation that improving the quality of life of cancer patients is
crucial across all oncology care. [277, 279, 280, 278] Until now, studies that evaluated
multiple co-occurring symptoms have used analytical techniques such as exploratory
factor analysis or cluster analysis.[208, 237, 209] One of the main research hypothesis
in this field is that symptoms that cluster together may share underlying mechanisms
that are potential targets for therapeutic interventions. [281] Nevertheless, the preva-
lent research on cancer symptom management has several limitations.[208] The current
analytical approaches have been limited in investigating the nature of the relationships
between and among individual symptoms and multiple-occurring symptoms. This lim-
itation has created a significant gap in knowledge about the presence of symptom(s)
that may exert an influence on other co-occurring symptoms. The accurate identifi-
cation of these symptoms (i.e., sentinel or core symptoms) may provide target(s) for
early therapeutic interventions to decrease patients’ symptom burden. In this study,
we explore the application of Bayesian Network Analysis (BNA) to evaluate the re-
lationships between and among multiple co-occurring symptoms in oncology patients
receiving chemotherapy (CTX). Being one of the first studies in the domain of the can-
cer symptom experience, we explore how BNA can be used to map the pathways that
illustrate how symptoms interact and influence each other. In addition, we elaborate
on the key analytical aspects that are needed to increase the reproducibility of this
work as well as for the extension/comparison of clinical findings to different samples of
cancer patients.
BNA is an analytical approach that can be used to explore multivariate relationships
with intuitive graphs, also known as causal graphs, causal diagrams or Directed Acyclic
Graphs (DAGs). Bayesian Networks (BNs) are probabilistic graphical models that
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represent a set of variables (e.g., cancer symptoms) and their conditional dependencies
using a DAG.[282] Using BNA, the multivariate relationships (i.e. joint probability
distributions) between these variables are quantified and visualised graphically, with
nodes and arcs (see Materials and Methods, Figure 6.1), making the discovery and
analysis of their inter-relatedness more comprehensive. In principle, such causal graphs
can be used to answer questions related to: (i) causal discovery (i.e., which symptoms,
among others, can influence another distinct symptom) and (ii) causal inference (i.e.,
of what magnitude and causal connection - direct or confounding - these symptoms
affect the aforementioned target symptom).[261] Because of BN’s ability to handle
both observable as well as uncertain information (i.e. latent factors from observational
data), [283, 284, 285] BNs have been used in biomedical informatics for more than two
decades.
BNs are suitable tools for the probabilistic inference that can aid in clinical decision
making for several reasons. [286, 266, 283, 287] For example, they provide a visual
representation of causality that can be easily understood by a clinician. [266, 267, 288]
They can also integrate knowledge from clinical experts into their modelling procedure
while learning the structure and parameters of a network through the available data.
[266, 268, 287] In addition to their capacity to provide information on observational
and causal inferences, [266, 269] BNs can extract parameter estimates through the
representation of the joint probability space among the nodes or clinical variables (e.g.,
symptoms) in a model. [266] Likewise, BNs can be used with and perform well with
incomplete data. [266, 270, 271, 272]
With respect to their healthcare applications, BNs are commonly used in genomics and
system biology. [216, 217, 218, 219] The usefulness of their causal diagrams has been
also explored and applied in epidemiology, public health and health services research.
[226, 233, 234] Causal diagrams have been used to control for and identify confounding
variables, [260, 263] estimate effect sizes from observational data, [261] select features
that are most predictive of a target variable, [265] test for external validity, [262] fault
diagnosis and health monitoring, [235] as well as missing data [264] and selection bias.
[263] Notably, BNs’ applications supported decision making in a wide spectrum of the
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clinical practise (e.g., diagnosis, treatment, prognosis, risk modeling). [286] In cancer
research, BNs’ applications have been evaluated for survival prediction and treatment
selection in patients with lung and colon cancer; [266, 270, 271, 272] mammography
interpretation; [276] detection, diagnosis and prognosis of breast cancer; [266, 270, 271,
272] modelling and predicting the occurrence of brain metastasis from lung cancer [289]
and revealing the genetic and environmental basis of bladder cancer. [282] They have
been even applied to model and asses the interrelationships between life-style, health-
related factors and quality of life for cancer patients. [290, 221]
Nevertheless, BNs’ applications with direct relevance to cancer symptoms research have
been relatively unexplored. To our knowledge, only one longitudinal study used BNA
to investigate the effect of sleep disturbance, fatigue, and mood disturbance on cogni-
tion and quality of life in breast cancer patients before, during, and after CTX. [221]
While this study illustrates the use of BNs to evaluate the relationships among cancer
symptoms, it does not provide an extensive summary of the types of BN algorithms
that can be used. In addition, it does not specify how the proposed model can drive
data-driven domain knowledge discovery when the various symptoms’ structures are
unknown. Finally, it doesn’t elaborate on the analytical challenges that such clinical
applications can have. While this study [221] provides important information on the
relationships among three common co-occurring symptoms and quality of life, the sam-
ple size was relatively small (n=74) and included only patients with breast cancer. In
addition, only three symptoms were evaluated in the BN. Given that oncology patients
receiving CTX report an average of 14 co-occurring symptoms, [205], the goals of our
study are multifold and use a broader approach than the existing work. We describe
how BNA methods can be used to explore the interrelationships among 38 co-occurring
symptoms in a large, clinically representative sample of 1328 cancer patients undergo-
ing CTX. In addition, we show how these methods can be used to build new clinical
knowledge to highlight the notable differences in the BNs created using gender and
age (i.e. <65 versus >65 years of age based on the definition of an older person from
the World Health Organisation). [291] Finally, we explain how our findings can be
used to guide the development and testing of future interventions to improve symptom
management in oncology patients.
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Our contributions in this chapter are two-fold. First, we implemented three different
families of BNA algorithms using cross-sectional data on the occurrence of 38 symp-
toms, as well as on symptom occurrence data dichotomised by age and gender, to assess
and compare their structure, performance and stability. Second, we provide the ana-
lytical implications, the clinical interpretations and the significance of our findings in
relationship to these 38 common co-occurring symptoms in cancer patients receiving
CTX. Our work provides a first case study on how to process a comprehensive set of 38,
different cancer symptoms to assess their interactions and explore all the potential tar-
get symptoms for early remedial interventions. Its additional contribution to the field
of symptom research lies in the demonstration of how to bring and utilise BNA find-
ings in clinical practice when using different algorithms, sample sizes and comparative
sub-populations.
6.2 Material and Methods
6.2.1 Dataset Description
This study reports on a secondary analysis of data from a longitudinal study of the
symptom experience of oncology outpatients receiving CTX. The methods for this
study are described in detail in our previous publications. [222, 223, 224] For the
BNA experiments, enrollment data from the parent, longitudinal study were analysed
(nComplete=1328). Patients were eligible to participate if they: were 18 years of age or
older; had a diagnosis of breast, gastrointestinal (GI), gynecological (GYN), or lung
cancer; had received CTX within the preceding four weeks; were scheduled to receive at
least two additional cycles of CTX; were able to read, write, and understand English;
and gave written informed consent. Patients were recruited from two Comprehensive
Cancer Centers, one Veterans Affairs hospital, and four community-based oncology
programs. This study was approved by the Committee on Human Research at the
University of California, San Francisco. Written informed consent was obtained from
all patients.
98 Chapter 6. Bayesian Networks and Causal Inference for the Interpretation of
Cancer Symptom Experience
6.2.2 Symptom dimensions
To determine the occurrence of 38 symptoms commonly associated with cancer and
its treatment, a modified version of the Memorial Symptom Assessment Scale (MSAS)
[225] was used. In addition to the original 32 MSAS symptoms, the following six
symptoms were assessed: hot flashes, chest tightness, difficulty breathing, abdominal
cramps, increased appetite, and weight gain. Using the MSAS, patients were asked
to indicate whether or not they had experienced each symptom in the past week (i.e.,
symptom occurrence; yes = presence of a symptom, no = absence of symptom). The
reliability and validity of the MSAS are well established in studies of oncology inpatients
and outpatients. [225]
6.2.3 Bayesian Networks
Bayesian Networks (BNs), also known as a Bayesian Belief Networks (BBNs) or Be-
lief Networks, [215] are graphical models representing the relationships among multiple
variables and describing the conditional dependencies between them. They comprise a
network structure in the form of a Directed Acyclic Graph (DAG) and a set of condi-
tional probabilities, one for each variable, characterising the dependencies represented
by the DAGs edges (see Figure 6.1).
In BNA terminology, when we have a directed edge (i.e., arc or arrow) going from node
X to node Y, node X is considered to be a parent of Y. Accordingly, node Y is considered
a child of X. Every variable (i.e., node) inside a DAG, given the values of its parents,
is considered to be conditionally independent of the set of all its predecessors in this
graph. [282, 292] Based on the Markov Condition when two nodes are not connected
directly through an arrow, we consider these two variables to be independent. Taking
advantage of the aforementioned graphical structure and the chain rule of probability
calculus the total joint probability distribution of the group of variables represented
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Figure 6.1: Parents, child nodes and Markov Blanket of node F in a directed graph
inside a BN can be expressed as the product of their conditional probabilities: [282]
p(x|θ) =
n∏
i=1
p(xi|pa(xi), θi) (6.1)
where x = {x1, ..., xn} are the variables (i.e., the nodes inside a BN) and θ = {θ1, ..., θn}
are the BNs parameters. Each i is the set of parameters necessary to specify the
distribution of the variable xi given its parents pa(xi). [282]
The structure mentioned above can support researchers and clinicians to understand
the main cause(s) of a certain problem (i.e., symptom). It can also be used to describe
the probabilities of different effects (i.e., exacerbation of other symptoms) given an
action (i.e., presence of a core or sentinel symptom). To predict the value or behaviour
of a specific node inside a DAG, we need its Markov Blanket. The Markov Blanket of a
node (i.e., variable or symptom) is a set of nodes, consisting of its parents, child nodes
and all the other nodes sharing a child with it. For example, in Figure 6.1, nodes C,
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D are the parent nodes and nodes G, H are the child nodes of node F. Node E is a
parent node of G, sharing the same child node with node F. Thus, the Markov Blanket
of variable F is the group of all the aforementioned variables or nodes (i.e., C, D, F,
E, G, H). The minimum set of nodes that are necessary to predict the behaviour of
variable F are the ones included in this Markov Blanket. [293]
6.2.4 Inference in Bayesian Belief Networks
The structure of the edges in BNs is based on two analytical assumptions. Based on
the Causal Markov Assumption, given the values of a variables immediate causes, this
variable is independent of its earlier causes. The second assumption is that no latent
or hidden variables exist that affect the observable variables.
Additionally, Bayesian networks are DAGs comprising of qualitative and quantitative
parts. [294, 286] The qualitative part is the network Structure that we have explored
in the main of this paper. The qualitative part is captured by the Conditional Proba-
bilities Table (CPT) of the nodes (i.e. symptoms) included in the aforementioned BN.
More specifically, the CPT displays the conditional probabilities of each symptom with
respect to the others (i.e., the probability of each possible value of one symptom if
we know the values taken on by the other symptoms). Based on both, physical and
biological processes, such as the symptom experience, can be modeled as a network of
causal influences. [295]
Consider a two-node network where A and B are binary variables with two states (N or
Y). The marginal table at node A would contain the marginal probability P(A = Y). For
simplicity, we’ll use A to mean A = Y and a to mean A = N so that P(A = Y) and P(A
= N) can be written more briefly as P(A) and P(a), respectively. By complementarity,
P(a) = 1 P(A). At node B we would have the conditional probabilities P(B|A) and
P(B|a) that define how the state of B depends on the state of A. The Conditional
Probability Table (CPT) can be completed using complementarity: P(b|A) = 1 P(B|A)
and P(b|a) = 1 P(B|a). Thus, the marginal table for A lists all possible states for A,
and the CBT lists all possible state combinations of A and B. Once the network is
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constructed and the probabilities are specified, Bayes’ theorem is used to propagate
probability through the model.
Figure 6.2 illustrates a simple BN to demonstrate its application in probabilistic and
causal inference. As mentioned above, we assume that no latent or hidden variables
exist in this particular BN. An edge occurs from N to W because being ”nervous”
has a direct influence on the occurrence of the symptom ”worry”. In addition, being
”nervous” has a direct influence on the occurrence of the symptom of ”difficulty con-
centrating”. ”Difficult sleeping” may be due to feeling ”worry” or having ”difficulty
concentrating” or to both of the symptoms. o direct edge occurs from W to DC. In
probabilistic terms, knowing W and DC renders N and DS independent.
Figure 6.2: A simple BN representing dependencies among four cancer symptoms
For example, lets say that we know a patient has ”difficulty sleeping” and we want to
know if this symptom was due to feeling ”worry” or ”difficulty concentrating”. We can
use Bayes Theorem to compute the posterior probability of each case. The probabilities
of W and DC conditional on DS will be computed from the following equation:
P (W |DS) = P (DS|W ) · P (W )
P (DS)
(6.2)
P (DC|DS) = P (DC|DS) · P (DC)
P (DS)
(6.3)
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By comparing these two probabilities, we can infer which symptom this patient is
more likely to report. Increased knowledge of the Markov structure and conditional
probabilities of all the symptoms a cancer patient can experience, will provide additional
information to answer this question.
6.2.5 Bayesian Network Learning Algorithms
The process of identifying and understanding the structure of a BN from the available
data is called Learning, and it requires two steps. [296] The first step, called as Network
Structure or Structure Learning (i.e., identification of the topology of the BN), [296]
consists in finding the graph structure that encodes the conditional independencies
present in the data. The second step, call as Parameter Learning, deals with the
estimation of the parameters of the global distribution given the identified network
topology. [296]
Regarding Network Structure Learning, there are three different types of algorithms
for constructing BNs from observational data, categorised as constraint-based, score-
based, and hybrid algorithms. [297] In the Parameter Learning, there are two main
categories of algorithmic approaches, one focusing on complete data (e.g., Maximum
Likelihood Estimate) and the other focusing on incomplete data (e.g., Expectation-
maximization, Monte-Carlo, Gaussian approximation). [298] In this study, we focus on
network structure learning.
6.2.6 Structural Learning Algorithms
In this study, we use three well known structural learning algorithmic implementations,
one for each of the aforementioned approaches. These algorithms are the Grow-shrink
(Constraint-based), the Hill-Climbing (Score-based) and the Max-Min Hill-Climbing
(Hybrid). [297]
Constraint-based algorithms focus on recognising the conditional independence (i.e.,
Markov Condition) of all the observed variables between them. [296] They learn the
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network structure with conditional independence tests, such as x2, to determine the
absence of edges between variables, and then construct a graph, adding directions to
edges that satisfy the d-separation criterion. Given a causal graph, d-separation is a
criterion for deciding whether a set X of variables is independent of another set Y, given
a third set Z. More specifically, if X, Y, Z are three disjoint sets of variables in a BN, Z is
said to d-separate X from Y if and only if Z blocks every path from a node in X to a node
in Y. [299] Thus, Grow-Shrink (GS) is based on the recovery of the optimal Markov
Blanket of every variable X, based on pairwise independence tests. [300] Grow-shrink’s
name refers to its two different phases, the growing and the shrinking one. Initially,
the GS algorithm starts with a variable X and an empty set S. [301, 282, 300] The
growing phase adds variables to S as long as they are dependent on X, conditional on
the rest of the variables in S. In the following shrinking phase, variables that violate
the Markov blanket property of X are removed from S. Then, the algorithm identifies
the local neighbourhood (direct parents and children) of each variable in the network
within the Markov blanket to recover the exact structure around each variable. Edge
directions are determined by examining the triples of variables using the d-separation
criterion.
Score-based methods calculate a number of possible BN structures and allocate a
score to each that measures how well it explains the observed set of data. [282] These
algorithms select the BN structure that maximizes this score. Because the number
of potential structures is exponential in the number of nodes, even datasets with few
variables have too many possible BN structures to allow for an exhaustive search.
That is the reason why most score-based algorithms have employed heuristic search
techniques, such as Hill-Climbing or simulated annealing. [282, 297] More specifically,
Hill-Climbing (HC) search starts from either an empty, full or possibly random
network and existing prior knowledge can also be used to seed the initial candidate
network. The main loop consists of attempting every possible single-edge addition,
removal, or reversal in a candidate network. The structure that increases the score,
the most becomes the current candidate. The process iterates until a change in a
single-edge does not increase the score.
104 Chapter 6. Bayesian Networks and Causal Inference for the Interpretation of
Cancer Symptom Experience
Finally, Hybrid algorithms have also been developed and combine the constraint-
and score-based methods to maximise their advantages. They consist of two steps,
called restrict and maximise. [297] During the restrict step, a constraint-based al-
gorithm is implemented to identify the skeleton of the network using conditional in-
dependence tests. During the maximise step, a score-based method is employed to
maximise the score function of this network and identify the best set of edge orienta-
tions. In that manner, Max-Min Hill-Climbing (MMHC) first learns the skeleton
of a Bayesian network using a local discovery algorithm called Max-Min Parents and
Children (MMPC). MMPC consists of a forward phase and a backward phase. In the
forward phase, all variables with an edge to and from variable are selected using a
heuristic function. In the backward phase, all false positives chosen in the first phase
are removed. After MMPC identifies the skeleton of the BN, a greedy Bayesian-scoring
Hill-Climbing search is used to orient the edges. The algorithm has the advantages of
reliably scaling up to thousands of variable in a reasonable time.
6.2.7 Computation, Performance, Stability, Reproducibility and Struc-
ture Assessment
We implemented each of the analysis mentioned in this study using the bnlearn R pack-
age. [302] We implemented the visualisations using the visNetwork R package [303].
The algorithms (i.e., GS, HC, MMHC) used were assessed upon their performance (i.e.,
the goodness of fit in respect to particular score functions), their stability (i.e., per-
formance and topology across different sample sizes) and structure (i.e., discrepancies
between the different algorithms).
Computation
To ensure the reliability of the identified DAGs, we bootstrapped 10.000 BNs, for each
analysis presented, and we averaged them to obtain the final, resultant network. To
identify the possible true, high-confidence arcs (i.e., directed edges), we assessed the
frequency of the presence of an arc (i.e., directed edge) across the aforementioned boot-
strapped networks. The final visualised BNs contained the arcs that had a predefined
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frequency/inclusion threshold. These were based on an ad-hoc approach and an 85%
frequency, according to Sachs et al. [304] or a statistically motivated approach and
statistically optimised frequency, according to Scutari et al. [305]). In the first case, for
example, for the final averaged BNs we kept only the edges that appeared in at least
85%[304] of the 10.000 bootstrapped networks (i.e., at least 8.500).
In order to to keep only the edges that were significantly towards a specific direction
we kept the ones that pointed from symptom X to symptom Y in at least 51% of
the 10.000 bootstrapped networks(i.e, at least 5.100). Finally, the selected arcs had
a different contribution to the the goodness of fit of the final BNs. This contribution
was represented by their width. Arcs which characterized the structure of the data
with more confidence were visualised thicker than others. The thicker an arc, the more
damaging it would be for the model fit to remove it from the network. [306]
You can see the full list of these networks at Appendix C, SF6 to SF41.
Performance
To evaluate the averaged networks learned, upon all the combinations of different al-
gorithms, thresholds, and samples sizes used, we compared their post-hoc scores on a
set of different scoring functions (Appendix C, Table C.2). The selected functions were
suitable for assessing the discrete BNs made from our categorical, symptom occurrence
variables (i.e., Yes/No). [302, 307] These metrics were the logarithm of the K2 score
(k2), the logarithm of the Bayesian Dirichlet Equivalent score (BDE), the Bayesian
Information Criterion score (BIC), the Akaike Information Criterion score (AIC) and
the multinomial log-likelihood (loglik) score. The values of such scoring metrics reflect
its goodness of fit, which the algorithm attempts to maximize. At Table C.2, Appendix
C, highest values reflect better goodness of fit.
Many of these scoring metrics are in the form of a penalised log-likehood (LL) function.
[308] The LL is the log probability of the dataset D, used, given a learnt network struc-
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ture B. With the assumption that the data are independent and identically distributed,
the likelihood of the data D given a structure B can be calculated as:[308]
LL(D|B) =
N∑
j
logP (Dj |B) =
n∑
i
N∑
j
logP (Dij |PAij) (6.4)
where Dij is the instantiation of Xi in data point Dj, and PAij is the instantiation of
Xi’s parents in Dj.
Adding an arc to a network increases the likelihood of the network. If this arc does
provide more information it is ignored. Extra arcs, nevertheless, may lead to overfitting
of the training data. To address the overfitting problem these penalized LL functions
add a penalty term which penalizes the complex networks. In this manner, despite the
fact that the complex networks may have a very good LL score, the high penalty term
will reduce their score to be below that of a less complex network.
Stability and Reproducibility
Our study examines the data-driven, exploratory usefulness of BNA for cancer symptom
data. Until now, there have been not only limited network analyses studies on the
domain. Furthermore, there have been no consensus or evidence for the true network
structure of the cancer symptoms’ interactions. [259] Finally, an inherent problem in
BNA is obtaining this ”true” network structure. [309] The identified structures could
be sensitive to the sample size, the dataset used, and/or the specific algorithms used.
To assess the stability and reproducibility of our findings we tested their consistency
among 4 four equally sized, bootstrapped and randomly assigned subsets (n1=332,
n2=664, n3=996, n4=1328). We ran 10.000 BNs for each bootstrapped and randomly
assigned subset.
In Appendix C, Table C.2 has the full list of the results of these analyses. These
analyses showed the stability of the identified networks as well as the reproducibility
of each BNA algorithm based on our cancer symptoms dataset.
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Comparing Networks
To facilitate comparison between the BNs in this study, we compared them on their
structural similarities and distances with the Hamming Distance (HD) and the Struc-
tural Hamming Distance (SHD). [302, 309, 310, 311] HD and SHD describe the changes
that have to be made to a network for it to turn into the one that it is being compared
with. HD simply counts the number of edges that are different between the skeleton
of two networks, ignoring the direction of their arcs. SHD counts how these networks
differ, taking into account the direction of their arcs, also. It sums the count of edges
that are present in the original structure but are missing in the comparator structure,
the count of edges that are found in the comparator structure but are not present in
the original structure, and the count of directed edges in the comparator structure that
are oriented differently.
We also provide a visual side-by-side comparison of the networks, identified with all
three algorithms (i.e., GS, HC, MMHC) on the complete dataset (nComplete=1328), and
the two sub-groups based on gender (nMale=295, nFemale=1033) and age(nAge below 65=958,
nAge above 65=370). Lacking a ”gold standard” network structure for cancer symptoms’
data, in order to compare the performance and stability of the GS, HC, MMHC algo-
rithms across the four different sub-samples (n1=332, n2=664, n3=996, n4=1328) we
used the networks obtained from the complete, unrandomised data set (nComplete=1328)
as the reference network. Figures S6 to S41, in Appendix C, provide a visual overview
of the structural differences between the networks identified in this study. More pre-
cisely, by taking one network as a reference network, we computed the true positive,
false positive and false negative arcs in the other network, and we created an interactive
visualisation of these differences.
6.3 Results
Sample Characteristics: Of the 1328 (nComplete=1328) patients in this study, 77.8% were
female (nFemale=1033, nMale=295) and 72.1% were under the age of 65 (nAge <65=1033,
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nAge >65=295), with a mean age of 57.3 (±12.3) years. The majority of the patients
had breast (40.2%) or gastrointestinal (30.6%) cancer. The remaining patients had
gynaecological cancer (17.5%) and lung cancer (11.7%). These 1328 patients reported
an average of 13.9 (±7.2) symptoms prior to their second or third cycle of CTX. Sample
characteristics together with symptom occurrence rate, are summarised in Appendix
C, Table C.1, and Figures S1-S5, respectively.
Table 6.1: Comparison of Bayesian Network Algorithms
Compared algorithms Threshold Hamming
Distance
(HD)
Structural
Hamming
Distance
(SHD)
Common
Arcs found
with both
algorithms
Arcs found
only with
the first
(1st) algo-
rithm
Arcs found
only with
the sec-
ond (2nd)
algorithm
Grow Shrink (1st)
vs Hill-Climbing
(2nd)
0.85 27 32 4 6 25
Statistical
Optimisa-
tion
59 64 8 14 51
Grow Shrink (1st)
vs Max-Min
Hill-Climbing
(2nd)
0.85 27 32 5 5 24
Statistical
Optimisa-
tion
61 66 9 13 53
Hill-Climbing
(1st) vs Max-Min
Hill-Climbing
(2nd)
0.85 0 0 28 1 1
Statistical
Optimisa-
tion
2 5 57 2 5
6.3.1 Grow Shrink (GS) Algorithm
To learn the structure of the 38 different symptoms using the Grow Shrink (GS) al-
gorithm, we set the nominal type I error rate to 0.05. We averaged 10,000 BNs and
parsed their edges with the two different statistical criteria described in the Methods
section.
Both of these networks were relatively sparse, with the majority of the symptoms not
connected by any edges. The network that was parsed with a 0.85 threshold identified
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10 directed arcs. The network parsed with the optimal threshold (0,4963), described
by Scurati and Nagarajan, [305] identified 22 directed arcs (Appendix C, Table C.2).
The results are illustrated in Appendix C, SF6, SF7.
6.3.2 Hill-Climbing (HC) Algorithm
To learn the structure of the 38 different symptoms using the Hill-Climbing (HC)
algorithm we set its hyperparameters to have 50 random restarts and 30 attempts to
randomly insert/remove/reverse an arc on every random restart. We constructed and
averaged 10,000 BNs and parsed their edges with the two different statistical criteria
described in the Methods section. The results are illustrated in Appendix C, SF8, SF9.
Compared to the GS algorithm, the BNs learned using the HC algorithm were denser
(Appendix C, SF12, SF13). As illustrated in SF12, the network that was parsed with a
0.85 threshold identified 29 directed arcs and seven symptoms (i.e, numbness/tingling
in hands/feet, problems with urination, itching, dizziness, difficulty swallowing, consti-
pation, swelling of arms and legs) were not included in the BN. The network that was
parsed using the optimal threshold (0.4989), described by Scurati and Nagarajan, [305]
identified 59 directed arcs (Appendix C, Table C.2). The only symptom not included
within the network was swelling of the arms and legs (Appendix C, SF13).
6.3.3 Max Min Hill-Climbing (MMHC) Algorithm
To learn the structure of the 38 different symptoms with the Max-Min Hill-Climbing
(MMHC) algorithm, we set its hyperparameters to have a nominal type I error rate
to 0.05, during the first phase of the algorithm. In addition, wee also included 50
random restarts and attempted 30 times to randomly insert/remove/reverse an arc on
every random restart, during the second phase. We constructed and averaged 10,000
BNs and parsed their edges with different statistical criteria described in the Methods
section. The results are illustrated in Appendix C, SF10, SF11.
Similar to the findings with the HC algorithm, the networks learning with the MMHC
algorithm were denser in comparison to the networks learned with the GS algorithm
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(Appendix C, SF14, SF15). As illustrated in SF14, the network that was parsed with a
0.85 threshold identified 29 directed arcs and seven symptoms (i.e, numbness/tingling
in hands/feet, problems with urination, itching, dizziness, difficulty swallowing, consti-
pation, swelling of arms and legs) were not included in the BN. The network that was
parsed using an optimal threshold (0.4989), described by Scurati and Nagarajan, [305]
identified 59 directed arcs (Appendix C, Table C.2).
6.3.4 Bayesian Network Algorithms Comparison
To asses the goodness of fit and findings of the networks constructed, we compared GS,
HC, and MMHC based on different scoring functions such as k2, BDE, AIC, BIC and
logik (Appendix C, Table C.2).
Based on these, both HC and MMHC performed better than GS. They also had similar
performance in all five scoring criteria with MMHC performing in overall better when
applied to the small and large subgroups of our analyses (Appendix C, Table C.2).
Using the complete dataset of cancer patients, HC and MMHC performed similarly in
their findings (see Table 6.1). Depending on the threshold used (i.e., 0.85 or optimal
threshold), the Hamming Distance (HD) of their networks were 0 and 2 respectively,
and their Structural Hamming Distance (SHD) was 0 and 5. Most of their edges were
common as it can be seen in Figure 6.3.
6.3.5 Stability of the Identified BNs
To evaluate the stability of the constructed BNs, we compared the total number of
arcs identified in four bootstrap sub-samples (n1=332, n2=664, n3=996, n4=1328). In
addition, we compared their similarity based on their common arcs. The averaged BNs
were created in a similar way, as explained above.
In general, MMHC provided more stable results across the four bootstrap sub-samples
(n1=332, n2=664, n3=996, n4=1328). Based on the scoring function, MMHC provided
a better fit for the data, and it contributed the highest number of common arcs across
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Figure 6.3: Bayesian Networks Comparison: a) Grow-Shrink vs Hill-Climbing, b) Max-
Min Hill-Climbing, c) Hill-Climbing vs Max-Min Hill-Climbing. The green dotted lines
represent common arcs between the compared networks. The blue and red arcs repre-
sent different arcs that belong to each of networks that were compared. For a better
view of the diagrams see Appendix C, SF12 to SF17
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the procedure (Appendix C, Table C.2). Of note, all of the algorithms seemed to be
affected by the sample size, with the score and the number of arcs increasing as the
sample size increased (Appendix C, Table C.2).
Table 6.2: Comparison of the Bayesian Networks identified on four different subgroups
of cancer patients based on gender and age, using the Max-Min Hill-Climbing (MMHC)
Algorithm.
Group Sample
Size
Threshold k2 BDE AIC BIC logik Number
of arcs
found
Cancer
patients
below 65
958 0.85 -20522.64 -20524.38 -20391.44 -20547.11 -20327.44 22
958 0.5033 -19820.67 -19822.95 -19611.51 -19922.86 -19483.51 59
370 0.85 -20768.43 -20771.37 -20655.08 -20781.56 -20603.08 14
370 0.5003 -20281.32 -20283.19 -20139.22 -20311.92 -20068.22 27
Cancer
patients
above 65
370 0.85 -7911.7 -7919.385 -7824.7 -7922.537 -7774.7 12
370 0.4929 -7525.235 -7534.852 -7397.404 -7589.166 -7299.404 42
Male
cancer
patients
295 0.85 -5985.751 -6005.247 -5905.206 -5993.694 -5857.206 10
295 0.5006 -5778.554 -5794.827 -5663.553 -5822.093 -5577.553 37
Female
cancer
patients
1033 0.85 -22202.87 -22204.15 -22064.96 -22232.93 -21996.96 25
1033 0.5023 -21452.37 -21454.11 -21240.93 -21557.1 -21112.93 59
295 0.85 -22675.85 -22677.4 -22564.81 -22688.32 -22514.81 12
295 0.5012 -22127.84 -22129.48 -21990.69 -22156.19 -21923.69 25
k2: logarithm of the K2 score
BDE: logarithm of the Bayesian Dirichlet Equivalent score
AIC: Akaike Information Criterion score
BIC: Bayesian Information Criterion score
logik: multinomial log-likelihood score
6.3.6 Bayesian Networks for Male and Female Cancer Patients
To demonstrate the potential applications and challenges of BNs in cancer symptom
research, we applied the MMHC algorithm on four different subgroups of cancer patients
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based on their gender and age.
The sample sizes in the two subgroups of male and female cancer patients were not
balanced (nmale=295, nfemale=1033). Checking their BNs’ similarities provides a view
that female cancer patients experience more symptoms than male patients (Tables
6.2, 6.3). More specifically, women seem to experience up to 59 different symptom
interactions, while men experience up to 37 symptoms. Male and female patients
experience up to 14 different symptoms in common (Table 6.3).
However, when we created the BNs using bootstrapped, random samples of female
cancer patients of equal size with the male cancer patients (n=295), then this view
reversed (Table 6.3). In this case, women seem to experience up to 25 different symptom
interactions compared to 37 in men.
These results are illustrated in Appendix C and Figures SF30-SF41. The differences
among the identified BNs between the two aforementioned groups of cancer patients
are illustrated in Figures SF36-SF41. From these diagrams we can see that when we
keep the sub-groups disproportional women seem to experience a more interconnected
network of symptoms than men. On the contrary, when we balance the gender sub-
groups with a similar sample size the findings reverse with men experiencing a more
interconnected network of symptoms than women this time.
6.3.7 Bayesian Network for younger (< 65 years) and older (> 65
years) cancer patients
In a similar fashion, we compared the BNs identified using the MMHC algorithm,
between older and younger cancer patients (nAge<65=958, nAge>65=370). The results
are illustrated in Appendix C and Figures SF18-SF29. The differences among the
identified BNs between the two aforementioned groups of cancer patients are shown in
Appendix C, Figures SF24-SF29.
In our initial comparison, keeping the the age sub-groups disproportional, younger
cancer patients seem to experience a more interconnected network of symptoms than
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Table 6.3: Comparison of the Bayesian Networks identified on four different subgroups
of cancer patients based on gender and age, using the Max-Min Hill-Climbing (MMHC)
Algorithm.
Sub-
Group
1
Sub-
Group
2
Sample
size of
sub-
group
1
Sample
size of
sub-
group
2
ThresholdHamming
Dis-
tance
(HD)
Structural
Ham-
ming
Dis-
tance
(SHD)
Number
of
com-
mon
arcs
Number
of arcs
found
only
in sub-
group
1
Number
of arcs
found
only
in sub-
group
2
Men Women 295 1033 0.85 17 20 6 4 19
Men Women 295 1033 Statistical
Optimi-
sation
56 67 14 23 45
Men Women 295 295 0.85 6 6 6 4 6
Men Women 295 295 Statistical
Optimi-
sation
34 41 8 29 17
Women Women 1033 295 0.85 13 16 10 15 2
Women Women 1033 295 Statistical
Optimi-
sation
34 48 20 39 5
Age <
65
Age >
65
958 370 0.85 12 15 7 15 5
Age <
65
Age >
65
958 370 Statistical
Optimi-
sation
53 62 18 42 24
Age <
65
Age >
65
370 370 0.85 6 6 8 6 4
Age <
65
Age >
65
370 370 Statistical
Optimi-
sation
35 45 13 14 29
Age <
65
Age <
65
958 370 0.85 8 10 12 10 2
Age <
65
Age <
65
958 370 Statistical
Optimi-
sation
32 48 25 35 2
older ones. More specifically, younger people seem to experience up to 59 different
symptom interactions, while older ones experience up to 42 symptoms. Younger and
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older cancer patients experience up to 18 different symptoms in common (Table 6.3).
As in our previous example, when we created the BNs using bootstrapped, random
samples of younger cancer patients of equal size with the male cancer patients (n=370),
this view reversed (Table 6.3). The comparison with the balanced sample sizes showed
that actually the older people are the ones who are experiencing a more interconnected
network of symptoms. In this case, younger cancer patients seem to experience up to
27 different symptom interactions compared to 42 in older ones. Younger and older
cancer patients experience up to 13 different symptoms in common, this time (Table
6.3).
6.3.8 Causal Reasoning in Bayesian Networks of Cancer Symptoms
For this example, we will focus on the network structure learnt with the Max-Min Hill
Climbing algorithm and optimal threshold according to Scutari et al. [305] (Appendix
C, Figure S11). Fitting our data on this network structure with the Expectation Maxi-
mization (EM) algorithm we learn the local probability distributions of all the 38 nodes
(i.e., symptoms) in our study (Figure 6.4).
Focusing on the symptom ”Changes in Skin” (node: ”skin”) we get the causational
model in Figure 6.5. Figure 6.5A depicts the Markov Blanket of the symptom ”skin”
with the local probability distributions of each symptom (i.e., ”myself”, ”skin”, ”hair-
loss”, ”itch”, ”taste”) inside it. Figure 6.5B depicts the conditional probabilities of the
occurence of symptom ”Hair Loss” (node: hairloss) based on the occurence (i.e., ”Yes”)
of its parents symptoms ”I Do Not Look Like Myself” (node: myself) and ”Changes in
Skin” (node: skin). The higher the probability, the more likely it will be that a specific
set of combined observations will happen. For example, having ”Changes in Skin”, ”I
Do Not Look Like Myself” and ”Hair Loss” can occur together with a probability of
0.733. Whereas, ”I Do Not Look Like Myself” can occur without ”Changes in Skin” or
”Hairloss” with a probability of only 0.330.
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Figure 6.4: The marginal probabilities for the complete set of 38 symptoms
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Figure 6.5: Causational model of cancer symptom experience. The cancer symptoms
represented in the graph are coded in the following fashion: myself: I Do Not Look Like
Myself, skin: Changes in Skin, itch: Itching, taste: Change in the Way Food Tastes,
hairloss: Hair Loss
Querying the aforementioned probability distributions, help us to understand how
symptoms interact with each other. More precisely, we can infer which symptom(s)
a patient is more likely to report or which symptom(s) are more probable to cause a
following one. On the occasion of a specific set of observations, the closer the prob-
ability gets to 1, the higher the chances are these combined observations will occur.
Based on this structure and the parameters learnt for each node, we can predict the
probability of occurrence (i.e., Yes) of ”Change in the Way Food Tastes” and ”Itching”
for a given set of observations for ”Changes in Skin” (e.g., Yes), ”Hair Loss” (e.g., No)
and ”I Do Not Look Like Myself” (e.g., Yes),
P (taste=Y es, itch=Y es|skin=Y es, hairloss=No,myself=Y es)=0.253 (6.5)
P (taste=Y es|skin=Y es, hairloss=No,myself=Y es)=0.635 (6.6)
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P (itch=Y es|skin=Y es, hairloss=No,myself=Y es)=0.390 (6.7)
or we can enter a required state of ”Hair Loss” (e.g. No), ”Itching” (e.g., No), ”Change
in the Way Food Tastes” (e.g., Yes), ”I Do Not Look Myself” (e.g. Yes) as observa-
tions to examine how the occurrence of ”Changes in Skin” can explain these specific
observations. [312]
P (skin=Y es|hairloss=No, itch=No, taste=Y es,myself=Y es)=0.647 (6.8)
This procedure can be done iteratively for all the cancer symptoms included in our BN
(Figure 6.4). This application can help clinicians to provide pre-emptive support to
patients with specific symptom profiles, based on their idiosyncratic demographic and
clinical characteristics (i.e., the BNs learnt based on gender and age). In future research,
it could also help clinicians to identify more accurately side-effects of medication regimes
or care interventions, based on how much a patient’s symptom experience deviates from
the usual symptom CPT of patients with similar demographic and clinical profiles.
6.4 Discussion
In this study, we compared the network structures that were learned using constraint-
based, score-based, and hybrid algorithms. [297] The hybrid algorithm identified more
dense network structures that were clinically relevant, not only for the entire sample
but for our case studies of gender and age differences. While our sample size was
relatively small (N=1328), and we evaluated the three methods on a constrained set
of confounding parameters (e.g. medication, care interventions), our results show that
the score-based and hybrid algorithms identified relatively similar structures. The
constraint-based algorithm identified less sparse networks which may be the results of
the relatively small sample size. [313] Future analyses, with a broader set of confounding
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factors (e.g. medication, care interventions) for structure-learning as well as different
subgroups of patients (e.g., different cancer diagnoses, different cancer treatments)
may provide additional insights into the use of BNA in cancer symptom research. In
addition, if our findings are confirmed concerning the existence of common core or
sentinel symptoms identified in the BNs of different subgroups of cancer patients, this
information can be used to develop and test interventions to decrease symptom burden
in oncology patients. One can hypothesize that if an intervention is directed at the
core/sentinel symptom, co-occurring symptoms associated with this parent symptom
will decrease as well.
We have listed methods and ways in which BNA could inform cancer care research.
Among the strengths of this study is the use of an extensive set of cancer symptoms
from a comprehensive sample of oncology patients, the complete evaluation of BNA
with different algorithms, performance, stability criteria and contrasting sub-groups
of patients, the use of bootstrap methods and different scoring functions which can
reduce overfit and improve replicability. Nevertheless, there are also limitations. We
still do not know what the true structure of cancer symptoms’ experience is. Also,
our analyses lacks the inclusion of important (e.g. medication, care interventions)
confounding factors that could provide additional insight for the side-effect or protective
response of such factors on cancer symptoms. Nevertheless, Bayesian Networks are an
exploratory tool that is well suited for hypothesis generation. Markov Blankets allow
us to identify factors that directly influence each symptom and thus be regarded a part
of a causal (mechanistic) model. In spite of the fact that it is very difficult to prove
causality from cross-sectional observational data, BNs can provide insights for specific
causal models that could be validated in experimental data and/or randomized trials.
Hence our findings need to be verified in other cohorts and/or randomized trials.
BNs and network analysis approaches [259] are promising in detecting patterns among
symptoms. The BNs approaches show potential in identifying possible causal path-
ways, with predictive value inside the Markov Blankets of each network. To take full
advantage of the network approach in cancer symptom research, we need to explore it
further on additional sets of data modelling parameters (e.g., new algorithms, hyper-
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parameters, statistical criteria). There is also the need to study multiple, diversified
sub-groups of patients, based on varied set of important clinical profiling criteria (e.g.,
genetic profiles, demographics, clinical characteristics, environmental exposure). Ap-
plying BNs to a broader set of parameters, similar to the study that we present in this
analysis, can provide new evidence regarding the mechanistic explanation of symptoms
among cancer patients during and after their chemotherapy.
Breinan et al. [257] distinguished two cultures of statistical modelling as algorithmic
and data modelling. The first one aims to optimise the predictions of the modelling
produced from a given set of inputs while treating the process itself as a black box.
The second group focus on identifying the patterns between all the given inputs and
outputs and explain how the specific modelling works. In the context of data modelling
for cancer symptoms, algorithmic modelling is crucial for implementing state-of-the-art
predictions that can be used in clinical practice. [258] The data modelling can also be
useful for the expansion of the conceptual knowledge of the domain itself. [205, 259] The
use of hybrid approaches such as Bayesian Network Analysis, combining the strengths
of both analytic fields, provides additional tools both to cancer care and research. Its
use on temporal data will offer more in-depth insights on the way that cancer symptoms
interact with each other both in a causal and transitional way.
Chapter 7
Conclusions and Future Work
This chapter concludes this thesis with a summary of the research contributions. It
also discusses the outcomes of the work. Furthermore, a discussion on directions for
further research has been presented.
7.1 Research Achievements
The research objectives specified in Sections 1.3 have been successfully fulfilled by the
following main contributions:
1. We have presented an overview of the concept of cancer symptom clusters, their
main analytic approaches, their data collection process, their relevant problems
as well as the future research challenges around their study. This overview has
been discussed in Chapters 1 and 2.
2. We selected five representative machine learning clustering algorithms and filtered
the best candidate (i.e., K-Modes) for grouping cancer patients by their symp-
toms’ occurrence. We compared this candidate algorithm with the gold standard
(i.e., Latent Class Analysis (LCA)) for grouping cancer patients. To our knowl-
edge, no other study was identified that evaluated for congruence between two
different analytic methods of classifying oncology patients based on their distinct
experiences with common symptoms associated with cancer treatment. This has
been discussed in Chapter 3 and the research results have been published in
[205, 121].
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3. As a first study of its kind, we implemented and evaluated the use two different
machine learning techniques (i.e., Support Vector Regression (SVR), Non-linear
Canonical Correlation Analysis by Neural Networks (n-CCA)) to accurately pre-
dict the severity of three common symptoms (i.e., sleep disturbance, anxiety,
depression) from one week before to one week after the administration of CTX.
The aim was to assess whether these types of predictive models can be used to
identify high risk patients. These analyses has been discussed in Chapter 4 and
the research results have been published in [314].
4. Using two different models of Pairwise Markov Random Fields (PMRF), we ex-
amined the nature and structure of interactions for three different dimensions of
patients symptom experience (i.e., occurrence, severity, distress). The aim was
multifold: i) to provide an approach of explaining the interactivity and role of
cancer symptoms inside their clusters; ii) to provide a first evidence that the
connections between and among symptoms differ depending on the symptom di-
mension used to create the network; iii) to provide insights that could be used
to guide the development of symptom management interventions based on the
identification of core symptoms and symptom clusters within a network. The
results of our work have been discussed in Chapter 5 and published in [315].
5. We implemented and evaluated the use of 3 different families of Bayesian Net-
work Analysis (BNA) algorithms on cancer symptoms. The aim of this study
was three-fold: i) we described how BNA methods can be used to explore the in-
terrelationships among 38 co-occurring symptoms in a large, clinically relevantly,
and representative sample of 1328 cancer patients undergoing CTX; ii) we showed
how these methods can be used in reproducible manner to explore the notable
differences in the Bayesian Networks (BNs) created using gender and age (i.e.,
<65 versus >65 years of age); iii) we explained how our findings can be used to
monitor cancer symptoms in clinical care and guide the development and testing
of of future intervention studies to improve symptom management.
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7.2 Lessons Learned
In this section, we highlight some of the decisions and assumptions made and revised
considerations that have been made throughout this research.
The subjective nature of cancer symptoms along with the scarcity of validated, multi-
modal and relevant data posed a big challenge in the start of this research. The domain
of cancer symptom clusters is rather new (i.e., 15 years old). Therefore, it suffers from
many methodological issues around symptoms’ data collection and analysis as well as
conceptualisation of how symptoms interact with each other inside and between clus-
ters. Initially, we followed the state of the science on the domain and tried to answer
some of the key challenges that were posed already in the literature. Therefore, we se-
lected (in Chapter 3) the rather new approach of clustering cancer patients and we made
an comparative assessment of multiple different ML algorithms with the gold standard
(i.e., Latent Class Analysis). This helped us to assess not only the consistency between
the different analytic models, but also to explore and evaluate further the relation of
these groupings with the clinical outcomes of cancer patients. Our main motivation
was to explore the domain and understand how the current analytic approaches fulfill
their cause.
Based on the data we had available, we made decisions that were relevant to the nature
and the size of the data. We focused on questions that were still unanswered and could
have important clinical or research value for the domain. Following this approach,
we made the first study on predicting symptom values across the different stages of
chemotherapy (in Chapter 4). We selected 3 important symptoms to be assessed (i.e.,
sleep disturbance, depression, anxiety), and we built a multi-step analytic strategy.
Along this analytic experiment, we explored the ”missing values” problem together
with the optimal selection of validation methods for our final predictive model. Our
approach provided a case study on how to risk profile cancer patients not only by
grouping categories, but also with personalised, continuous symptom values that can
be more close to their own symptom experience.
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Getting more experience and exposure to the domain of symptom clusters, we contin-
ued with the parallel exploration of similar analytic problems in other domains (e.g.,
psychology, psychiatry). It became more apparent that a gap in the literature was
relevant to the interactivity of cancer symptoms and their possible role inside their
clusters. Taking advantage of the recent advancement in network science and network
analysis, we made the first study exploring the complex interactivity structure inside
and between cancer symptom clusters (in Chapter 5). For the first time, we assessed
how symptoms interact with each across 3 different dimensions (i.e., occurrence, sever-
ity, distress) and how they create different communities depending on these dimensions.
This study provided clinical insights about the differentiation of distress to the other
dimensions. It provided also a novel and analytic approach to explore and visualise,
intuitively the interactivity among cancer symptom clusters.
Finally, as a last goal of this research we set the exploration of the symptom clusters
interactivity with further analytic approaches. Bayesian Networks has been a useful
tool for applying artificial intelligence in medicine for almost 20 years. We compared
the three representative algorithms and assessed the use of Bayesian Network Analysis
in four different subgroups of cancer patients. The combination of our network analysis
findings (in Chapters 5, 6) can provide further understanding not only of how symptoms
interact or form symptom clusters, but also on how they may influence each other in a
directional, causal way.
7.3 Future Work
The future direction of this research includes the development of solutions around
the problems we faced during our experiments. The full set of techniques and methods
used can be aggregated into an analytic tool for supporting cancer symptom researchers
validate and replicate our results to their own context. It could help healthcare admin-
istrators and clinicians to take better advantage of the data that are collected nowadays
through mobile Electronic Data Capture Forms. Such a tool can be particular useful as
we focus more on multimorbidity and how symptom clusters overlap between different
7.3. Future Work 125
diseases and risk profiles. It could help us understand further the medication toxicity
and provide insights about the multidimensional causal pathway of cancer symptoms.
Such an endeavor would help to assess, also, in a more exhaustive way the problems
of missing values and small datasets. Identifying possible patterns or patient profiles
that are relevant to these missing values could help researchers or clinicians to take
appropriate action. Exploring how we could create synthetic datasets of real-life cancer
symptom data could support researchers to validate further their data collection and
analytic tools, making their use more practical in the clinical practise.
Finally, the analytic approaches we explored need to be challenged against themselves,
against the temporal profile of cancer symptom clusters as well as the multi-modal
nature of symptoms’ exposures. Comparing these approaches across all the available
performance metrics (e.g., distance metrics) could provide further insights of the over-
laps and discrepancies between them. Assessing how symptom or cluster groupings and
patients’ profiles change over time will strengthen or challenge further our understand-
ings about them. Finally, combining the practicalities of these analytic approaches
through multi-view learning on multi-modal symptom data will help us to identify
phenotypes in a more precise and effective manner. Exploring the structure of the can-
cer symptom experience of different subgroups of cancer patients, could help us identify
and filter groups of high risk profile patients for further analysis all across the latent
factors (e.g., genome, behavioral profile) that could affect the manifestation of cancer
symptoms.
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Appendix A
Table A.1: Differences in Symptom Occurrence Rates Among the Patient Subgroups
Using Latent Class Analysis or K-Modes Analysis
Symptom Method All Lowa,b (0)) MPLP (1) MPHP (2) All High (3) Statistics
Physical Symptoms
Lack of energy LCA 54.9 98.7 93 99.4 X2 = 357.44, p<.001
0 <1, 2, and 3
1 >2; 2 <3
K-Modes 64.7 95.6 93.9 97.4 X2 = 221.00, p<.001
0 <1, 2, and 3
Difficult concen-
trating
LCA 18.1 48.4 69 97.8 X2 =391.45, p<.001
0 <1 <2 <3
K-Modes 25.4 36.1 76.1 86.7 X2 = 386.45, p<.001
0 <1 <2 <3
Feeling drowsy LCA 24.3 73.7 70.7 96.6 X2 = 366.85, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 32.1 71.2 77.9 86 X2 = 309.61, p<.001
0 <1, 2, and 3
1 <3
Nausea LCA 16.7 63.9 45.4 95.5 X2 = 358.73, p<.001
0 <1, 2, and 3
1 >2; 1 and 2 <3
K-Modes 22.6 77.6 34.6 82.5 X2 = 377.42, p<.001
0 <1, 2, and 3
1 >2; 2 <3
Pain LCA 33.4 70.3 65.6 94.4 X2 = 231.14, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 36 75.1 71.1 83.4 X2 = 233.65, p<.001
0 <1, 2, and 3
2 <3
Difficulty sleep-
ing
LCA 45.8 71.5 80.5 92.7 X2 = 178.97, p<.001
0 <1 <2 <3
K-Modes 53.7 69.3 75.7 89.6 X2 = 125.66, p<.001
0 <1, 2, and 3
1 and 2 <3
Dry mouth LCA 21.2 65.8 36.8 86 X2 = 282.43, p<.001
0 <1, 2, and 3
Continued on next page
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Table A.1 – continued from previous page
Symptom Method All Lowa,b (0)) MPLP (1) MPHP (2) All High (3) Statistics
1 >2; 1 and 2 <3
K-Modes 26.1 72.2 31.4 73.7 X2 = 261.36, p<.001
0 <1 and 3
1 >2; 2 <3
Lack of appetite LCA 14.1 56 39.2 84.3 X2 = 292.58, p<.001
0 <1, 2, and 3
1 >2; 1 and 2 <3
K-Modes 18.7 71.2 26.8 74 X2 = 349.43, p<.001
0 <1 and 3
1 >2; 2 <3
Change in the
way food tastes
LCA 27.4 63.3 46.2 83.7 X2 = 190.76, p<.001
0 <1, 2, and 3
1 >2; 1 and 2 <3
K-Modes 32.3 70.7 32.5 80.2 X2 = 249.04, p<.001
0 <1 and 3
1 >2; 2 <3
Numbness/tingling
in hands/feet
LCA 33.4 62 51.9 79.8 X2 = 125.76, p<.001
0 <1, 2, and 3
1 >2; 1 and 2 <3
K-Modes 35.6 75.1 45 72.4 X2 = 158.32, p<.001
0 <1 and 3
1 >2; 2 <3
Hair loss LCA 33.7 61.4 60.8 78.7 X2 = 128.15, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 34 69.8 64.6 72.1 X2 = 160.60, p<.001
0 <1, 2, and 3
Constipation LCA 21.5 47.5 47.6 78.7 X2 = 177.03, p<.001
0 <1, 2, and 3
1 <2 and 3
K-Modes 22.9 61.5 36.1 74 X2 = 242.11, p<.001
0 <1, 2, and 3
1 >2; 1 and 2 <3
Feeling bloated LCA 10.3 28.8 40.4 77.5 X2 = 269.93, p<.001
0 <1 <2 <3
K-Modes 16 24.4 32.5 69.2 X2 = 258.27, p<.001
0 <2 and 3
1 and 2 <3
Changes in skin LCA 11.5 38.9 41.8 77 X2 = 245.68, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 16.4 35.6 36.1 71.4 X2 = 256.15, p<.001
0 <1, 2, and 3
1 and 2 <3
Sweats LCA 13.6 27.8 33.7 73 X2 = 208.28, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 17.5 21 26.4 66.2 X2 = 235.56, p<.001
0 <2 and 3
1 and 2 <3
Dizziness LCA 6.4 39.9 32.9 70.8 X2 = 260.76, p<.001
0 <1, 2, and 3
Continued on next page
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Symptom Method All Lowa,b (0)) MPLP (1) MPHP (2) All High (3) Statistics
1 and 2 <3
K-Modes 9.3 56.6 23.6 59.7 X2 = 304.91, p<.001
0 <1, 2, and 3
1 >2; 2 <3
Hot flashes LCA 16.7 33.5 29.3 70.2 X2 = 166.73, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 21.3 21.5 23.9 64.3 X2 = 195.29, p<.001
0, 1, and 2 <3
Problems with
sexual interest or
activity
LCA 10.5 24.1 41.8 57.9 X2 = 175.13, p<.001
0 <1 <2 <3
K-Modes 13.2 25.9 30.7 60.7 X2 = 212.26, p<.001
0 <1 and 3
1 and 2 <3
Cough LCA 18.4 40.5 30.5 56.7 X2 = 95.62, p<.001
0 <1, 2, and 3
1 >2; 1 and 2 <3
K-Modes 22.4 31.7 28.2 54.9 X2 = 97.52, p<.001
0, 1, and 2 <3
Diarrhea LCA 12.9 32.6 32.7 56.2 X2 = 119.84, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 16.8 38.5 32.9 42.9 X2 = 77.50, p<.001
0 <1, 2, and 3
Psychological Symptoms
Worrying LCA 22.4 14.2 90.6 98.9 X2 = 732.68, p<.001
0 >1
0 and 1 <2 and 3; 2
<3
K-Modes 24.3 27.8 81.1 90.3 X2 = 488.89, p<.001
0 and 1 <2 and 3
2 <3
Feeling irritable LCA 8.4 25.6 64.9 91.6 X2 = 500.74, p<.001
0 <1 <2 <3
K-Modes 13.8 22.4 65.7 79.5 X2 = 451.86, p<.001
0 <2 <3
1 <2 and 3
Feeling sad LCA 14.3 16.1 81.3 91.6 X2 = 639.54, p<.001
0 and 1 <2 and 3
2 <3
K-Modes 15.7 25.9 81.1 80.5 X2 = 518.29, p<.001
0 <1, 2, and 3
1 <2 and 3
Feeling nervous LCA 9.5 18.4 60.6 87.1 X2 = 467.74, p<.001
0 <1 <2 <3
K-Modes 10.6 18.5 69.3 70.1 X2 = 454.62, p<.001
0 <1, 2, and 3
1 <2 and 3
I dont look like
myself
LCA 13.6 28.2 54.1 74.2 X2 = 263.69, p<.001
0 <1 <2 <3
K-Modes 14.6 25.9 58.2 67.9 X2 = 303.48, p<.001
Continued on next page
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Symptom Method All Lowa,b (0)) MPLP (1) MPHP (2) All High (3) Statistics
0 <1, 2, and 3
1 <2 and 3
Symptoms Not Included Formation of Patient Groups
Difficulty swal-
lowing
LCA 4.1 18.7 10.6 35.4 X2 = 113.35, p<.001
0 <1, 2, and 3
1 >2; 1 and 2 <3
K-Modes 4.7 21.5 8.2 29.5 X2 = 119.48, p<.001
0 <1 and 3
1 >2; 2 <3
Abdominal
cramps
LCA 8.1 21.5 21.9 59.6 X2 = 190.13, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 10.3 22.4 20.7 45.5 X2 = 139.63, p<.001
0 <1, 2, and 3
1 and 2 <3
Shortness of
breath
LCA 10.3 30.1 28.1 57.3 X2 = 144.71, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 14.4 30.7 28.2 44.8 X2 = 94.90, p<.001
0 <1, 2, and 3
1 and 2 <3
Difficulty breath-
ing
LCA 7.4 22.8 17.5 50 X2 = 145.13, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 10.4 21 18.9 36.7 X2 = 84.69, p<.001
0 <1, 2, and 3
1 and 2 <3
Chest tightness LCA 5.5 16.8 18 48.3 X2 = 156.69, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 6.9 16.6 18.2 37.3 X2 = 123.91, p<.001
0 <1, 2, and 3
1 and 2 <3
Itching LCA 12.2 29.1 24.8 47.2 X2 = 86.76, p<.001
0 <1, 2, and 3
1 <3
K-Modes 14.6 27.3 24.3 41.6 X2 = 77.24, p<.001
0 <1, 2, and 3
1 and 2 <3
Weight loss LCA 13.1 30.4 24.3 46.6 X2 = 80.44, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 14.2 40 17.1 41.9 X2 = 113.46, p<.001
0 <1 and 3
1 >2; 2 <3
Increased ap-
petite
LCA 16 23.7 28.8 46.1 X2 = 61.84, p<.001
0 <2 and 3
1 and 2 <3
K-Modes 18.3 22.4 25.4 41.9 X2 = 58.54, p<.001
Continued on next page
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Symptom Method All Lowa,b (0)) MPLP (1) MPHP (2) All High (3) Statistics
0, 1 and 2 <3
Mouth sores LCA 9.1 21.8 24.3 39.3 X2 = 75.02, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 10.3 23.9 22.5 36 X2 = 80.90, p<.001
0 <1, 2, and 3
1 and 2 <3
Problems with
urination
LCA 5.7 12.3 13.2 38.8 X2 = 114.92, p<.001
0 <1, 2, and 3
1 and 2 <3
K-Modes 6.9 12.2 11.8 29.9 X2 = 88.17, p<.001
0, 1, and 2 <3
Weight gain LCA 16.2 25.9 28.8 37.6 X2 = 35.37, p<.001
0 <1, 2, and 3
K-Modes 18.1 23.9 28.2 36.4 X2 = 36.08, p<.001
0 <2 and 3
1 <3
Vomiting LCA 4.1 16.5 9.6 30.9 X2 = 91.05, p<.001
0 <1, 2, and 3
1 >2; 1 and 2 <3
K-Modes 5.8 19 8.9 22.4 X2 = 61.61, p<.001
0 <1 and 3
1 >2; 2 <3
Swelling in the
arms and/or legs
LCA 7.6 17.1 14.7 26.4 X2 = 37.76, p<.001
0 <1, 2, and 3
2 <3
K-Modes 8.8 16.1 15 23.4 X2 = 34.06, p<.001
0 <1 and 3
Abbreviations: LCA = Latent Class Analysis, MPLP = Moderate Physical & Lower Psychological, MPHP = Moderate
Physical & Higher Psychological
aFor LCA All Low (n=419, 31.5%), Moderate Physical & Lower Psychological (n=316, 23.8%), Moderate Physical &
Higher Psychological (n=416, 31.3%), All High (n=178, 13.4%).
bFor K-modes analysis All Low (n=536, 40.3%), Moderate Physical & Lower Psychological (n=205, 15.4%), Moderate
Physical & Higher Psychological (n=280, 21.13%) and All High (n=303, 23.24%).
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Appendix B
Supplemental Tables B.1-B.2
Table B.1: Demographic and Clinical Characteristics of the Sample (n=1328)
Characteristic Mean (SD)
Age (years) 57.2 (12.4)
Education (years) 16.2 (3.0)
Body mass index (kg/m2) 26.2 (5.7)
Karnofsky Performance Status score 80.0 (12.5)
Self-administered Comorbidity Questionnaire score 5.5 (3.2)
Time since diagnosis (years) 2.0 (3.9)
Time since diagnosis (years, median) 0.42
Number of prior cancer treatments 1.6 (1.5)
Number of metastatic sites including lymph node
involvementa
1.2 (1.2)
Number of metastatic sites excluding lymph node
involvement
0.8 (1.1)
% (n)
Gender (% female) 77.7 (1044)
Self-reported ethnicity
White 69.5 (921)
Non-white 30.5 (405)
Married or partnered (% yes) 64.5 (854)
Lives alone (% yes) 21.4 (284)
Currently employed (% yes) 35.1 (466)
Annual household income
Less than $30,000 18.4 (221)
$30,000 to $70,000 21.1 (254)
$70,000 to $100,000 16.9 (203)
Greater than $100,000 43.5 (523)
Child care responsibilities (% yes) 22.1 (290)
Elder care responsibilities (% yes) 8.0 (97)
Exercise on a regular basis (% yes) 70.8 (929)
Cancer diagnosis
Breast cancer 40.2 (540)
Gastrointestinal cancer 30.7 (412)
Continued on next page
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Table B.1 – continued from previous page
Mean (SD)
Gynecological cancer 17.3 (233)
Lung cancer 11.8 (158)
Prior cancer treatment
No prior treatment 24.9 (325)
Only surgery, CTX, or RT 42.1 (549)
Surgery and CTX, or surgery and RT, or CTX
and RT
19.8 (259)
Surgery and CTX and RT 13.2 (172)
Metastatic sites
No metastasis 32.3 (428)
Only lymph node metastasis 22.1 (292)
Only metastatic disease in other sites 21.1 (280)
Metastatic disease in lymph nodes and other
sites
24.5 (324)
Cycle length
14 day cycle 42.2 (565)
21 day cycle 50.6 (678)
28 day cycle 7.2 (97)
a Total number of metastatic sites evaluated was 9.
Abbreviations: CTX = chemotherapy, kg = kilograms, m2 = meters squared, RT = radiation therapy
SD = standard deviation
Table B.2: Summary of Centrality Measures for Each of the Symptom Dimensions
Symptom Betweenness Rank Closeness Rank Strength Rank
Occurrence
nausea 2.47 1 1.97 1 2.35 1
lack of appetite 2.07 2 1.56 2 1.94 3
feeling bloated 2.03 3 1.11 1.04 5
lack of energy 1.5 4 1.41 3 0.8
difficulty breathing 1.44 5 -0.09 2.12 2
worrying 0.8 0.69 1.41 4
vomiting 0.2 1.36 4 -0.07
difficulty concentrating 0.67 1.29 5 0.68
Severity
Continued on next page
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Symptom Betweenness Rank Closeness Rank Strength Rank
lack of appetite 3.55 1 2.49 1 2.38 2
lack of energy 2.56 2 2.15 2 0.22
difficulty breathing 1.42 3 0.31 2.52 1
difficulty with urination 0.9 4 1.15 4 -0.3
difficulty swallowing 0.9 4 1.02 0.67
weight loss 0.64 1.15 5 1.31 3
increased appetite -0.45 0.05 1.28 4
change in way food tastes 0.75 1.23 3 -0.04
nausea 0.38 1.07 1.1 5
Distress
lack of appetite 2.9 1 1.97 1 2.31 1
lack of energy 1.67 2 0.38 0.42
worrying 1.33 3 0.21 0.61
abdominal cramps 1.33 4 1.71 2 1.04
I dont look like myself 1.06 5 0.06 0.09
feeling bloated 1.06 5 1.36 4 -0.28
diarrhea 0.31 1.4 3 0.37
weight loss 0.72 1.25 5 1.25 5
weight gain 0.31 0.67 2.25 2
increased appetite -0.07 0.41 1.71 3
hot flashes 0.86 1.11 1.44 4
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Supplemental Figures B.1-B.7
The 38 cancer symptoms represented in the graphs below are coded in the
following fashion: difcon: Difficulty Concentrating, pain: Pain, energy: Lack of En-
ergy, cough: Cough, nervous: Feeling Nervous, hotflash: Hot Flashes, drymouth: Dry
Mouth, nausea: Nausea, drowsy: Feeling Drowsy, numb: Numbness or Tingling in
Hands or Feet, chest: Chest Tightness, difbreath: Difficulty Breathing, difsleep: Diffi-
culty Sleeping, bloat: Feeling Bloated, urinate: Problems with Urination, vomit: Vom-
itting, sob: Shortness of Breath, diarrhea: Diarrhea, sad: Feeling Sad, sweats: Sweats,
sexual: Problems with Sexual Interest or Activity, worry: Worrying, itch: Itching,
appetite: Lack of Appetite, abdominal: Abdominal Cramps, increaseapp: Increased
Appetite, wtgain: Weight Gain, dizzy: Dizziness, swallow: Difficulty Swallowing, irri-
table: Feeling Irritable, mouthsore: Mouth Sore, wtloss: Weight Loss, hairloss: Hair
Loss, constipat: Constipation, swelling: Swelling, taste: Change in the Way Food
Tastes, myself: I Do Not Look Like Myself, skin: Changes in Skin.
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Figure B.1: Frequency of the 38 Symptoms (Occurrence Dimension)
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Figure B.2: Frequency of the 38 Symptoms (Severity Dimension)
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Figure B.3: Frequency of the 38 Symptoms (Distress Dimension)
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Figure B.4: Bootstrap 95% confidence intervals for estimated edge weights for the net-
work of the 38 cancer symptoms across the three dimensions (i.e. occurrence, severity,
distress). The edge weights, each horizontal line representing one edge, are represented
by the red line, the 95% confidence intervals by the grey area.
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Figure B.5: Average correlations between the centrality indices of the networks of
the 38 cancer symptoms across the three dimensions (i.e. occurrence, severity, distress)
sampled with cases or nodes dropped and the original sample. Lines indicate the means
and areas indicate the range from the 2.5th quantile to the 97.5th quantile.
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Figure B.6: Average correlations between the centrality indices of the networks of the
38 cancer symptoms in each of 4 equally divided groups, across each dimension (i.e.
occurrence, severity, distress) sampled with cases dropped and the original sample.
Lines indicate the means and areas indicate the range from the 2.5th quantile to the
97.5th quantile. Across the symptom dimension of Occurrence, the statistic Closeness
does not contain any variance and is therefore not shown.
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Figure B.7: Average correlations between the centrality indices of the networks of the
38 cancer symptoms in each of 4 equally divided groups, across each dimension (i.e.
occurrence, severity, distress) sampled with nodes dropped and the original sample.
Lines indicate the means and areas indicate the range from the 2.5th quantile to the
97.5th quantile. Across the symptom dimension of Occurrence, the statistic Closeness
does not contain any variance and is therefore not shown.
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Appendix C
Supplemental Tables C.1-C.2
Table C.1: Demographic and Clinical Characteristics of the Sample (n=1328)
Characteristic Mean (SD)
Age (years) 57.3 (12.3)
Education (years) 16.2 (3.0)
Body mass index (kg/m2) 26.2 (5.7)
Karnofsky Performance Status score 80.1 (12.4)
Self-administered Comorbidity Questionnaire score 5.5 (3.2)
Time since diagnosis (years) 2.0 (3.9)
Time since diagnosis (years, median) 0.4
Number of prior cancer treatments 1.6 (1.5)
Number of metastatic sites including lymph node involvementa 1.2 (1.2)
Number of metastatic sites excluding lymph node involvement 0.8 (1.0)
Average number of symptoms reported prior to their next dose of CTX 13.9 (7.2)
% (n)
Gender (% female) 77.8 (1033)
Self-reported ethnicity
White 69.9 (916)
Non-white 30.1 (412)
Married or partnered (% yes) 64.4 (843)
Continued on next page
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% (n)
Lives alone (% yes) 21.5 (282)
Currently employed (% yes) 35.2 (462)
Annual household income
Less than $30,000 18.4 (219)
$30,000 to $70,000 21.2 (252)
$70,000 to $100,000 16.7 (198)
Greater than $100,000 43.7 (520)
Child care responsibilities (% yes) 22.0 (286)
Elder care responsibilities (% yes) 7.9 (95)
Exercise on a regular basis (% yes) 71.0 (922)
Cancer diagnosis
Breast cancer 40.2 (534)
Gastrointestinal cancer 30.6 (407)
Gynecological cancer 17.5 (232)
Lung cancer 11.7 (155)
Prior cancer treatment
No prior treatment 25.0 (323)
Only surgery, CTX, or RT 42.0 (542)
Surgery and CTX, or surgery and RT, or CTX and RT 19.9 (257)
Surgery and CTX and RT 13.1 (169)
Metastatic sites
No metastasis 32.3 (423)
Only lymph node metastasis 22.1 (289)
Only metastatic disease in other sites 21.1 (277)
Metastatic disease in lymph nodes and other sites 24.5 (321)
Cycle length
14 day cycle 42.1 (558)
21 day cycle 50.5 (670)
Continued on next page
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% (n)
28 day cycle 7.3 (97)
a Total number of metastatic sites evaluated was 9.
Abbreviations: CTX = chemotherapy, kg = kilograms, m2 = meters squared,
RT = radiation therapy, SD = standard deviation
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Table C.2: Performance and Stability of Bayesian Network Algorithms
Abbreviations stand for the following: GS = Grow-Shrink algorithm, HC = Hill
Climbing algorithm, MMHC = Max-Min Hill Climbing algorithm. Better scores have
greed shading. Worst scores have red shading.
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Supplemental Figures C.1-C.41
The 38 cancer symptoms represented in the graphs below are coded in the
following fashion: difcon: Difficulty Concentrating, pain: Pain, energy: Lack of En-
ergy, cough: Cough, nervous: Feeling Nervous, hotflash: Hot Flashes, drymouth: Dry
Mouth, nausea: Nausea, drowsy: Feeling Drowsy, numb: Numbness or Tingling in
Hands or Feet, chest: Chest Tightness, difbreath: Difficulty Breathing, difsleep: Diffi-
culty Sleeping, bloat: Feeling Bloated, urinate: Problems with Urination, vomit: Vom-
itting, sob: Shortness of Breath, diarrhea: Diarrhea, sad: Feeling Sad, sweats: Sweats,
sexual: Problems with Sexual Interest or Activity, worry: Worrying, itch: Itching,
appetite: Lack of Appetite, abdominal: Abdominal Cramps, increaseapp: Increased
Appetite, wtgain: Weight Gain, dizzy: Dizziness, swallow: Difficulty Swallowing, irri-
table: Feeling Irritable, mouthsore: Mouth Sore, wtloss: Weight Loss, hairloss: Hair
Loss, constipat: Constipation, swelling: Swelling, taste: Change in the Way Food
Tastes, myself: I Do Not Look Like Myself, skin: Changes in Skin.
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Figure C.1: Frequency of the 38 Symptoms on the Occurrence Dimension for all the
cancer patients (n=1328)
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Figure C.2: Frequency of the 38 Symptoms on the Occurrence Dimension for the male
cancer patients (n=295)
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Figure C.3: Frequency of the 38 Symptoms on the Occurrence Dimension for the female
cancer patients (n=1033)
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Figure C.4: Frequency of the 38 Symptoms on the Occurrence Dimension for the <65
years cancer patients (n=958)
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Figure C.5: Frequency of the 38 Symptoms on the Occurrence Dimension for the >65
years cancer patients (n=370)
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Figure C.6: Network on symptom data for all the cancer patients (n=1328), made with
the Grow-Shrink algorithm and 0.85 threshold (Sachs et al., 2005). To view the in-
teractive diagram of this network visit: https://nikolaospapachristou.github.io/Paper-
Cancer-Symptoms-Networks/GSmod1.html
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Figure C.7: Network on symptom data for all the cancer patients (n=1328),
made with the Grow-Shrink algorithm and optimal threshold according to
Scurati Nagarajan, 2013. To view the interactive diagram of this net-
work visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/GSmod2.html
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Figure C.8: Network on symptom data for all the cancer patients (n=1328), made with
the Hill Climbing algorithm and 0.85 threshold (Sachs et al., 2005). To view the in-
teractive diagram of this network visit: https://nikolaospapachristou.github.io/Paper-
Cancer-Symptoms-Networks/HCmod1.html
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Figure C.9: Network on symptom data for all the cancer patients (n=1328),
made with the Hill Climbing algorithm and optimal threshold according to
Scurati Nagarajan, 2013. To view the interactive diagram of this net-
work visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/HCmod2.html
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Figure C.10: Network on symptom data for all the cancer patients
(n=1328), made with the Max-Min Hill Climbing algorithm and 0.85 thresh-
old (Sachs et al., 2005). To view the interactive diagram of this net-
work visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/MMHCmod1.html
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Figure C.11: Network on symptom data for all the cancer patients (n=1328),
made with the Max-Min Hill Climbing algorithm and optimal threshold ac-
cording to Scurati Nagarajan, 2013. To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/MMHCmod2.html
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Figure C.12: Cancer symptoms network differences between the Grow-Shrink and
Hill Climbing models made with the 0.85 threshold (Sachs et al., 2005) on cancer
symptom data for all the cancer patients (n=1328). To view the interactive diagram
of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/GSHCmod1.html
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Figure C.13: Cancer symptoms network differences between the Grow-Shrink and Hill
Climbing models made with optimal threshold according to Scurati Nagarajan, 2013
on cancer symptom data for all the cancer patients (n=1328). To view the interactive
diagram of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-
Symptoms-Networks/GSHCmod2.html
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Figure C.14: Cancer symptoms network differences between the Grow-Shrink and Max-
Min Hill Climbing models made with the 0.85 threshold (Sachs et al., 2005) on cancer
symptom data for all the cancer patients (n=1328). To view the interactive diagram
of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/GSMMHCmod1.html
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Figure C.15: Cancer symptoms network differences between the Grow-Shrink and Max-
Min Hill Climbing models made with optimal threshold according to Scurati Nagara-
jan, 2013 on cancer symptom data for all the cancer patients (n=1328). To view the in-
teractive diagram of this network visit: https://nikolaospapachristou.github.io/Paper-
Cancer-Symptoms-Networks/GSMMHCmod2.html
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Figure C.16: Cancer symptoms network differences between the Hill Climbing and
Max-Min Hill Climbing models made with the 0.85 threshold (Sachs et al., 2005) on
cancer symptom data for all the cancer patients (n=1328). To view the interactive
diagram of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-
Symptoms-Networks/HCMMHCmod1.html
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Figure C.17: Cancer symptoms network differences between the Hill Climbing and Max-
Min Hill Climbing models made with optimal threshold according to Scurati Nagara-
jan, 2013 on cancer symptom data for all the cancer patients (n=1328). To view the in-
teractive diagram of this network visit: https://nikolaospapachristou.github.io/Paper-
Cancer-Symptoms-Networks/HCMMHCmod2.html
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Figure C.18: Network on symptom data of cancer patients with age be-
low 65 (n=958), made with the Max-Min Hill Climbing algorithm and the
0.85 threshold (Sachs et al., 2005). To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/Agebelow65MMHCmod1.html
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Figure C.19: Network on symptom data for the cancer patients with age below 65
(n=958), made with the Max-Min Hill Climbing algorithm and the optimal thresh-
old according to Scurati Nagarajan, 2013. To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/Agebelow65MMHCmod2.html
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Figure C.20: Network on symptom data for the cancer patients with age below 65
(n=370, boostrapped sampling), made with the Max-Min Hill Climbing algorithm
and the 0.85 threshold (Sachs et al., 2005). To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/age65down370MMHCmod1.html
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Figure C.21: Network on symptom data for the cancer patients with age below 65
(n=370, boostrapped sampling), made with the Max-Min Hill Climbing algorithm and
the optimal threshold according to Scurati Nagarajan, 2013. To view the interactive
diagram of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-
Symptoms-Networks/age65down370MMHCmod2.html
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Figure C.22: Network on symptom data for the cancer patients with age
above 65 (n=370), made with the Max-Min Hill Climbing algorithm and the
0.85 threshold (Sachs et al., 2005). To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/Ageabove65MMHCmod1.html
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Figure C.23: Network on symptom data for the cancer patients with age below 65
(n=370), made with the Max-Min Hill Climbing algorithm and the optimal thresh-
old according to Scurati Nagarajan, 2013. To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/Ageabove65MMHCmod2.html
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Figure C.24: Cancer symptoms network differences between the cancer patients below
the age of 65 (n=958) and above the age of 65 (n=370), made with the Max-Min Hill
Climbing algorithm and the 0.85 threshold (Sachs et al., 2005). To view the interactive
diagram of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-
Symptoms-Networks/Agemod1.html
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Figure C.25: Cancer symptoms network differences between the cancer pa-
tients below the age of 65 (n=958) and above the age of 65 (n=370), made
with the Max-Min Hill Climbing algorithm and the optimal threshold ac-
cording to Scurati Nagarajan, 2013. To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/Agemod2.html
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Figure C.26: Cancer symptoms network differences between the cancer pa-
tients below the age of 65 (n=370, bootstrapped sampling) and above the
age of 65 (n=370), made with the Max-Min Hill Climbing algorithm and
the 0.85 threshold (Sachs et al., 2005). To view the interactive diagram
of this network: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/agebelowSubabovemod1.html
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Figure C.27: Cancer symptoms network differences between the cancer patients
below the age of 65 (n=370, bootstrapped sampling) and above the age of 65
(n=370), made with the Max-Min Hill Climbing algorithm and the optimal thresh-
old according to Scurati Nagarajan, 2013. To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/agebelowSubabovemod2.html
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Figure C.28: Cancer symptoms network differences between the cancer pa-
tients below the age of 65 (n=958) and below the age of 65 (n=370, boot-
strapped sampling), made with the Max-Min Hill Climbing algorithm and the
0.85 threshold (Sachs et al., 2005). To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/agebelowbelowSubmod1.html
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Figure C.29: Cancer symptoms network differences between the cancer patients be-
low the age of 65 (n=958) and below the age of 65 (n=370, bootstrapped sam-
pling), made with the Max-Min Hill Climbing algorithm and the optimal thresh-
old according to Scurati Nagarajan, 2013. To view the interactive diagram
of this network: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/agebelowbelowSubmod2.html
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Figure C.30: Network on symptom data for the male cancer patients
(n=295), made with the Max-Min Hill Climbing algorithm and the 0.85
threshold (Sachs et al., 2005). To view the interactive diagram of this net-
work visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/MenMMHCmod1.html
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Figure C.31: Network on symptom data for the male cancer patients (n=295),
made with the Max-Min Hill Climbing algorithm and the optimal threshold
according to Scurati Nagarajan, 2013. To view the interactive diagram
of this network: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/MenMMHCmod2.html
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Figure C.32: Network on symptom data for the female cancer patients
(n=1033), made with the Max-Min Hill Climbing algorithm and the 0.85
threshold (Sachs et al., 2005). To view the interactive diagram of this net-
work visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/WomenMMHCmod1.html
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Figure C.33: Network on symptom data for the female cancer patients (n=1033),
made with the Max-Min Hill Climbing algorithm and the optimal threshold
according to Scurati Nagarajan, 2013. To view the interactive diagram
of this network: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/WomenMMHCmod2.html
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Figure C.34: Network on symptom data for the female cancer patients (n=295,
bootstrapped sampling), made with the Max-Min Hill Climbing algorithm and
the 0.85 threshold (Sachs et al., 2005). To view the interactive diagram
of this network: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/women295MMHCmod1.html
190 Appendix C. Appendix C
Figure C.35: Network on symptom data for the female cancer patients (n=295, boot-
strapped sampling), made with the Max-Min Hill Climbing algorithm and the opti-
mal threshold according to Scurati Nagarajan, 2013. To view the interactive diagram
of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/women295MMHCmod2.html
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Figure C.36: Cancer symptoms network differences between the male (n=295)
and female (n=1033) cancer patients, made with the Max-Min Hill Climbing and
the 0.85 threshold (Sachs et al., 2005). To view the interactive diagram of
this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/MenWomenmod1.html
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Figure C.37: Cancer symptoms network differences between the male (n=295) and
female (n=1033) cancer patients, made with the Max-Min Hill Climbing and the opti-
mal threshold according to Scurati Nagarajan, 2013. To view the interactive diagram
of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/MenWomenmod2.html
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Figure C.38: Cancer symptoms network differences between the male (n=295) and
female (n=295, bootstrapped sampling) cancer patients, made with the Max-Min Hill
Climbing and the 0.85 threshold (Sachs et al., 2005). To view the interactive diagram
of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/menwomenSubmod1.html
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Figure C.39: Cancer symptoms network differences between the male
(n=295) and female (n=295, bootstrapped sampling) cancer patients, made
with the Max-Min Hill Climbing and the optimal threshold according to
Scurati Nagarajan, 2013. To view the interactive diagram of this net-
work visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/menwomenSubmod2.html
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Figure C.40: Cancer symptoms network differences between the female (n=1033) and
female (n=295, bootstrapped sampling) cancer patients, made with the Max-Min Hill
Climbing and the 0.85 threshold (Sachs et al., 2005). To view the interactive diagram
of this network visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/womenwomenSubmod1.html
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Figure C.41: Cancer symptoms network differences between the female
(n=1033) and female (n=295, bootstrapped sampling) cancer patients, made
with the Max-Min Hill Climbing and the optimal threshold according to
Scurati Nagarajan, 2013. To view the interactive diagram of this net-
work visit: https://nikolaospapachristou.github.io/Paper-Cancer-Symptoms-
Networks/MenWomenmod2.html
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